5-8-2020

Defining the let-7 microRNA-mediated molecular mechanisms regulating T cell differentiation

Constance C. Angelou
University of Massachusetts Amherst

Recommended Citation

DEFINING THE LET-7 MICRORNA-MEDIATED MOLECULAR MECHANISMS REGULATING T CELL DIFFERENTIATION

A Dissertation Presented

by

CONSTANCE C. ANGELOU

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of

DOCTOR OF PHILOSOPHY

May 2020

Molecular and Cellular Biology Graduate Program

**DEFINING THE LET-7 MICRORNA-MEDIATED MOLECULAR
MECHANISMS REGULATING T CELL DIFFERENTIATION**

A Dissertation Presented

by

CONSTANCE C. ANGELOU

Approved as to style and content by:

_____
Leonid A. Pobezinsky, Chair

_____
Cynthia L. Baldwin, Member

_____
Barbara A. Osborne, Member

_____
Wilmore C. Webley, Member

_____
Scott C. Garman, Director
Molecular and Cellular Biology

DEDICATION

For my parents, who, despite not having a single clue of what I wanted to do, let me do it anyways. If that is not true love, I don't know what is.

ACKNOWLEDGEMENTS

First and foremost, I would like to express my gratitude to my thesis advisor, Dr. Leonid Pobezinsky, for showing me how fascinating the immune system is, and for contributing to shaping the scientist I have become. Thank you for all the time you spent training me, giving me many projects to explore, and thereby letting me learn all the techniques I have (hopefully) now mastered. Thank you for the many hours you invested in teaching me how to make efficient presentations and considerably improving my public speaking skills. Thank you for being open-minded to and supportive of the career path I want to pursue, even though you often doubt about how useful your mentorship was in this regard. This experience is unforgettable, and I now feel like I can accomplish anything, and this is predominantly because of you.

I would also like to acknowledge my thesis committee members, Dr. Cynthia Baldwin, Dr. Barbara Osborne, and Dr. Wilmore Webley, for their support, enthusiasm, and utmost valuable insights on my thesis research, without which this dissertation would never have been what it turned out to be.

I would like to address special thanks to Dr. Elena Pobezinskaya. Thank you for agreeing to teach me a little bit of all the things you know. I think of you as my role model of the strong, brilliant and confident scientist and accomplished woman I aspire to become one day. This dissertation would not have been possible without your scientific and technical advice, and I will always be grateful for all your help and patience.

Many thanks to my other fantastic mentors, Dr. Kimberly Tremblay, Dr. Jesse Mager, Dr. Lisa Minter, and Shana Passono, for always taking the time to check in with me on how I felt, for listening to me when I needed someone to talk to, and for giving me

such precious advice and insights regarding my personal and professional aspirations. You were instrumental to my development as a person and scientist.

I would also like to thank past and present members of the Pobezinsky lab, Alex Wells, Lizzy Iverson, Eric Fagerberg, Eugenia Roberts, and Daniel Ryan, for their scientific and non-scientific support, as well as their friendship. I also thank my colleagues in other labs, as well as my MCB and VASCI friends, for providing the indispensable emotional support without which this thesis would have been impossible.

I would also like to acknowledge my Belgian friends for their constant support, even though I was far away and did no visit often, and for making me feel like Belgium was never really far away through monthly Skype sessions. Thank you for making sure I was not losing all of my French. Thank you for all the waffles, mulled wine, beer, delicious foods, and parties, and for always being there when I needed you during this experience.

Extremely special thanks go to my amazing boyfriend, Joe, who was the most patient, supportive, and helpful person in my entourage during my Ph.D. experience. Thank you for listening to and soothing all my doubts and fixations, for repeatedly reminding me that everything was going to be alright, for being my very personal scientific consultant, tennis partner, hiking companion, and for making sure I was well-fed when I had no time to think about my wellbeing.

And last but not least, I would like to thank my family. Even though you really did not want me to leave Belgium for such a remote location as the United States, and had no idea of what I was precisely going to do here, you understood that completing my

Ph.D. was very important to me. Thank you for supporting me throughout this process and making sure I had everything I needed.

ABSTRACT

DEFINING THE LET-7 MICRORNA-MEDIATED MOLECULAR MECHANISMS REGULATING T CELL DIFFERENTIATION

MAY 2020

CONSTANCE ANGELOU, B.S., UNIVERSITÉ CATHOLIQUE DE LOUVAIN

M.S., UNIVERSITÉ CATHOLIQUE DE LOUVAIN

PH.D. UNIVERSITY OF MASSACHUSETTS, AMHERST

Directed by: Leonid A. Pobezinsky, Ph.D.

$CD4^+$ and $CD8^+$ T cells are lymphocytes of the adaptive immune system that play essential roles in immunity. Both T cell subsets recognize their cognate antigen through the T cell receptor (TCR), which induces the proliferation and differentiation of these antigen-specific cells into effector T cells. $CD4^+$ T cells have the potential to differentiate into one of multiple lineages of helper T (Th) cells and participate indirectly in antigen clearance by orchestrating the function of other cells. $CD8^+$ T cells differentiate into cytotoxic T lymphocytes (CTL), which directly contributes to the resolution of an infection by killing cancerous or virally-infected cells. Upon antigen clearance, most effector T cells die, but some survive and generate long-lived memory T cells that will respond faster and more efficiently to subsequent encounters with the same antigen. When antigen fails to be cleared, such as in chronic infections and cancer, effector T cells are diverted into a hyporesponsive state, exhaustion, characterized by the upregulation of co-inhibitory receptors that transmits inhibitory signals resulting in the loss of effector function and memory potential. Moreover, when T cell differentiation is dysregulated, T cell responses become aberrant, causing autoimmune diseases. Therefore, understanding

the molecular mechanisms controlling T cell responses is important to develop innovative treatments that can enhance T cell activity during infections and cancer, and dampen the generation of disease-causing T cells in autoimmunity. We have uncovered a novel post-transcriptional mechanism regulating T cell differentiation. Particularly, we showed that the let-7 family of miRNAs is highly expressed in naive T cells, but gets dramatically downregulated upon antigen encounter, proportionally to both the strength and duration of TCR stimulation. Specifically, let-7 downregulation was required for the differentiation of pathogenic Th17 cells in experimental autoimmune encephalomyelitis (EAE), a mouse model of the autoimmune disease multiple sclerosis (MS). In CD8$^+$ T cells, although let-7 inhibits CTL differentiation *in vitro*, let-7 was demonstrated both *in silico* and *in vivo* to promote memory CD8$^+$ T cell formation, while repressing the differentiation of terminal effectors, which are susceptible to exhaustion. Thus, let-7 constitutes a promising tool for the therapeutic manipulation of T cell responses.

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

CHAPTER 1

INTRODUCTION

1.1 The immune system

The immune system comprises numerous types of bone marrow-derived (hematopoietic) cells that have evolved to recognize and react to foreign substances, known as antigens (Janeway, 1992; Medzhitov, 2007). The immune system's reaction, or immunity, constitutes the body's defense against diseases caused by infectious pathogens, such as viruses, bacteria, protozoa, fungi, and parasites, as well as cancer (Janeway et al., 2017). The immune system can be divided into two distinct, but intertwined, components – the innate and adaptive immune systems **(Figure 1.1)** (Vivier & Malissen, 2005). The innate immune system is a series of broad and immediate defense mechanisms that serve as a first physical and chemical line of defense against pathogens that gets established within minutes after the onset of infection. Innate defense mechanisms consist of physical barriers or epithelia (e.g. skin, oral mucosa, respiratory epithelium, intestine), as well as circulating antimicrobial proteins, and innate immune cells. Innate immune cells include granulocytes, macrophages, dendritic cells, innate lymphoid cells, and natural killer cells, which recognize a wide variety of pathogen- or damage-associated molecules (Akira et al., 2006; Bird et al., 2018). The adaptive immune system is unique to vertebrates, and encompasses B and T cells, which express surface receptors that specifically recognize individual immune determinants, or epitopes, on antigens (Burnet, 1959; Pancer & Cooper, 2007). Adaptive immunity gets activated by antigen-presenting cells, such as dendritic cells, when pathogens resist to innate immune responses, and participates in pathogen elimination by using processes that specifically target antigen-expressing

1

pathogens (Busso, 2008; Iwasaki & Medzhitov, 2015). B cells develop in the bone marrow, and contribute to immune responses through the production of antibodies (humoral immunity), while T cells mature in the thymus and secrete effector molecules and cytokines which contribute either directly or indirectly to pathogen clearance (cellular immunity) (Waksman et al., 1962; Ryser & Vassalli, 1974; Spits, 2002; Cooper, 2015). Unlike the innate immune system, adaptive immune responses are slower, as adaptive immune cells need to differentiate and acquire their function after responding to presented antigen. However, the duration of these responses lasts longer and results, after the resolution of an infection, in the formation of long-lived memory cells. These memory cells respond faster, with higher affinity, and more efficiently upon subsequent exposures to the same antigen **(Figure 1.2)** (Hammarlund et al., 2003).

1.2 T lymphocyte development in the thymus

T lymphocyte progenitors are generated following Notch signaling in common lymphoid progenitors in the bone marrow and then migrate to the thymus where they become thymocytes and develop into mature T cells **(Figure 1.3)** (Kondo et al., 1997; Pui et al., 1999; Spits, 2002). The thymus is also the site where thymocytes acquire their lineage identity, characterized by the mutually exclusive surface expression of the co-receptors CD4 and CD8, which will determine whether the generated mature T cells will have the potential to differentiate into helper CD4$^+$ T (Th) cells or CD8$^+$ cytotoxic T lymphocytes (CTLs) (Singer et al., 2008). At the beginning of thymic education, thymocytes are double-negatives (DN), as they do not express any of these surface co-receptors, and undergo irreversible random genetic recombinations of T cell receptor (TCR) gene segments, thereby generating a broad diversity (repertoire) of different

2

antigen-specific TCR from only a limited pool of gene segments (Davis & Bjorkman, 1988; Engel & Hedrick, 1988). Each thymocyte then expresses a unique TCR that is transmitted to its progeny, or clone. After productive TCR rearrangement, thymocytes upregulate both co-receptors, thereby becoming double-positives (DP), and are subjected to repertoire (positive) selection (Nikolić-Žugić, 1991; Mombaerts et al., 1992; Starr et al., 2003). During this process, thymocytes interact with thymic epithelial cells, which express self-peptide antigens presented on major histocompatibility complex (MHC) molecules (Scott et al., 1989; Anderson et al., 1996). Thymocytes that fail to recognize self-MHC die "by neglect", while cells that are able to do so are positively selected and thus receive survival signals, thus establishing an MHC-restricted T cell repertoire (Klein et al., 2014). Positively selected thymocytes subsequently go through the process of negative selection, during which thymocytes that have too strong of an affinity for self-peptides receive apoptotic signals, resulting in the deletion of these potentially harmful autoreactive T cells (Ashton-Rickardt et al., 1994). During the same process, DP thymocytes also transition to an intermediate stage during which CD8 gets downregulated, and CD4 versus CD8 lineage commitment occurs following mutually exclusive signaling events (Brugnera et al., 2000). Persistence of positively selecting TCR signals induces the transient expression of the transcription factor ThPOK and results in the generation of single-positive CD4[+] T cells (He et al., 2005; Luckey et al., 2014). In contrast, cessation of TCR signaling following positive selection allows thymocytes to respond to the cytokine IL-7, the signaling of which drives the upregulation of the transcription factor Runx3, leading to ThPOK repression, co-receptor reversal, and

commitment of intermediate thymocytes to the CD8[+] T cell lineage (Sato et al., 2005; McCaughtry et al., 2012).

The goal of T cell development in the thymus is thus to produce a functional pool of mature MHC-restricted and self-tolerant mature T cells with distinct differentiation potentials. After thymic education, mature T cells exit the thymus and migrate to secondary lymphoid organs, such as the spleen and lymph nodes (McCaughtry et al., 2007).

1.3 T cell differentiation

1.3.1 Activation of naive T cells

Mature T lymphocytes that migrate to the secondary lymphoid organs after developing in the thymus are naive and appear small and round, with a low cytoplasm-to-nucleus ratio (Donnadieu et al., 1994). Naive T cells are antigen-inexperienced and exist in an inactive, or quiescent, state defined by rare mitotic divisions, minor transcriptional activity, and absence of any effector function (Hamilton & Jameson, 2012). Because of their low activity level, naive T cells have limited metabolic needs, which they fulfill by using oxidative phosphorylation as the predominant metabolic pathway (Chapman et al., 2020). Although devoid of any effector function, naive T cells constitute a sustained homeostatic pool of potential effector cells that will only acquire their function upon antigen recognition, thereby avoiding any spontaneous activity that could become detrimental to the host and would result in the depletion of the naive T cell reservoir (Tzachanis et al., 2004).

Antigen presentation to antigen-specific naive T cells initiates effector T cell differentiation with T cell activation, a process achieved by the combination of three distinct, but synergistic signals **(Figure 1.4)** (Smith-Garvin et al., 2009). The first signal directly derives from the recognition of the cognate antigen presented on MHC molecules (Cone, 1981). MHC class I is recognized by $CD8^+$ T cells and is expressed by all nucleated cell types, while $CD4^+$ T cells recognize MHC class II, which is expressed only on antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells, as well as by thymic epithelial cells (Rudolph et al., 2006). Antigens recognized by $CD4^+$ T cells consist of exogenous peptides that get processed in acidified endocytic vesicles (endocytic pathway) into fragments of up to 18 residues-long, whereas $CD8^+$ T cells recognize short, 8-10 residues-long endogenous peptides generated in the cytosol (Stern & Wiley, 1994). The interaction between the TCR and peptide-antigen:MHC complex is stabilized by co-receptor binding to constant domains on MHC molecules (Gao et al., 2002). This interaction further induces conformation changes in the intracellular portion of the co-receptor, which is connected to the kinase Lck, and brings Lck close to the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 complex, which constitutes the signaling component of the TCR (Samelson et al., 1986; Artyomov et al., 2010). Lck phosphorylates the CD3 ITAMs, which trigger TCR signaling, a highly complex series of signal transduction pathways that initiate T cell activation (Glaichenhaus et al., 1991). These pathways promote the nuclear translocation and subsequent activity of transcription factors that are already expressed in naive T cells, but remain in the cytosol in an inactive state until they receive activating signals to translocate into the nucleus and transcribe genes required for the initiation of T cell differentiation

(Figure 1.5). For instance, calcium influx, triggered upon TCR stimulation, activates calmodulin, which interacts with and thereby activates the phosphatase calcineurin (Jain et al., 1993). In turn, calcineurin dephosphorylates the transcription factor NFAT, which is initially sequestered in the cytoplasm, thereby enabling NFAT nuclear translocation and transcriptional activity. Similarly, the MAPK pathway leads to c-Jun phosphorylation, which interacts with phosphorylated c-Fos in the nucleus to form the active transcriptional complex AP-1 (Maciàn et al., 2001). Notably, NFAT and AP-1, by binding to common gene promoters, enhance the strength of TCR activation (Maciàn, 2005). On the other hand, the transcription factor NF-κB is kept in the cytoplasm when bound to the inhibitor IκB. TCR signaling events induce the phosphorylation and subsequent degradation of IκB, which enables the translocation of NF-κB to the nucleus, where it drives the transcription of target genes (Schulze-Luehrmann & Ghosh, 2006). Enabling the transcriptional activity of these three transcription factors thus initiates the expression of genes required for effector T cell differentiation in a timely manner, which is critical to achieve efficient T cell responses.

The second signal results from interactions between co-stimulatory ligands and receptors, such as the CD28 receptor on the T cell and molecules of the B7 family on APCs, and leads to the amplification of the TCR signal, and in the generation of mitogenic, metabolic, and survival signals (Boise et al., 1995; Pagès et al., 1996, Vella et al., 1998; Frauwirth et al., 2002). In fact, absence of co-stimulation during T cell activation elicits a dysfunctional state known as anergy (Harding et al., 1992).

The third signal is mediated by cytokines, which are secreted by multiple immune and non-immune cell types, including APCs, and differ in nature according to the type of

pathogen detected by the host (Curtsinger et al., 1999). For instance, CD28-dependent co-stimulation of activated T cells leads to the expression of IL-2 and the IL-2 receptor high-affinity chain, IL-2Rα, also known as CD25. Binding of IL-2 to its high-affinity receptor is critical during early T cell activation as it promotes T cell survival, growth, and clonal expansion (Pape et al., 1997, Refaeli et al., 1998). Cytokine signaling also plays a decisive role in the acquisition of effector T cell function, which will be discussed later.

1.3.2 Metabolic reprogramming and proliferation

In response to these three stimulatory signals, activated T cells exit quiescence and undergo dramatic transcriptional, morphological, and metabolic transitions, as they prepare to rapidly proliferate in order to produce a large progeny of antigen-specific effector T cells that will mount an efficient response against the antigen (Butz & Bevan, 1998; Frauwirth et al., 2002). The intensified rates of RNA and protein synthesis result in the accumulation of newly produced molecules in the cytoplasm of activated T cells, which leads to cell growth characterized by a greater cytoplasm-to-nucleus ratio (Donnadieu et al., 1994). The exit of activated T cells from quiescence is also marked by their entry into the cell cycle, which promotes the rapid expansion of antigen-specific T cell clones (Butz & Bevan, 1998). This increased cellular activity requires greater amounts of energy and biomacromolecules, which activated T cells satisfy by switching their metabolism from oxidative phosphorylation to glycolysis. In addition to providing ATP more rapidly, glycolysis also results in the production of a large variety of metabolites necessary for the cellular processes needed for T cell proliferation and

functional differentiation, including DNA replication and biomacromolecules synthesis (Chapman et al. 2020).

The initiation of the metabolic switch and cell cycle entry requires the expression of the transcription factor Myc, which is rapidly induced upon T cell activation by both TCR and co-stimulatory signals, and enhanced by IL-2 signaling at later stages of T cell activation (Reed et al., 1985; Wang et al., 2011). On the one hand, Myc drives the expression of glucose transporters and glycolytic enzymes, which contributes to increased glucose uptake and ATP production by glycolysis. On the other hand, Myc also directly induces the expression of cyclins, cyclin-dependent kinases, and transcription factor of the E2F family, while repressing cell cycle inhibitors, thereby promoting cell cycle progression from the G1 to S phase (Grandori & Eisenman, 1997). However, because the continuous expression of Myc is detrimental to T cell survival, Myc is only expressed in a transient manner, but its activity is preserved by upregulation of the transcription factor AP-4, a direct Myc target gene which maintains the metabolically active and proliferative state of differentiating T cells after Myc downregulation (Butz & Bevan, 1998; Chang et al., 2000; Hoffman & Liebermann, 2008; Jung et al., 2008; Chou et al., 2014).

1.3.3 The acquisition of effector T cell function

1.3.3.1 CD4[+] helper T cells

As mentioned earlier, cytokine signaling plays an important role in the acquisition of effector T cell function. In the case of CD4[+] T cells, which have the potential to differentiate into one of several helper T (Th) cell lineages, cytokines present during CD4[+] T cell activation play a central role in inducing specific Th differentiation programs

(Zhu et al., 2010). Each Th cell subset is tailored to respond effectively to distinct types of pathogens, as they each express a signature transcription factor which controls the expression of specific cytokines **(Figure 1.6)** (Zhu & Paul, 2008). The cytokines IL-12 and IFNγ drive the Th1 differentiation program, which is characterized by the expression of the transcription factor T-bet and secretion the cytokine IFNγ. Th1 cells contribute to the clearance of intracellular pathogens and tumor cells by promoting the phagocytic activity and antigen-presenting function of macrophages, as well as the function of CD8$^+$ cytotoxic T lymphocytes (CTLs) (Hsieh et al., 1993; Szabo et al., 2000; Lighvani et al., 2001). Th2 differentiation is induced by IL-4 signaling, which induces the expression of the transcription factor GATA-3 and secretion of the cytokines IL-4, IL-5, and IL-13. Th2 cells activate eosinophils, basophils, and mast cells, and elicit mucus secretion in goblet cells and smooth muscle contraction, all of which work towards the elimination of extracellular pathogens (Swain et al., 1990; Zheng et al., 1997, Kishikawa et al., 2001; Min et al., 2004). The Th17 lineage is promoted by IL-6 in combination with TGF-β, which drives RORγt expression, secretion of IL-17, IL-21, and IL-22, and helps in the clearance of mucosal bacteria and fungi by activating neutrophils and inducing antimicrobial peptide secretion in epithelial cells (Aggarwal et al., 2003; Mangan et al., 2006; Zhou et al., 2007; Yang et al., 2008). Follicualr T (T$_{FH}$) cells are generated upon exposure to IL-6 alone, express the transcription factor Bcl-6, and can secrete different cytokines, depending on the type of immune response, including IL-21, IFNγ, IL-4, IL-5, and TGF-β (Yu et al., 2009). The role of T$_{FH}$ cells is to specify the production of high-affinity antigen-specific antibodies of the appropriate isotype by B cells, phenomena known as somatic hypermutation and immunoglobulin isotype switching, which are

dependent on the interaction between the co-stimulatory molecules CD40 and CD40L (Kawabe et al., 1994; Xu et al., 1994). Thus, through cytokine secretion and cell-cell interactions, Th cells play a critical role in the establishment, coordination, and potentiation of adaptive immune responses by enabling or enhancing the function of immune and non-immune cells, as well as by attracting appropriate immune cells to the site of infection, hence their "helper" appellation. A distinct type of effector CD4$^+$ T cells, regulatory T (Treg) cells, are induced upon exposure to TGF-β and IL-2, express FOXP3, and secrete the immunosuppressive cytokines IL-10 and TGF-β to regulate the magnitude and intensity of immune responses and prevent detrimental consequences on the host (Sakaguchi et al., 1995; Chen et al., 2003; Fontenot et al., 2003; DiPaolo et al., 2007; Kim et al., 2007). The regulation of Th cell responses is essential, as spontaneous or sustained Th cell activity can result in the development of pathologies, such as hypersensitivities and autoimmune disorders (Ohashi, 2002). However, despite undergoing negative selection in the thymus and being kept in check by Tregs, some autoreactive T cell clones are able to escape these regulatory mechanisms and drive autoimmune diseases upon recognition of self-peptide antigens (Yui et al., 1990; Kariv et al., 1993).

1.3.3.2 CD8$^+$ cytotoxic T lymphocytes

Following antigen encounter, CD8$^+$ T cells differentiate into cytotoxic T lymphocytes (CTLs) in the presence of the cytokine IL-2 (Andrus et al., 1984). As the name suggests, CTLs are able to kill targets cells, specifically those infected by intracellular pathogens, such as viruses, or that are cancerous, thus directly contributing to infection clearance **(Figure 1.7)** (Sawamura et al., 1989; Dharakul et al., 1990; Harty et al., 1992; Rodrigues et al., 2003). Differentiation of naive CD8$^+$ T cells into CTLs

requires a complex regulatory interplay between the transcription factors Notch, Runx3, T-bet, Eomesodermin (Eomes), Blimp-1, Id2, and Zeb2 (Pearce et al., 2003; Sullivan et al., 2003; Cannarile et al., 2006; Cho et al., 2009; Cruz-Guilloty et al., 2009; Kallies et al., 2009; Backer et al., 2014; Dominguez et al., 2015). This differentiation program induces the expression by CTLs of the effector molecules Perforin, Granzyme A, and Granzyme B, as well as the death receptor ligand FasL, and the cytokines IFNγ and TNFα (Ruby & Ramshaw, 1991; Suda & Nagata, 1994; Janas et al., 2005, Brehm et al., 2005). Effector molecules are contained within lysosome-derived structures, called secretory granules, and mediate direct cytolysis of target cells upon release, which is triggered upon antigen recognition by CTLs on target cells through TCR:MHC I interactions, a process known as degranulation (Peters et al., 1991). Degranulation involves the reorientation of the Golgi apparatus towards the target cell, where perforin forms a pore in the target cell membrane to enable the entry of the proteases Granzymes A and B (Masson & Tschopp, 1985). Granzyme A is a tryptase that can initiate caspase-independent cell death by cleaving NDUFS3, a protein from complex I of the mitochondrial electron chain, resulting in the disruption of the NADH oxidation process and reactive oxygen species production (Martinvalet et al., 2008). Other identified substrates of Granzyme A are histones and proteins involved in DNA repair pathways, which sensitizes target cells to DNA damage and degradation upon Granzyme A-mediated cleavage (Lieberman, 2010). Granzyme B is a serine-protease that induces apoptosis by cleaving inactive initiator pro-caspases-8 and -10, as well as inactive executioner pro-caspases-3 and -7 into their active forms, which contributes to cell disassembly (Adrain et al., 2005). In human but not in mouse, Granzyme B is also able to induce the intrinsic pathway of apoptosis by cleaving

the pro-apoptotic protein BID, leading to cytochrome c release (Sutton et al., 2000, Casciola-Rosen et al., 2007). Similarly to granule-mediated cytolysis, expression of FasL on CTLs can trigger apoptosis of the target cell through the extrinsic apoptotic pathway by binding to its cognate receptor Fas on the target cell (Rouvier et al., 1993; Suda & Nagata, 1994). In contrast to effector molecules, cytokines secreted by CTLs do not contribute directly to target cell killing. Rather, IFNγ promotes CTL proliferation, motility, and cytotoxicity by stimulating perforin expression (Whitmire et al., 2005; Bhat al., 2017), potentiates Th1 cell differentiation and function, and enhances antigen presentation and Fas expression on target cells (Portnoy et al., 1989; Früh & Yang, 1999; Müllbacher et al., 2002). CTLs are able to produce both soluble and membrane-bound forms of TNFα. Soluble TNFα activates and recruits immune cells to the site of infection, and enhances T cell survival and CTL cytotoxicity (Bancroft et al., 1989; McKenzie et al., 2006; Calzascia et al., 2007; Allie et al., 2013). On the other hand, membrane-bound TNFα has been suggested to participate in "slow lysis" of target cells upon interaction with its receptor TNFR1 (Ratner & Clark, 1993).

1.4 T cell motility, homing and migration to tissues

Efficient immune responses require T cells to adopt appropriate trafficking patterns throughout their lifetime. T cell motility arises from the combination of three distinct processes: autonomous cell locomotion, physical guidance, and response to chemical signals (Krummel et al., 2016). Autonomous cell locomotion depends on the cell-intrinsic motility machinery, including the actin cytoskeleton and motor proteins, while physical guidance is controlled by interactions with the extracellular matrix and surrounding cells, and the response to chemical signals relies on the expression of

chemokine receptors on the T cell surface **(Figure 1.8)**. Depending on their stage of differentiation, T cells express distinct chemokine receptors that sense specific chemokines. The signaling events resulting from these interactions lead to the rearrangement of the actin cytoskeleton, which enables the migration of T cells towards peripheral tissues, where these cells participate in processes ranging from development in the thymus, homing, antigen encounter, and ongoing immune responses at inflamed sites (Griffith et al., 2014). For instance, mature naive T cells traveling in the bloodstream express CCR7, the receptor that recognizes and guides these cells towards gradients of the chemokines CCL19 and CCl21, which are secreted by stromal cells of the secondary lymphoid organs, such as the spleen and lymph nodes, where antigen presentation occurs (Gunn et al., 1998; Förster et al., 1999; Luther et al., 2000). T cells constantly interact with endothelial cells through repeated bind-release events between adhesion molecules, such as L-selectin (CD62L), and their ligands, a process termed "rolling" (Kishimoto et al., 1990). T cells that respond to CCL19/CCL21 upregulate surface adhesion molecules that will bind more strongly to the endothelium, and undergo rearrangement of their actin cytoskeleton that promotes the transmigration of these cells from the bloodstream into the secondary lymphoid organs through specialized blood vessels, high endothelial venules (HEV) (Stein et al., 2000). Engagement of the TCR with peptide antigen:MHC results in the transient upregulation of CD69, as well as the reciprocal downregulation of S1PR1 on activated T cells, which results in their retention in secondary lymphoid organs during activation and differentiation (Matloubian et al., 2004; Shiow et al., 2006). TCR engagement is also accompanied by the reciprocal downregulation of CD62L and upregulation of the adhesion molecule CD44 (DeGrendele et al., 1996). After

differentiation, effector T cells downregulate CD69 expression and restore S1PR1 expression, which facilitates their exit from the secondary lymphoid organs and re-entry into the circulation through diapedesis by following gradients of the S1P1R ligand S1P (Pappu et al., 2007; Bankovich et al., 2010). Many cell types at sites of ongoing immune responses secrete chemokines that will also generate gradients, and result in the recruitment of the appropriate types of effector T cells, which will be specifically responsive to these signals through the expression of the corresponding cognate chemokine receptors (Kagnoff & Eckmann, 1997; Griffith et al., 2014). Once in the inflamed tissue, effector T cells keep following chemokine gradients, and come to an arrest upon antigen re-encounter.

1.5 Memory T cell formation

Upon entry into inflamed sites, large numbers of antigen-specific T cells, peaking at about a week after antigen challenge, accomplish their effector function and participate in antigen clearance (De Boer et al., 2003). After resolution of an infection, these cells are no longer needed, and may even be detrimental to the host, due to the tissue toxicity of the effector molecules and cytokines they secrete (Hutcheson et al., 2008). Accordingly, antigen clearance is followed by the withdrawal of co-stimulatory signals and cytokines, including the survival factor IL-2, which will cause approximately 90% of expanded effector T cell clones to undergo apoptosis mediated by the pro-apoptotic factor Bim, an event known as contraction (Badovinac et al., 2002; Pellegrini et al., 2003, McKinstry et al., 2010). Because they express high levels of the chemokine receptor IL-7α (CD127), Bcl-2, and other anti-apoptotic proteins, the remaining 10% are able to survive and differentiate into long-lived memory T cells. These cells preserve the memory

of the initial antigen exposure and respond more rapidly and efficiently to subsequent challenges with the same antigen **(Figure 1.9)** (Akbar et al., 1993; Mueller et al., 1996, Grayson et al., 2000; Wojciechowski et al., 2006; Whitmire et al., 2008). Memory CD4[+] T cell differentiation remains poorly understood, but shares many similarities with the mechanisms of CD8[+] T cell memory formation, which have been more extensively studied (Seder & Ahmed, 2003). In contrast to effector T cells, which are highly active and glycolytic, memory T cells exist in a quiescent state characterized by the preferential utilization of oxidative phosphorylation and fatty acid oxidation, but retain an intermittent self-renewal capacity, and can survive in the absence of interaction with their cognate antigen (Seder & Ahmed, 2003; Pearce et al., 2009; van der Windt et al., 2012).

Several models have proposed distinct explanations for the determination of this terminal-effector (contraction-sensitive)-versus-memory (contraction-resistant) T cell fate dichotomy (Kaech & Cui, 2012). In the asymmetric cell fate model, a single T cell precursor gives rise to both a terminal effector and a memory T cell precursor at the time of the first division during antigen presentation, which depends on APC-proximal versus -distal T cell identity, respectively (Chang et al., 2007). The underlying uneven acquisition of factors following cell division programs the daughter cells to adopt distinct differentiation programs (Arsenio et al., 2014). For instance, the proximal daughter cell obtains more of T-bet, as well as the high-affinity alpha chain of the IL-2 receptor (IL-2Rα or CD25), the signaling of which negatively regulates IL-7Rα (CD127), and thus contributes to inducing terminal effector differentiation (Xue et al., 2002; Kalia et al., 2010; Chang et al., 2011). In contrast, the signal-strength model suggests that the strength of signals 1, 2, and 3 initially received by a T cell during antigen presentation determines

T cell fate. That is, a weak signal strength generates memory-like T cells, while strong signals induce terminal effector-like T cells (Stemberger et al., 2007; Gerlach et al., 2010). In the decreasing-potential model, the cumulative amounts of signals 1, 2, and 3 received throughout the effector T cell stage will similarly shape T cell fate (Kaech & Ahmed, 2001; Harbertson et al., 2002; Williams et al., 2008; Plumlee et al., 2013). Finally, the T memory stem cell model proposes the existence of a subset of memory T cells with stem-like properties that can maintain the memory T cell pool, while being able to give rise to effector T cells (Gattinoni et al., 2011; Graef et al., 2014).

T cells that will become terminal effectors or memory cells can already be distinguished during the primary immune response by specific markers. Memory precursor effector cells (MPECs) highly rely on IL-7 signaling for their maintenance, and accordingly express high levels of its cognate receptor IL-7Rα (CD127), whereas short-lived effector cells (SLECs) express high levels of the terminal effector marker KLRG1 (Kaech et al., 2003; Kondrack et al., 2003; Seddon et al. 2003, al; Lenz et al., 2004; Joshi et al., 2007). Memory T cell differentiation also requires the expression of transcription factors, including Eomes, FOXO1, and Id3, as well as IL-15 and Wnt signaling, which induces the expression of the transcription factors TCF-1 and LEF1 (Zhang et al., 1998; Becker et al., 2002; Gattinoni et al., 2009; Zhou et al., 2010; Yang et al., 2011; Zhou & Xue, 2012; Hess Michelini et al., 2013). However, the memory T cell pool is heterogeneous, and as such exhibit distinct differentiation capacities, proliferative potentials, effector function, and homing characteristics (Buchholz et al,. 2013). T memory stem cells (T_{SCM}) are multipotent and can give rise to all types of memory T cells **(Figure 1.10)**, and accordingly exhibit a high proliferative and self-renewal ability, but

do not display any effector function, and reside in the secondary lymphoid organs (Gattinoni et al., 2011; Lugli et al., 2013). On the contrary, tissue-resident memory T cells (T_{RM}) display the lowest differentiation capacity, but proliferate rapidly and exhibit strong effector function upon recall, and accordingly occupy non-lymphoid organs, such as the lung, liver, skin, and adipose tissue (Beura et al., 2019). In between T_{SCM} and T_{RM} are central-memory (T_{CM}) and effector-memory T (T_{EM}) cells, T_{CM} being less differentiated than T_{EM}, which can be distinguished by their level of CD62L expression (Sallusto et al., 1999; Ahmadzadeh et al., 2001; Pepper & Jenkins, 2011). T_{CM} exhibit high CD62L expression, and accordingly reside in the secondary lymphoid organs. These cells also have a higher proliferative potential and can give rise to T_{RM} that populate the skin (Osborn et al., 2019), but display weaker effector function upon antigen re-challenge (Wherry et al., 2003). T_{EM} express low levels of CD62L, and are found in the circulation (Masopust et al., 2001). This memory T cell subset has a lower proliferation ability than T_{CM}, but elicits a more potent effector response upon antigen re-encounter (Sallusto et al., 2004; Olson et al., 2013; Roberts et al., 2014). Despite their apparent more differentiated phenotype, T_{RM} and T_{EM} have the capacity to give rise to T_{CM} that populate the secondary lymphoid organs (Wherry et al., 2003; Bromley et al., 2013; Beura et al., 2018).

1.6 T cell exhaustion

In distinction from acute infections during which antigen is effectively cleared by functional effector T cells and memory T cells are formed following contraction, antigen persists during chronic infections and cancer, resulting in an unresponsive state known as exhaustion which has been more extensively studied in CD8[+] T cells than in CD4[+] T cells (Moskophidis et al., 1993; Crawford et al.; 2014). The exhausted state is characterized by

17

compromised effector T cell proliferation, cytotoxic function, and pro-inflammatory cytokine production, as well as by the loss of memory T cell potential (Zajac et al., 1998; Fuller et al., 2003; Wherry et al., 2004; Angelosanto et al., 2012). T cell exhaustion is established progressively through continuous TCR signaling provoked by recurring contacts with the lingering antigen, during which T cells upregulate co-inhibitory receptors, such as PD-1, TIM-3, LAG-3, CD160, 2B4, and CTLA-4 **(Figure 1.11)** (Day et al., 2006; Grosso et al., 2007; Wherry, 2007; Cai et al., 2008; Jones et al., 2008; Bucks et al., 2009; Razziorrouh et al., 2010). During acute infections, these surface molecules get expressed transiently on activated T cells following antigen encounter, and promote self-tolerance by negatively regulating T cell activation and proliferation when bound to their ligand, hence their designation as "immune checkpoints" (Brunet et al., 1987; Triebel et al., 1990; Maïza et al., 1993; Valiante & Trinchieri, 1993; Agata et al., 1996; Monney et al., 2002; Probst et al., 2005). In contrast, during chronic inflammation, exhausted T cells continuously express high levels of these receptors, which can inhibit T cell responses by transmitting negative signals or inducing cell death upon ligand binding (Blackburn et al., 2009). Cognate ligands for these co-inhibitory receptors are upregulated in response to immune signals, such as cytokines, on APCs, as well as on non-hematopoietic cells, including endothelial cells, and are also abundantly expressed in immunosuppressive environments typical of chronic infections and cancer (Mazanet & Hughes, 2002; Liang et al., 2003; Rodig et al., 2003; Mühlbauer et al., 2006). For instance, PD-1 suppresses effector T cell function after interaction with PD-L1 or PD-L2, TIM-3 elicits calcium-dependent cell death when bound to Galectin-9, and CD160 inhibits T cell activation upon binding herpesvirus entry mediator (HVEM) (Freeman et

al., 2000; Latchman et al., 2001; Iwai et al., 2002; Zhu et al., 2005; Mühlbauer et al., 2006; Cai et al., 2008; Mengshol et al.; 2010; Malissen et al., 2019). Other co-inhibitory receptors function by competing for co-stimulatory ligand binding (Blackburn et al., 2009). Specifically, LAG-3 competes with its homolog CD4 for binding to MHC-II, 2B4 competes with CD2 for interacting with CD48, and CTLA-4 competes with CD28 for binding to the B7-family molecules (Baixeras et al., 1992; Brown et al., 1998; Fallarino et al, 1998). Suppression of T cell function following co-inhibitory receptor signaling occurs in a sequential fashion, starting with compromised IL-2 production, proliferation, motility, and cytotoxicity, followed by the loss of the ability to produce TNFα and IFNγ, and eventually concluding with the death of the exhausted T cells (Wherry et al., 2003; Zinselmeyer et al., 2013).

The establishment of the exhausted state in T cells is induced by a dysregulated terminal effector differentiation program derived from persistent TCR stimulation that results in aberrant expression of multiple transcription factors, including BATF, Blimp-1, Eomes, Id2, IRF4, NFAT, TOX, as well as transcription factors from the NR4A family, which in turn control the expression of some co-inhibitory receptors (Cannarile et al., 2006; Wherry, 2007; Oestreich et al., 2008; Shin et al., 2009; Quigley et al., 2010; Buggert et al., 2014; Martinez et al., 2015; Man et al., 2017; Li et al., 2019; Seo et al., 2019). In recent years, the possibility of reverting exhausted T cells back to a functional state has been demonstrated by inhibiting the interaction between co-inhibitory receptors and their ligands using blocking antibodies, thereby preventing co-inhibitory receptor signaling (Leach et al., 1996; Barber et al., 2006; Sakuishi et al,. 2010; Wolchok et al., 2013). This strategy, termed "checkpoint blockade immunotherapy" (CBI), has since

been developed for human therapeutic purposes, and many "checkpoint inhibitors", mainly targeting PD-1, PD-L1, and CTLA-4, have already been approved for the treatment of various types of cancer (Hargadon et al., 2018). However, most patients are resistant to CBI, and some of them experience detrimental effects due to the tissue toxicity of these treatments, especially when used in combination (Topalian et al., 2012; Wolchok et al., 2013; Topalian et al., 2014; Larkin et al., 2015). Studies investigating the possibility of using CBI to treat chronic infectious diseases, such as HIV, hepatitis B, tuberculosis, and malaria, are ongoing (Wykes & Lewin, 2018).

Aside from co-inhibitory receptors, anti-inflammatory cytokine signaling also participates in the induction of T cell exhaustion, as these are abundant during chronic infections and in the tumor microenvironment (Landskron et al., 2014; Beltra & Decaluwe, 2016). Two potent immunosuppressive cytokines are IL-10 and TGFβ, which are secreted by Tregs, but also other T cells, including exhausted T cells and APCs (Tinoco et al., 2009; Ng & Oldstone, 2012; Parish et al., 2014). These cytokines contribute to the suppression of effector T cell function both directly, by restraining T cell proliferation, cytokine production, and cytotoxicity, as well as indirectly, by preventing the upregulation of MHC molecules on APCs, and by suppressing the response of other innate immune cells that normally support effector T cell function, notably macrophages (Geiser et al., 1993; Lee et al., 1997; Corinti et al., 2001; Thomas & Massagué, 2005; Wilson & Brooks, 2011; Stephen et al., 2014; Ip et al., 2017). Similarly to CBI, blocking IL-10 signaling during chronic viral infection using neutralizing antibodies has been shown to restore effector T cell function and result in viral clearance (Brooks et al., 2006; Ejrnaes et al., 2006). However, TGFβ blockade alone

fails to ameliorate effector T cell function in chronic disease, and needs to be combined with CBI to enhance T cell-mediated anti-tumor responses (Garidou et al., 2012; Mariathasan et al., 2018; Tauriello et al., 2018).

1.7 Regulation of T cell differentiation by microRNAs

1.7.1 Biogenesis and function of microRNAs

MicroRNA (miRNA)-mediated RNA interference is one of the most well-studied post-transcriptional mechanisms that potently regulates gene expression (Elbashir et al., 2001; Kim et al., 2008). MiRNAs are short, 20-22 nucleotide-long, non-coding RNAs that bind target mRNAs in a sequence-specific manner to inhibit translation by inducing target mRNA degradation or ribosome stalling (Lee et al., 1993; Lee & Ambros, 2001; Bartel et al., 2009). Several hundreds of miRNAs have been identified in the mammalian genome, and many of these are evolutionarily conserved (Lagos-Quintana et al., 2001; Lewis et al., 2003). Single miRNAs have many target mRNAs, and individual mRNAs can be directly regulated by multiple miRNAs (Lim et al., 2005; Friedman et al., 2009). MiRNAs are involved in the control of a broad range of cellular functions, including cell differentiation, cell cycle progression and apoptosis, which makes these an essential component of the cellular machinery, as they confer robustness to a wide range of biological processes, including development and immunity (Abbott et al., 2005; Farh et al., 2005; Stark et al., 2005). It has been estimated that miRNAs control the expression of approximately one third of the total human gene pool, including genes involved in immune cell differentiation (Lewis et al., 2005). However, dysregulation of miRNA-mediated RNA interference has been shown to result in pathologies, such as

developmental defects, cancer, obesity, and autoimmune diseases (Zhao et al., 2007; Wang et al., 2008; Frost & Olson, 2011; Xu et al., 2013).

MiRNAs can be encoded by genes located either in intergenic regions of the genome, where they rely on their own promoter for transcription, or within gene introns, in which case the transcription of these miRNAs is controlled by the promoter of the neighboring gene (Rodriguez et al., 2004; Baskerville & Bartel, 2005). Because in this situation both the adjoined gene and the miRNA are transcribed at the same time, mRNA splicing and processing is needed to separate the miRNA from the gene mRNA (Kim & Kim, 2007; Melamed et al., 2013; Ramalingam et al., 2014). In addition, miRNA genes can include either a single miRNA (monocistronic) or a cluster of multiple miRNAs (polycistronic), which all share the same promoter (Altuvia et al., 2005; Ozsolak et al., 2008).

MiRNA gene transcription, mediated by RNA polymerases II and III, produces long primary miRNA (pri-miRNA) transcripts, consisting of a succession of hairpin structures **(Figure 1.12)** (Lee et al., 2004; Borchert et al., 2006). Pri-miRNAs are then cleaved by the ribonuclease (RNase) III enzyme Drosha of the microprocessor complex in the nucleus into precursor miRNAs (pre-miRNAs), which are composed of 60-70 nucleotide-long single hairpin structures (Lee et al., 2003). Pre-miRNAs are next exported from the nucleus to the cytoplasm by Exporting 5, where they undergo cleavage of their hairpin loop, mediated by the RNase III enzyme Dicer, which generates mature miRNA duplexes (Knight & Bass, 2001; Yi et al., 2003). Only one strand of this double-stranded mature miRNA, the guide strand, will bind to the RNAse III enzyme Argonaute (AGO) and other proteins to generate the RNA-induced silencing complex (RISC), while

the other strand, the passenger strand, will be degraded (Williams & Rubin, 2002; Kloosterman et al., 2004; Rand et al., 2004; Leuschner et al., 2006; Ameres et al., 2007; MacRae et al., 2008).

MiRNAs recognize their target mRNAs through their seed region, located at their 5' end at positions 2-8, and miRNAs with conserved seed regions are grouped into families which share common mRNA targets (Lewis et al., 2005; Bartel, 2018). RISC antagonizes protein translation by mediating the degradation of target mRNAs when the loaded miRNA seed region is perfectly complementary to the mRNA, or by ribosome stalling in cases of partial mRNA-miRNA seed region complementarity (Vella et al., 2004; Bagga et al., 2005; Baek et al., 2008). MiRNA seed regions most commonly bind sequences canonically located within the 3' untranslated region (UTR) of mRNAs, but some miRNAs binding sites can be found in non-canonical sites outside the 3' UTR, such as within the mRNA 5' UTR or coding sequence (CDS) (Lai, 2002; Lytle et al., 2007; Majoros & Ohler, 2007; Schnall-Levin et al., 2010). Interestingly, recent studies have described a role for sequences outside the seed region in miRNA-mediated RNA interference (Grimson et al., 2007; Brancati & Großhans, 2018).

1.7.2 Role of microRNAs in CD4[+] T cell differentiation

The crucial regulatory functions of miRNAs in many aspects of T cell development, homeostasis, and differentiation, have been extensively studied (Baumjohann & Ansel, 2013; Wells et al., 2020). Pioneer studies using ectopic overexpression of miRNAs demonstrated that miRNAs were able to direct hematopoietic lineage differentiation (Chen et al., 2004). Moreover, T cell-specific deletion of factors involved in miRNA biogenesis, such as Dicer and Drosha, led to diminished survival and

proliferation of activated T cells (Cobb et al., 2005), but also resulted in enhanced Th1 cell differentiation and inflammatory disease with reduced T_{reg} presence, which suggested that miRNAs can control the quiescent state of naive T cells (Muljo et al., 2005; Cobb et al., 2006; Chong et al., 2008). Subsequent studies identified regulatory roles for individual miRNAs at distinct steps of CD4[+] T cell differentiation (Baumjohann & Ansel, 2013). For instance, miR-155 and miR-181a enhance CD4[+] T cell activation and clonal selection (Banerjee et al., 2010; Palin et al., 2013), while miR-146a inhibits it (Yang et al., 2012). Moreover, the miR-17-92 miRNA cluster promotes CD4[+] T cell proliferation and survival, ultimately resulting in lymphoproliferative disease and autoimmunity (Xiao et al., 2008). Furthermore, Th1 cell differentiation is enhanced by the miR-17-92 cluster and miR-155, but negatively regulated by miR-29, miR-125b, and miR-146a (O'Connell et al., 2010; Jiang et al., 2011; Rossi et al., 2011; Steiner et al., 2011; Yang et al., 2012). MiR-21 facilitates the differentiation of Th2 cells, while miR-27, miR-126, and miR128 prevents it (Mattes et al., 2009; Guerau-de-Arellano et al., 2011; Sawant et al., 2013). Th17 cell differentiation is increased by miR-155, miR-301a, and miR-326, but suppressed by miR-10a (Du et al., 2009; O'Connell et al., 2010; Mycko et al., 2012; Takahashi et al., 2012). The differentiation of T_{FH} cells is positively regulated by the miR-17-92 cluster, whereas miR-10a prevents it (Baumjohann et al., 2013; Takahashi et al., 2012). Finally, T_{reg} cell differentiation is promoted by miR-10a, miR-146a and miR-155, but repressed by the miR-17-92 cluster (Lu et al., 2009; Lu et al., 2010; Jiang et al., 2011; Jeker et al., 2012; Takahashi et al., 2012).

1.7.3 Role of microRNAs in CD8[+] cytotoxic T lymphocyte differentiation

The importance of miRNA-mediated regulation of CD8[+] T cell responses was demonstrated through CD8-specific deletion of Dicer, which led to enhanced activation and proliferation, but also diminished survival, effector function, and migratory potential (Zhang & Bevan, 2010). A later study found that Dicer deletion at the naive stage, but not at the activated stage, potentiated CD8[+] T cell responses through upregulation of Granzyme B, IFNγ, as well as Eomes and its direct transcriptional target Perforin, due to the absence of mature miR-139 and miR-342 (Trifari et al., 2013). Other miRNAs, such as miR-15a/16 and miR-150, were also identified as critical drivers and suppressors of CTL differentiation, respectively (Smith et al., 2015; Yang et al., 2017). Interestingly, some miRNAs that play a role in the regulation of Th1 cell differentiation also control CTL differentiation, such as the miR-17-92 cluster, miR-29, and miR-155, which inhibit the T-bet/IFNγ signaling axis that both CTL and Th1 differentiation programs rely on (Ma et al., 2011; Wu et al., 2012; Gracias et al., 2013).

Although studies profiled the expression of a wide array of miRNAs at different stages of CD8[+] T cell differentiation, the molecular mechanisms underlying the miRNA-mediated regulation of the CD8[+] T cell memory versus terminal-effector fate specification remain largely unknown (Wu et al., 2007). Some miRNAs, such as miR-143, miR-155, and the miR-200 family, have been shown to promote memory CD8[+] T cell formation (Tsai et al., 2013; Guan et al., 2018; Zhang et al., 2018). In contrast, other miRNAs, including miR-15/16, the miR-17-92 cluster, miR-23a, miR-31, and miR-150, have been found to skew the CD8[+] T cell fate towards terminal effectors and exhausted cells (Wu et al., 2012; Khan et al., 2013; Lin et al., 2014; Ban et al., 2017; Chen et al.,

2017; Moffett et al., 2017; Gagnon et al, 2019). Despite the fact that all these studies significantly contributed to the understanding of the miRNA-mediated control of T cell differentiation and fate determination, whether specific miRNAs consistently play regulatory roles throughout T cell differentiation remains an outstanding question in the field.

1.8 The lethal-7 (let-7) family of microRNAs

1.8.1 Phylogeny and genomic organization of let-7 microRNAs

Lethal-7 (let-7) miRNAs were discovered in the nematode *Caenorhabditis elegans* and were initially described as critical regulators of larval development, in which let-7 deficiency results in premature death (Meneely & Herman, 1984; Lee et al., 1993; Reinhart et al., 2000; Slack et al., 2000). The let-7 family of miRNAs was later found to be highly conserved across bilaterian animals, in which more let-7 isoforms, or members, are found in comparison to *C. elegans*, due to multiple let-7 miRNA gene duplications (Pasquinelli et al., 2000; Hertel et al., 2012). In the mouse, 14 paralog let-7 genes produce 8 mature let-7 members, while in humans 12 miRNA genes give rise to 10 mature let-7 members (Lagos-Quintana et al., 2002). Paralog let-7 miRNA genes are located on distinct chromosomes and different members are identified by a unique letter (e.g. let-7a, let-7b). In addition, identical mature let-7 miRNAs can be generated from distinct let-7 genes, which is indicated by a unique number after the let-7 member name (e.g. let-7a-1, let-7a-2) (Ambros et al., 2003; Roush & Slack, 2008).

1.8.2 Regulation of let-7 microRNA expression

Let-7 miRNAs are expressed in numerous different cell types and control many biological processes, such as cell survival, metabolism, and differentiation (Büssing et al., 2008; Zhu et al., 2011). Particularly, let-7 miRNAs were found to silence the mRNAs of cell cycle progression regulator genes such as Cdc25a and Cdk6, as well as genes involved in carcinogenesis, including HMGA2, Myc, and Ras, demonstrating their robust tumor-suppressing function (Mayr et al, 2007; Büssing et al., 2008). The tight and complex regulation of let-7 miRNAs is well illustrated by the differences in its expression levels in distinct cell types (Reinhardt et al., 2000, Johnson et al., 2003). For instance, in embryonic stem cells, mature let-7 miRNAs cannot be detected, but both pri- and pre-let-7 forms are present, which indicates that let-7 expression is regulated at the post-transcriptional level, at different steps of let-7 biogenesis (Suh et al,. 2004; Thomson et al., 2006). Well-studied factors that inhibit mature let-7 miRNA expression are the fetal proteins Lin28 and Lin28B, which bind to a specific and conserved sequence in the stem-loop region of pri- and pre-let7, thereby preventing Drosha- and Dicer-mediated processing (Piskounova et al., 2008; Viswanathan et al., 2008). Moreover, binding of Lin28 to pre-let-7 leads to the recruitment of the terminal uridylyl transferases (TUTases) TUT4 and Zcchc11, which polyuridylate pre-let-7, thereby marking it for degradation by the exoribonuclease Dis3l2 (Heo et al., 2008; Hagan et al., 2009; Heo et al., 2009; Piskounova et al,. 2011; Chang et al., 2013). Lin28-mediated let-7 miRNA repression therefore constitutes a potent regulatory mechanism during early embryonic development, and has also been shown to play an important role in establishing neonatal immunity (Wang et al., 2016).

1.8.3 Let-7 microRNAs in immunity

In contrast to embryonic stem cells, let-7 miRNAs are highly expressed in lymphocytes (Kuchen et al., 2010). As such, many lymphocyte subsets have been shown to be dependent on let-7 miRNAs for their development, homeostasis, and differentiation. For instance, the upregulation of let-7 miRNAs during natural killer T (NKT) cell development in the thymus is necessary for the differentiation of IFNγ-producing effectors (Pobezinsky et al., 2015). In the periphery, let-7 miRNA expression is required for the survival and maintenance of the quiescent phenotype in naive T cells (Wells et al., 2017; Pobezinskaya et al., 2019). During lymphocyte activation, let-7 miRNAs have been shown to inhibit the metabolic reprogramming of both B cells and $CD8^+$ T cells by negatively regulating the expression of the transcription factor Myc and the glycolytic enzyme hexokinase 2 (Wells et al., 2017; Jiang et al., 2018). Moreover, let-7 miRNAs have been shown to play a regulatory role in $CD8^+$ cytotoxic T lymphocyte (CTL) function by directly targeting the transcription factor Eomes, as well as in $CD4^+$ helper T cell responses during HIV infection and airway inflammation by regulating the expression of the cytokines IL-10 and IL-13, respectively (Polikepahad et al., 2010; Kumar et al., 2011; Swaminathan et al., 2012; Wells et al., 2017). One study also proposed a regulatory role for let-7f expression in Th17 cell function in women with severe asthma (Newcomb et al., 2015). In addition, the exosome-mediated transfer of let-7 miRNAs to various immune cells has been proposed as a suppressive mechanism used by regulatory T (Treg) cells, and has also been reported to inhibit the generation and function of Treg cells (Okoye et al., 2014; Kimura et al., 2018). Although many studies have described regulatory roles for let-7 in T cells, the molecular mechanisms underlying

the control of T cell differentiation and the determination of memory versus terminal effector/exhausted T cell fate remains unclear.

1.9 Rationale, central hypothesis, specific aims, and significance

We have previously shown that all let-7 family members are abundantly expressed in naive $CD8^+$ T cells, but get dramatically downregulated upon antigen recognition, which enables CTL differentiation and function (Wells et al., 2017). Based on these findings, the central hypothesis of this dissertation is that let-7 acts as a central regulator of effector T cell differentiation and fate specification. This main hypothesis will be investigated through two specific aims. The first aim will be to determine the regulatory role of let-7 miRNAs during $CD4^+$ T helper cell differentiation. The second aim will elucidate the signaling pathways controlled by let-7 miRNAs in memory versus terminal-effector/exhausted $CD8^+$ T cell fate specification. Completion of the proposed aims will identify let-7 miRNAs as key regulators of T cell responses. Determining the let-7-mediated regulatory mechanisms governing the differentiation of $CD4^+$ T helper cells and specifying the differentiation of $CD8^+$ T cells towards the memory or terminal effector/exhausted fate will significantly advance our understanding of the post-transcriptional mechanisms controlling the function and fate of T cells. Moreover, this research has the potential to establish let-7 miRNAs as a promising novel therapeutic target or cargo that can adjust T cell responses in the contexts of infectious diseases, cancer, and autoimmunity.

Figure 1.1: Innate and adaptive immune cells and response kinetics. Innate processes of the immune system constitute the first defenses against pathogens, while adaptive mechanisms of immunity, which are mediated by activated lymphocytes, are slower to appear. ILC, innate lymphoid cell; NK, natural killer. Adapted from Cellular and Molecular Immunology, 8th edition, Figure 1-1.

Figure 1.2: The innate and adaptive immune systems show distinct kinetics and amplitudes in primary and secondary response to antigen. The primary adaptive immune response to antigen is low in both duration and amplitude, while subsequent exposure to the same antigen results in secondary responses. These secondary responses recruit memory cells and are thus faster to appear, stronger in amplitude, and more specific to the antigen than was the primary response (dark blue). In contrast, innate immune responses, which do not form immunological memory, remain unchanged every time the antigen is encountered (light blue). Adapted from Cellular and Molecular Immunology, 8th edition, Figure 1-8.

Figure 1.3: T cell selection in the thymus. T cell progenitors migrate from the barrow to the thymus, where they become thymocytes and complete their development by rearranging their T cell receptor genes and undergoing repertoire selection. (a & b) During the process of positive selection, immature T cells that are able to bind self-MHC receive survival signals, while those which fail to recognize self-MHC are eliminated through the induction of apoptosis. (c) Next, the process of negative selection selects self-tolerant thymocytes by providing survival signals, whereas those which react too strongly with self-antigen are deleted from the repertoire by apoptosis.

Figure 1.4: Efficient activation of naive T cells by antigen-presenting cells require three types of signals. Upon antigen recognition in the context of peptide:self-MHC complex by the T cell receptor (TCR) on the surface of an antigen-presenting cell (APC), the CD3 complex of the TCR and the co-receptor (CD4 in this example) send signal 1 to the activated T cell (arrow 1). Signal 2 is transmitted by ligation of co-stimulatory receptors, expressed on T cells (CD28 in this example), to their ligand expressed by the APC (molecules of the B7 family in this example) and provide survival, metabolic, and mitogenic signals (arrow 2). Signal 3 is mediated by cytokine signaling, which is important for directing the differentiation of T cells, particularly in the case of CD4[+] T cells which can differentiate into multiple distinct lineages, depending on the nature of signal 3. Adapted from Owen Kuby Immunology, 7th edition, Figure 11-3.

Figure 1.5: Engagement of the T cell receptor results in the activation of transcription factors that initiate the differentiation process. Model representing signaling events occurring upon T cell receptor (TCR) engagement. Recognition of cognate antigen by TCR, which is associated to the CD3 complex, elicits a cascade of phosphorylation events eventually leading to the activation and nuclear translocation of the transcription factors NFκB, NFAT, and AP-1, the latter being a complex comprising c-Fos and c-Jun. Adapted from Cellular and Molecular Immunology, 8th edition, Overview Figure 3-5.

Figure 1.6: CD4⁺ T cells can differentiate into multiple subsets of helper T cells. Each helper T cell lineage is induced by distinct cytokines and specialize in enhancing the function of or recruiting other cells that will directly participate in the elimination of different types of pathogens. Adapted from Janeway's Immunobiology, 9th edition, Figure 9.30.

Figure 1.7: CD8+ T cells differentiate into cytotoxic T lymphocytes that can directly kill target cells. Differentiated cytotoxic CD8+ T lymphocytes (CTLs) specialize in lysing cancerous cells and cells infected with intracellular pathogens upon recognition of pathogen fragments presented on MHC class I molecules on the surface of target cells. Adapted from Janeway's Immunobiology, 9th edition, Figure 9.22.

Figure 1.8: Effector T cells reach sites of ongoing immune responses by following physical and chemical cues that induce rearrangements in their actin cytoskeleton.
Effector T cells express surface receptors for cell-adhesion molecules such as selectins and integrins, as well as chemokine receptors. Interactions with cells expressing ligands for selectins and integrins, as well as chemokine gradients, direct the migration of these cells to inflames tissues. Adapted from Cellular and Molecular Immunology, 8th edition, Figure 3-3.

Figure 1.9: Phases of a T cell response in the context of acute infections. Antigen-specific T cells undergo massive clonal expansion upon activation, but most effector T cells undergo apoptosis upon antigen clearance during the contraction phase, while only a small T cell population remains and form long-lasting immunological memory. Adapted from Kaech & Cui, 2012.

Figure 1.10 Heterogeneity of the memory T cell pool. Multiple memory T cell subsets can differentiate from naïve T cells and exhibit distinct differentiation potential and preferential anatomic location. T memory stem cells (T_{SCM}) are multipotent, reside in the secondary lymphoid organs, and have the greatest proliferative, self-renewal and differentiation capacity. On the other hand, tissue-resident memory T (T_{RM}) cells show the lowest differentiation ability and populate peripheral tissues. In between T_{SCM} and T_{RM} are central (T_{CM}) and effector (T_{EM}) memory T cells, which can be distinguished by differential expression of CD62L. T_{CM} express high levels of CD62L and thus reside in the secondary lymphoid organs, while T_{EM} exhibit low expression of CD62L and are found in the circulation. Despite their apparent more differentiated phenotype, T_{RM} and T_{EM} can give rise to T_{CM} that migrate to the lymphoid organs. Effector T cells (T_{Eff}) cells represent terminally-differentiated cells, which eventually undergo cell death. is one outcome of increased antigen exposure and proliferation. Adapted from Farber et al., 2014.

Figure 1.11: Chronic inflammation induces T cell exhaustion. In contrast to acute infection, during which antigen gets cleared efficiently, antigen lingers during persistent viral infection and in the tumor microenvironment, which recurrently signals to the T cell receptor, resulting in the upregulation of co-inhibitory receptors, such as PD-1, LAG-3, 2B4, and CD160. In turn, ligation of these receptors to their cognate ligands present in these immunosuppressive environments transmits negative signals to the T cell, leading to the loss of effector function and memory potential. Adapted from Wherry, 2007.

Figure 1.12: MicroRNA biogenesis and function. MicroRNAs (miRNAs) are encoded as genes in the genome and are transcribed by RNA polymerase II into long primary miRNAs (pri-miRNAs), which undergo a first cleavage by the endonuclease Drosha in the nucleus, resulting in the generation of precursor miRNAs (pre-miRNAs.) These pre-miRNAs then get exported by Exportin 5 into the cytoplasm , where the endonuclease Dicer will cleave the loop region to produce mature miRNA duplexes. Only the guide strand will be incorporated into the RNA-induced silencing complex (RISC) and participate in the silencing of messenger RNA (mRNA) targets, while the passenger strand will undergo degradation. Adapted from Baumjohann & Ansel, 2013.

CHAPTER 2

DIFFERENTIATION OF PATHOGENIC TH17 CELLS IS NEGATIVELY REGULATED BY LET-7 MICRORNAS IN A MOUSE MODEL OF MULTIPLE SCLEROSIS

2.1 Introduction

CD4[+] helper T cells play essential roles in the function of the immune system by orchestrating immune responses against a broad range of pathogens, supporting the function of CD8[+] T cells, helping B cells produce antibodies, activating macrophages and granulocytes, eliciting memory responses, as well as by regulating the magnitude and persistence of immune responses (Zhu & Paul, 2008). However, the dysregulation of CD4[+] T cell responses causes aberrant effector CD4[+] T cell activity, including overproduction of pro-inflammatory cytokines, eventually resulting in the manifestation of autoimmune disorders, such as multiple sclerosis (MS) and related diseases (Wucherpfennig, 2001; Goodnow, 2007). MS is a chronic inflammatory disease of the central nervous system (CNS) that affects approximately 2.5 million people worldwide, with a strong predominance in women (Compston & Coles, 2008). The animal model of neuroinflammation, experimental autoimmune encephalomyelitis (EAE), recapitulates the pathological and clinical symptoms of MS and has been extensively used to study this disorder (Rangachari & Kuchroo, 2013). In both MS and EAE, autoreactive CD4[+] type-17 helper T (Th17) cells that are generated by exposure to IL-23 and IL-1β (Langrish et al., 2005; Sutton et al., 2006, Komuczki et al., 2019) migrate to the CNS and cross the blood-brain barrier by following gradients of chemokines secreted by CNS-resident innate lymphoid cells (Kwong et al., 2017). The transcription factor Bhlhe40, which is

induced in encephalitogenic Th17 by IL-1β signaling, positively regulates the secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) (Martínez-Llordella et al., 2013; Lin et al., 2014; Lin et al., 2016). GM-CSF is a proinflammatory cytokine essential for disease induction as it promotes the activation, differentiation, and recruitment of monocytes and dendritic cells to the CNS, as well as the mobilization of the local microglia (McQualter et al., 2001; Ponomarev et al., 2007; Codarri et al., 2011; El-Behi et al., 2011; Spath et al., 2017; Komuczki et al., 2019). In turn, GM-CSF-stimulated glial and dendritic cells secrete IL-6 and IL-23, thereby reinforcing the differentiation and maintenance of pathogenic Th17 cells (Sonderegger et al., 2008). Inflammatory myeloid cells produce reactive oxygen species and cytokines that cause neuron demyelination and axonal damage, which leads to the disruption of neuronal signaling, eventually resulting in disabling physical symptoms, including progressive loss of motor function, which reflect the extent of neurodegeneration (Compston & Coles, 2008).

About a third of the total risk factors for MS development can be attributed to genetic variation, and genome-wide association studies have identified more than 100 different genetic variants associated with MS and related autoimmune disorders (Lock et al., 2002; Duerr et al., 2006; Stuart et al., 2010; International Multiple Sclerosis Genetics Consortium et al., 2013). Many of these susceptibility factors consist of variants of genes which are involved in Th17 pathways and contain single nucleotide polymorphisms within the untranslated regions (UTRs) of their mRNA. Given that UTR sequences are targeted by factors controlling mRNA translation and stability (Barrett et al., 2012), the post-transcriptional dysregulation of these genes, particularly by miRNAs, may be

responsible for the aberrant cytokine responsiveness and effector function observed in autoreactive Th17 cells. In fact, altered miRNA expression has been shown in encephalitogenic Th17 cells from active MS lesions, and specific upregulated miRNAs, such as miR-155 and miR-326, were demonstrated to promote the pathogenic Th17 phenotype (Du et al., 2009; Junker et al., 2009; O'Connell et al., 2010; Ma et al., 2014).

Although regulatory roles have been described for let-7 miRNAs in the control of the differentiation of cytotoxic CD8$^+$ T cells and various subsets of effector CD4$^+$ T cells (Polikepahad et al., 2010; Kumar et al., 2011; Swaminathan et al., 2012; Okoye et al., 2014; Wells et al., 2017; Kimura et al., 2018), the precise contribution of let-7 miRNAs in autoreactive Th17 cell differentiation and MS pathogenesis has been controversial (Ma et al., 2014). Disease-promoting roles have been proposed for individual let-7 miRNA family members (Junker et al., 2009; Guan et al., 2013; Kimura et al., 2018), but other reports have suggested that let-7 miRNA expression may confer protection against MS (Cox et al., 2010; Martinelli-Boneschi et al., 2012). Therefore, the objective of this project was to investigate the role of let-7 miRNAs in the regulation of pathogenic Th17 cell generation and identify the underlying molecular mechanisms.

We demonstrated that the differentiation of pathogenic Th17 cells in EAE requires the downregulation of let-7 miRNAs in naive CD4$^+$ T cells upon antigen stimulation. Specifically, we found that high let-7 miRNA expression in activated CD4$^+$ T cells prevents EAE development by inhibiting the clonal expansion, IL23R/IL-1R1-dependent acquisition of pathogenic function, and CCR2/CCR5-dependent chemokine-mediated migration of Th17 cells to the CNS, while depletion of let-7 miRNAs enhances Th17 cell pathogenicity and aggravates EAE. Therefore, let-7 miRNA delivery to pathogenic Th17

cells may be a promising therapeutic strategy for the treatment of autoimmune diseases such as MS.

2.2 Results

2.2.1 Let-7 expression in CD4[+] T cells inhibits EAE development

The role of let-7 miRNAs in the differentiation of pathogenic CD4[+] T cells remains unclear (Junker et al., 2009; Cox et al., 2010; Martinelli-Boneschi et al., 2012; Guan et al., 2013; Ma et al., 2014; Kimura et al., 2018). Previously, we have shown that let-7 miRNA expression in CD8[+] T cells prevents the differentiation of CTLs and must be downregulated during antigen stimulation (Wells et al., 2017). Here, we found that, similarly to CD8[+] T cells, naive CD4[+] T cells expressed high levels of let-7, which were rapidly downregulated upon activation, proportionally to both the duration **(Figure 2.1A)** and strength of TCR stimulation **(Figure 2.1B)**. Based on these observations, we hypothesized that let-7 miRNAs inhibit the differentiation of CD4[+] T cells and may therefore compromise the generation of pathogenic Th17 cells, thereby suppressing the development of autoimmune disorders.

To test our hypothesis *in vivo*, we acquired mice with a doxycycline-inducible let-7g transgene (Let-7Tg) in order to maintain high let-7g expression in activated CD4[+] T cells (Zhu et al., 2011). We used EAE susceptibility as a readout of CD4[+] T cell differentiation in doxycycline- or vehicle-treated Let-7Tg and WT control mice immunized with the peptide antigen myelin oligodendrocyte glycoprotein, residues 35-55 (MOG$_{35-55}$), in complete Freund's adjuvant (CFA). Only doxycycline-treated Let-7Tg mice developed a significantly milder disease in comparison to control mice **(Figure**

2.2A). Strikingly, the number of mononuclear cells **(Figure 2.2B)** and CD4$^+$ T lymphocytes **(Figure 2.2C)** that infiltrated the CNS was strongly diminished in these mice. Overall, the frequencies and numbers of cytokine-producing CD4$^+$ T cells were greatly reduced in the CNS of doxycycline-treated Let-7Tg mice **(Figure 2.2D)**. In addition, *in vitro* MOG$_{35-55}$-restimulated splenocytes from the same mice secreted less IL-17, IFNγ, and GM-CSF in comparison to that of control mice **(Figure 2.2E)**. We obtained similar results using WT and Let-7Tg mice on a 2D2 RAG2-deficient (2D2Rag2KO) background, in which all CD4$^+$ T cells express the 2D2 transgenic T cell receptor that recognizes the MOG$_{35-55}$ peptide (Bettelli et al., 2003) **(Figure 2.3)**. To assess whether the absence of let-7 miRNAs in CD4$^+$ T cells leads to aggravated EAE, we used Lin28 transgenic mice (Lin28Tg) with T-cell specific ectopic overexpression of the fetal protein Lin28B, which blocks let-7 miRNA biogenesis (Heo et al., 2008; Piskounova et al., 2008; Newman et al., 2008; Heo et al., 2009; Piskounova et al., 2011; Pobezinsky et al., 2015). 2D2Rag2KO Lin28Tg mice developed stronger symptoms of EAE, during which the phenotype of cytokine-producing pathogenic CD4$^+$ T cells was enhanced, even though the extent of CD4$^+$ T cell infiltration into the CNS was unchanged in comparison to controls **(Figure 2.3)**, suggesting that let-7 miRNAs inhibit EAE development.

To determine whether the let-7 miRNA-mediated protection against EAE is CD4$^+$ T cell-intrinsic, we adoptively transferred naive 2D2Rag2KO CD4$^+$ T cells from Let-7Tg, Lin28Tg and control mice, into Rag2KO recipient mice that were subsequently immunized with MOG$_{35-55}$ in CFA. At day 9 post-EAE induction, disease outcome **(Figure 2.4A)**, CNS infiltration **(Figure 2.4B)**, as well as frequencies and numbers of

cytokine-producing donor 2D2Rag2KO CD4$^+$ T cells that had differentiated into pathogenic CD4$^+$ T cells **(Figures 2.4C and 2.4D)** recapitulated the results from our previous EAE experiments **(Figures 2.2 and 2.3)**. These results demonstrate that let-7 abolishes the development of EAE in a CD4$^+$ T cell-intrinsic manner.

Although Let-7Tg CD4$^+$ T cells were largely absent in the CNS of EAE-induced mice, they were found in the spleen, albeit at lower numbers than control cells **(Figure 2.4E)**. To explain this phenotype, we proposed four potential mechanisms: 1) poor cell survival, 2) reduced proliferation, 3) compromised differentiation, or 4) impaired trafficking.

2.2.2 Let-7 promotes survival but restricts the proliferation of activated CD4$^+$ T lymphocytes

To examine whether let-7 miRNAs negatively regulate the survival of activated CD4$^+$ T cells during EAE, we measured the survival rate of Let-7Tg, Lin28Tg and WT control CD4$^+$ T cells activated *in vitro* for 3 days. Interestingly, Let-7Tg cells survived better than their WT counterparts, while the recovery of Lin28Tg lymphocytes was significantly lower **(Figure 2.5A)**. In fact, these results are in agreement with our recently published findings in naive CD4$^+$ and CD8$^+$ T cells (Pobezinskaya et al., 2019), suggesting that let-7 expression also supports the survival of activated CD4$^+$ T cells. Thus, the reduced numbers of CNS-infiltrated Let-7Tg CD4$^+$ T cells recovered during EAE cannot be explained by increased cell death.

Based on our data in CD8$^+$ T cells (Wells et al., 2017), we tested whether let-7 miRNAs suppress CD4$^+$ T cell proliferation as well. To address this question, Let-7Tg, Lin28Tg and WT control naive CD4$^+$ T cells were labeled with CellTrace Violet (CTV)

and activated *in vitro*. We observed that Let-7Tg CD4$^+$ T cells proliferated less than activated control T cells, while Lin28Tg CD4$^+$ T lymphocytes proliferated more **(Figure 2.5B)**, even though this effect was less pronounced than in CD8$^+$ T cells. These findings suggest that let-7 restricts CD4$^+$ T cell proliferation, which, in turn, can contribute to the diminished numbers of CNS-infiltrated Let-7Tg CD4$^+$ T cells observed in EAE.

Given that Let-7Tg CD4$^+$ T cells exhibit a lower proliferative potential, we investigated whether let-7 inhibits the expression of genes that regulate cell cycle progression and the metabolic switch in antigen-stimulated CD4$^+$ T cells. Similarly to the results observed in CD8$^+$ T cells, activated Let-7Tg CD4$^+$ T cells expressed low levels of cyclin D2 (*Ccnd2*), cyclin-dependent kinase 6 (*Cdk6*), phosphatase Cdc25a (*Cdc25a*), and ubiquitin-conjugating enzyme Cdc34 (*Cdc34*), as well as the transcription factor *Myc* and several Myc target genes involved in glycolysis and protein synthesis (*Tfap4*, *Glut3*, *Hk2*, *Ldha*, *Qars*, *Yars*), while in Lin28Tg cells those genes were derepressed (Galaktionov et al., 1996; Johnson et al., 2007; Legesse-Miller et al., 2009; Wells et al., 2017) **(Figures 2.5C and 2.5D)**. These results indicate that let-7 miRNAs may restrain CD4$^+$ T cell proliferation by suppressing the metabolic switch and cell cycle progression. These data also suggest that Lin28Tg CD4$^+$ T cells are able to elicit aggravated EAE because of their proliferative and metabolic advantage over WT CD4$^+$ T cells, despite a survival defect.

2.2.3 Let-7 negatively regulates the differentiation of pathogenic Th17 cells

Alternatively, the low frequency of effector CD4$^+$ T cells in the CNS of Let-7Tg mice during EAE could be due to a defect in autoreactive CD4$^+$ T cell differentiation. Therefore, we tested the ability of let-7 miRNAs to influence the differentiation of

pathogenic Th17 cells. Naive 2D2Rag2KO CD4$^+$ T cells with different levels of let-7 expression were polarized *in vitro* towards the TGFβ-independent pathogenic Th17 lineage in the presence of the cytokines IL-1β, IL-6, and IL-23 (Chung et al., 2009; Ghoreschi et al., 2010). We confirmed that, while the expression of let-7 miRNAs was downregulated over time in 2D2Rag2KO WT cells **(Figure 2.6A)**, the expression of the let-7g transgene remained high in 2D2Rag2KO Let-7Tg cells before and after differentiation **(Figure 2.6B)**, and Lin28 expression could only be detected at substantial levels in 2D2Rag2KO Lin28Tg cells **(Figure 2.6C)**. Notably, very low frequencies of Let-7Tg pathogenic Th17 cells expressed IL-17 and GM-CSF as compared to WT controls, whereas Lin28Tg cells had increased percentages of cells that expressed these cytokines **(Figure 2.7A)**. This trend was also observed in the frequencies of IL-17$^+$GM-CSF$^+$ double positive cells, suggested to be the most pathogenic Th17 cells in EAE (Ponomarev et al., 2007; Sonderegger et al., 2008; Codarri et al., 2011; El-Behi et al., 2011; Spath et al., 2017). Furthermore, the extent of *Il17a* and *Csf2* mRNA expression correlated with the percentage range of IL-17A- and GM-CSF-producing cells **(Figure 2.7B)**. These results suggest that let-7 expression in CD4$^+$ T lymphocytes prevents the differentiation of pathogenic Th17 cells.

We observed that the expression of the cytokine receptors *Il1r1* and *Il23r*, both previously described as essential for the differentiation of pathogenic Th17 cells in EAE (Langrish et al., 2005; Matsuki et al., 2006; McGeachy et al., 2009; El-Behi et al., 2011; Komuczki et al., 2019), was profoundly inhibited in Let-7Tg and derepressed in Lin28Tg pathogenic Th17-polarized cells. Analysis of *Il1r1* and *Il23r* mRNA sequences revealed multiple potential let-7 binding motifs which can be directly targeted by let-7 **(Figure**

2.7C). In fact, such regulation was previously proposed for the mRNA of *IL23R* in human memory CD4[+] T cells (Li et al., 2011). Interestingly, although miRNA binding sites are most commonly found within the 3' UTRs of mRNAs, some let-7 binding sites were located within the coding sequence of mouse and human *Il1r1* and *Il23r* mRNAs. On the other hand, the expression of the transcription factor *Bhlhe40*, shown to be induced by IL-1R signaling (Lin et al., 2016) and essential for the pathogenicity of Th17 cells in EAE (Martínez-Llordella et al., 2013; Lin et al., 2014), was only slightly reduced in Let-7Tg pathogenic Th17-polarized cells, but drastically enhanced in Lin28Tg lymphocytes **(Figure 2.7B)**. Let-7 miRNAs did not repress the expression of other genes controlling the Th17 cell fate, such as *Il6ra*, *Il6st*, *Irf4* and *Rorc*, and had little impact on *Stat3* expression **(Figure 2.7D)**, even though *Il6ra*, *Stat3*, and *Rorc* are predicted direct let-7 targets (Agarwal et a;., 2015). Thus, these results suggest that let-7 miRNAs negatively regulate the acquisition of pathogenic Th17 phenotype and may act through directly targeting *Il1r1* and *Il23r* transcripts.

Of note, in agreement with previously published reports (Polikepahad et al., 2010; Kumar et al., 2011; Swaminathan et al., 2012), we confirmed that let-7 expression also blocks the differentiation of Th0, Th1, and Th2 cells. Surprisingly, let-7 did not suppress the differentiation of non-pathogenic Th17 cells generated in the presence of IL-6 and TGF-β **(Figures 2.8A and 2.8B)** (McGeachy et al., 2007). Moreover, there was no obvious effect of let-7 on the generation of iTregs in polyclonal polarization cultures, but in monoclonal 2D2Rag2KO cells iTreg differentiation was quite substantially inhibited by let-7 **(Figures 2.8A and 2.8B)**. The expression level of *Ifng*, *Il4*, and *Csf2* mRNAs was consistent with the range of frequencies of IFNγ[+], IL-4[+] and GM-CSF[+] cells in Th0,

Th1, and Th2 cultures **(Figures 2.9)**. The expression of genes encoding lineage-specific cytokine receptors, such as *Il12rb2* (Th1) and *Il4ra* (Th2), as well as lineage-specific transcription factors, including *Tbx21* (Th1) and *Gata3* (Th2), and the transcription factor *Bhlhe40*, which has been shown to promote a proinflammatory phenotype in Th1 cells (Yu et al., 2018), was also repressed in Let-7Tg Th0, Th1, and Th2 cells, but increased in Lin28Tg cells. Thus, these results suggest a broader suppressive role for let-7 miRNAs in the regulation of effector CD4$^+$ T cell differentiation.

2.2.4 Let-7 prevents the chemokine-mediated migration of pathogenic Th17 cells

In addition to reduced proliferation potential and compromised differentiation, the lower number of effector Let-7Tg CD4$^+$ T cells in the CNS may be due to impaired cell trafficking. Antigen-stimulated T cells upregulate chemokine receptors to sense, migrate, and home to the location of inflammatory sites by following gradients of chemokines (Griffith et al., 2014). Two chemokine receptors, CCR2 and CCR5, have been shown to be critical for the migration of pathogenic T cells to the CNS and subsequently for EAE development (Fife et al., 2000; Szczuciński & Losy, 2007; Kara et al., 2015; Gu et al., 2016). To determine whether let-7 regulates CCR2 and CCR5 expression, we measured *Ccr2* and *Ccr5* mRNA levels in *in vitro*-generated 2D2Rag2KO pathogenic Th17 cells from WT, Let-7Tg and Lin28Tg mice. Surprisingly, the expression of both *Ccr2* and *Ccr5* was very low in Let-7Tg cells, while in Lin28Tg cells it was enhanced **(Figures 2.10A)**. Interestingly, we found potential let-7 binding sites within the mRNA of both *Ccr2* and *Ccr5* **(Figures 2.10B)**. To test whether these binding sites were functional, we transfected NIH3T3 fibroblasts, which have high endogenous expression of let-7 miRNAs, with dual luciferase vectors containing the wild-type sequence of these binding motifs. An ability

for let-7 to bind to both sites in the *Ccr2* mRNA, and one site in *Ccr5* mRNA was demonstrated by a significant reduction in luciferase activity **(Figures 2.10C)**. Mutation of these binding sites restored luciferase activity, confirming direct let-7 targeting. To test whether the let-7-mediated suppression of CCR2 and CCR5 expression is sufficient to prevent chemokine-mediated migration of Th17 cells towards their specific ligands, CCL2 and CCL4, we subjected *in vitro*-generated 2D2Rag2KO WT, Let-7Tg and Lin28Tg pathogenic Th17 cells to chemokine-mediated migration assays. Indeed, 2D2Rag2KO Let-7Tg cells exhibited compromised trafficking in response to both chemokines alone and in combination, while Lin28Tg cells migrated more efficiently than WT cells **(Figures 2.10D)**. Even though changes in cell motility can contribute to the difference in trafficking of Th17 cells, neither speed nor other intrinsic motility variables (track length, track straightness, and cell displacement) were negatively affected by let-7 expression **(Figures 2.11)**. To test whether let-7 miRNAs prevent the migration of pathogenic Th17 cells by inhibiting CCR2 and CCR5 expression, we overexpressed *Ccr2* or *Ccr5* in *in vitro*-generated 2D2Rag2KO WT and 2D2Rag2KO Let-7Tg pathogenic Th17 cells **(Figures 2.10E)** and tested the migratory potential of these cells using chemokine-mediated migration assays. Surprisingly, only overexpression of *Ccr5*, but not *Ccr2*, partially rescued the chemotaxis of 2D2Rag2KO Let-7Tg pathogenic Th17 cells towards CCL4, and enhanced the migration of 2D2Rag2KO WT pathogenic Th17 cells **(Figures 2.10F)**. These results strongly suggest that let-7 miRNAs restrict the CCR5-mediated migration of pathogenic Th17 cells by directly binding to *Ccr5* mRNA and inhibiting CCR5 expression, and additional let-7-mediated regulatory mechanisms are involved in the CCR2-mediated migration of these cells.

Altogether, our data show that let-7 miRNAs control the pathogenicity of Th17 cell in EAE by restricting their clonal expansion, inhibiting IL-1R1/IL-23R-dependent differentiation and preventing CCR2/CCR5-mediated migration to the CNS. As such, we propose that let-7 miRNAs may constitute a promising therapeutic target for the treatment of autoimmune diseases such as MS.

2.3 Discussion

In the present study, we have identified let-7 miRNAs as critical negative regulators of pathogenic Th17 cell differentiation and EAE development. Specifically, we found that, similarly to CD8$^+$ T cells (Wells et al., 2017), the expression of let-7 miRNAs in naive CD4$^+$ T cells is downregulated upon activation, which is essential for the clonal expansion, acquisition of pathogenic Th17 phenotype, and migration to the CNS. We demonstrate that high let-7 miRNA expression in activated CD4$^+$ T cells confers almost complete protection against EAE by preventing CD4$^+$ T cell pathogenicity and infiltration in the CNS, while in the absence of let-7 miRNAs the development of EAE is exacerbated.

The role of miRNAs in the regulation of T cell differentiation and function has been extensively studied (Baumjohann & Ansel, 2013). However, despite the growing number of reports describing miRNA dysregulation in MS patients (Ma et al., 2014), their contribution to MS pathogenesis remains largely unknown. Although let-7 is one of the most highly expressed miRNA families in CD4$^+$ T cells (Kuchen et al., 2010) and it has been shown to play regulatory roles in helper T cell responses (Polikepahad et al., 2010; Kumar et al., 2011; Swaminathan et al., 2012; Okoye et al., 2014; Kimura et al., 2018), published reports have yielded conflicting conclusions regarding the contribution of let-

7 miRNAs to Th17 cell pathogenicity during MS and EAE, and have remained unresolved (Ma et al., 2014). For example, Junker et al., 2009 found an upregulation of let-7c in MS lesions, while Kimura et al., 2018 described an increase in exosomal let-7i in MS patients and proposed a disease-promoting role for let-7i. On the other hand, Cox et al., 2010 showed a downregulation of let-7d, f, i, and, together with Martinelli-Boneschi et al., 2012, let-7g, in peripheral blood samples of MS patients, whereas Guan et al., 2013 reported a decrease in let-7g and let-7i in pathogenic CD4+ T cells in EAE, but at the same time let-7b, c, d, f and especially let-7e, were upregulated. Moreover, overexpression of let-7e in CD4+ T cells led to aggravated EAE, while knockdown of this miRNA attenuated the disease. Our findings are in discordance with Guan et al., 2013, since we show that EAE is aggravated upon adoptive transfer of Lin28Tg naive CD4+ T cells, in which all let-7 members are suppressed, into Rag2KO recipients. These disparities could be due to the use of different mouse models and treatments, as the cited study employed CD44 KO CD4+ T cells and lentivirus-mediated overexpression or silencing of let-7e expression, while we used transgenic mice with specific modulation of let-7 miRNA expression.

Our most striking finding is that let-7 miRNAs keep pathogenic CD4+ T cells from infiltrating the CNS. This effect was not due to a detrimental impact of let-7 miRNAs on the survival of activated CD4+ T cells, as maintenance of high let-7 miRNA expression improved the survival rate of activated CD4+ T cells, while let-7 deficiency caused an increase in cell death, which is consistent with our recently published observations in both naive CD4+ and CD8+ T cells that let-7 miRNAs promote

homeostatic survival through IL-7-independent stabilization of Bcl2 expression (Pobezinskaya et al., 2019).

In comparison to CD8$^+$ T cells (Wells et al., 2017), we observed only an incremental contribution of let-7 to the proliferation of CD4$^+$ T cells, despite the fact that we found let-7-mediated suppression of *Myc* and Myc target genes involved in glycolysis and protein synthesis. Furthermore, we demonstrate that let-7 miRNAs inhibit the expression of *Cdc25* and *Cdc34*, both of which are involved in the positive regulation of cell cycle progression and are also documented direct Myc and let-7 miRNA target genes (Gakationov et al., 1996; Johnson et al., 2007; Legesse-Miller et al., 2009). Thus, our results indicate that let-7 miRNAs may regulate cell cycle progression in CD4$^+$ T cells both directly by inhibiting *Cdc25a* and *Cdc34*, as well as indirectly through *Myc*.

It is well-known that regulatory T cells play an indispensable role in preventing autoimmunity (Wing & Sakaguchi, 2010). Based on our EAE experiments, it was reasonable to hypothesize that let-7 miRNA expression may enhance the development or function of Tregs while let-7 deficiency may compromise it. Surprisingly, our data show the opposite results, in which let-7 miRNAs inhibited the differentiation of monoclonal (2D2Rag2KO) iTregs *in vitro*. Furthermore, we noticed that, even though Lin28Tg CD4$^+$ T cells have an enhanced potential to differentiate into pathogenic Th17 cells, Lin28Tg mice are healthy and do not show any sign of autoimmunity, suggesting unaltered Treg function in the absence of let-7 miRNAs. Based on these observations we can conclude that let-7 expression does not enhance Treg differentiation or function. Therefore, in order to understand the observed phenotype, we focused our research on the role of let-7 miRNAs in the differentiation and function of pathogenic Th17 cells.

We show that let-7 miRNAs prevent the *in vitro* differentiation of naive CD4[+] T cells towards the pathogenic Th17 lineage, as reflected by the reduced frequencies of IL-17A[+], GM-CSF[+], and IL-17A[+]GM-CSF[+] cells, and the downregulation of the cytokine genes *Il17a* and *Csf2* (encoding GM-CSF), as well as the cytokine receptor genes *Il1r1*, and *Il23r*. Both IL-1R1 and IL-23R signaling play critical roles in Th17 cell differentiation, as mice deficient in either cytokine receptor or their respective ligand are completely resistant to EAE development (Cua et al., 2003; Matsuki et al., 2006; Sutton et al., 2006; McGeachy et al., 2009). It was later found that IL-23R signaling, as well as IL-1R-mediated expression of the transcription factor Bhlhe40, induces the expression of the cytokine GM-CSF, which stimulates peripheral inflammatory macrophages and promotes their migration to the CNS, where they are responsible for demyelination and neuroaxonal damage (El-Behi et al., 2011; Lin et al., 2016; Spath et al., 2017; Komuczki et al., 2019). Both Bhlhe40 and GM-CSF have been shown to be indispensable for EAE induction, since deficiency in either factor confers protection against EAE (McQualter et al., 2001; Ponomarev et al., 2007; Codarri et al., 2011; Martínez-Llordella et al., 2013; Lin et al., 2014), and elevated GM-CSF levels have been correlated with the active phase of MS (Carrieri et al., 1998). In addition, two earlier reports proposed a role for specific members of the let-7 family in the regulation of *Il23r* expression. Specifically, potential let-7f binding sites were identified in *IL23R* mRNA in human memory CD4[+] T cells (Li et al., 2011), and loss of let-7e- and let-7f-mediated regulation of a human *IL23R* gene variant was shown to be associated with inflammatory bowel disease, due to a polymorphism in the 3' UTR of *IL-23R* mRNA sequence (Zwiers et al., 2012). In our study, we found additional let-7 binding sites within the mRNA sequence of *Il23r* and

described the regulatory role of let-7 miRNAs in the context of pathogenic Th17 cell differentiation. Furthermore, we identified potential let-7 binding sites within the mRNA sequence of *Il1r1*, which has never been suggested to be a direct let-7 miRNA target. Therefore, we propose a novel let-7 miRNA-mediated regulatory mechanism in which let-7 miRNAs prevent both IL-1R1 and IL-23R expression in CD4[+] T cells by directly targeting their respective transcripts. Consistent with knock-out studies, CD4[+] T cells that do not express these cytokine receptors are unable to receive the necessary signals for the induction of Bhlhe40 and GM-CSF, thereby aborting the differentiation of encephalitogenic Th17 cells and EAE development.

We also tested whether the let-7 miRNA-mediated restriction of CNS infiltration by pathogenic CD4[+] T cells in EAE was due to the inhibition of cell migration to the CNS. Even though there was no difference in intrinsic motility of *in vitro*-generated pathogenic Th17 cells, we demonstrated, using transwell assays, that let-7 repressed the chemokine-mediated migration of these cells in response to the chemokines CCL2 and CCL4 by suppressing the expression of their cognate receptors CCR2 and CCR5. Although chemokine receptors are normally upregulated in differentiating T cells, enabling them to migrate and home to the location of ongoing immune responses, CCL2 and CCL4 have been detected at high levels in the cerebrospinal fluid, brain tissue, and active lesions of patients with MS, and elevated expression of both chemokine receptors on pathogenic CD4[+] T cells has been correlated with the active phase of MS (Sørensen & Sellebjerg, 2011; Teleshova et al., 2002; Szczuciński & Losy, 2007). In fact, the role of CCR2 and CCR5 in pathogenic CD4[+] T cell trafficking to the CNS in MS has been confirmed in EAE using receptor-deficient mice (Fife et al., 2000; Gu et al., 2016).

Despite the fact that the observed dysregulation of these receptors could be indirectly resulting from the let-7-mediated inhibition of pathogenic Th17 differentiation, we found that the mRNA sequences of both chemokine receptors contain potential let-7 miRNA binding sites. We showed, using luciferase reporter assays, that both sites identified in *Ccr2* mRNA, but only one site in *Ccr5* mRNA, are functional let-7-binding sites. Furthermore, we showed, in transwell assays using *Ccr2-* and *Ccr5-*overexpressing cells, that let-7 can inhibit the CCR5-, but not the CCR2-mediated migration of pathogenic Th17 cells. Therefore, we propose that let-7 miRNAs, in addition to possibly targeting *Il1r1* and *Il23r* transcripts, also inhibit CCR5-mediated chemotaxis by directly targeting *Ccr5* mRNA in pathogenic CD4$^+$ T cells. The repression of CCR2-mediated chemotaxis appears to be controlled by unknown let-7-mediated regulatory mechanisms, as it is not rescued upon CCR2 overexpression. In accordance with chemokine receptor deficiency studies in EAE, we can conclude that the inability to express the adequate levels of CCR5 suppresses the responsiveness of pathogenic Th17 cells to their respective ligands, thereby preventing their migration to the CNS and EAE induction.

Our study strongly highlights a potential therapeutic application for let-7 miRNAs in the treatment of autoimmune diseases such as MS. Besides, we show that let-7 expression did not interfere with the differentiation of non-pathogenic Th17 cells, which are generated with IL-6 and TGF-β (McGeachy et al., 2007). This was consistent with our findings that let-7 expression does not inhibit the expression of genes expressed in both Th17 subsets, such as the transcription factors *Rorc* and *Irf4*, as well as the IL-6 receptor components *Il6ra* and *Il6st*. In contrast to their pathogenic counterparts, these cells are not able to induce EAE, likely due to their inability to secrete GM-CSF in the

absence of IL-1β and IL-23 signaling. Instead, non-pathogenic Th17 cells secrete the anti-inflammatory cytokine IL-10, which antagonizes autoimmune responses (Kühn et al., 1993). Therefore, it would be interesting to test whether let-7 affects the normal function of these cells, the preservation of which would be important in the context of the proposed therapeutic strategy. Furthermore, because the phenotypic plasticity of the Th17 subset is well known, assessing whether the let-7-mediated inhibition of pathogenic Th17 differentiation can contribute to the conversion of these cells towards the non-pathogenic Th17 lineage in the presence of the adequate signals would also have significant implications for this therapy (McGeachy et al., 2007; McGeachy et al., 2009).

Altogether, our data demonstrate that let-7 miRNAs have a protective effect in EAE rather than a role in promoting disease pathogenesis. Therefore, delivering let-7 miRNAs to pathogenic Th17 cells may constitute a promising therapeutic strategy for the treatment of MS and related autoimmune diseases.

Figure 2.1 Let-7 miRNAs are highly expressed in naive CD4$^+$ T cells, but get downregulated upon activation, proportionally to the duration and strength of TCR stimulation. (A) Quantitative RT-PCR analysis of individual let-7 miRNA expression in naive CD4$^+$ T cells activated with plate-bound α-CD3 mAbs (5 µg/mL) and α-CD28 mAbs (5 µg/mL) for increasing time periods as indicated, presented relative to results obtained for the small nuclear RNA U6 (control) and normalized to the unstimulated (0 hours) control. **(B)** Quantitative RT-PCR analysis of individual let-7 miRNA expression in naive CD4$^+$ T cells activated for 24 hours with plate-bound α-TCR mAbs (as indicated) and α-CD28 mAbs (5 µg/mL), presented relative to results obtained for the small nuclear RNA U6 (control) and normalized to the unstimulated (0 hours) control. Data are from one experiment representative of two independent experiments (A, B; mean ± S.E.M. of technical triplicates).

A EAE

Mean clinical score vs Days post-induction

- WT no dox
- WT + dox
- Let-7Tg no dox
- Let-7Tg + dox

B Mononuclear cells (CNS)

Cell number (x10⁶)

Dox: − + − +
WT Let-7Tg

C CD4⁺ T cells (CNS)

Cell number

Dox: − + − +
WT Let-7Tg

- WT no dox
- WT + dox
- Let-7Tg no dox
- Let-7Tg + dox

D Gated on CD4⁺ T cells (day 9 post-EAE induction)

Isotype control | WT no dox | WT + dox | Let-7Tg no dox | Let-7Tg + dox

IL-17A vs IFNγ

| 0 | 0.4 | 27.7 | 15.1 | 49.7 | 13.2 | 10.4 | 9.9 | 29.5 | 4.6 |
| 0 | 0 | 20.8 | | 7.4 | | 36.6 | | 15.9 | |

IL-17A⁺ | IFNγ⁺ | IL-17A⁺IFNγ⁺

IL-17A vs GM-CSF

| 0 | 0.4 | 32.1 | 15.1 | 44.8 | 18.0 | 13.2 | 7.1 | 22.7 | 11.4 |
| 0 | 0 | 8.6 | | 5.1 | | 18.3 | | 4.6 | |

IL-17A⁺ | GM-CSF⁺ | IL-17A⁺GM-CSF⁺

IFNγ vs GM-CSF

| 0 | 0.4 | 17.6 | 16.2 | 7.9 | 11.5 | 21.4 | 21.9 | 13.6 | 6.8 |
| 0 | 0 | 4.9 | | 13.4 | | 5.5 | | 9.1 | |

IFNγ⁺ | GM-CSF⁺ | IFNγ⁺GM-CSF⁺

- WT no dox
- WT + dox
- Let-7Tg no dox
- Let-7Tg + dox

E ELISA on MOG-restimulated splenocytes from EAE-induced mice

IL-17 | IFNγ | GM-CSF

Concentration (ng/mL) vs MOG (μg/mL)

- WT
- Let-7Tg

61

Figure 2.2 Downregulation of let-7 miRNAs upon activation is required for CD4$^+$ T cell pathogenicity in EAE. (A) Mean clinical scores in vehicle- (no dox) treated wild-type (WT) (n=3) and Let-7Tg (n=4) mice or doxycycline- (+ dox) treated WT (n=7) and Let-7Tg (n=7) mice immunized with MOG$_{35-55}$ in complete Freund's adjuvant (CFA) and pertussis toxin (60 ng). **(B)** Number of total mononuclear cells at the peak of the disease (day 9-15 post-immunization) in the CNS of vehicle- (no dox) or doxycycline- (+ dox) treated WT versus Let-7Tg mice. **(C)** Number of CNS-infiltrated CD4$^+$ T cells at the peak of the disease (day 9-15 post-immunization) in vehicle- (no dox) or doxycycline- (+ dox) treated WT versus Let-7Tg mice as analyzed by flow cytometry. **(D)** Intracellular staining of CD4$^+$ T cells from the CNS of vehicle- (no dox) or doxycycline- (+ dox) treated WT versus Let-7Tg mice (left). Numbers indicate the frequencies of cytokine-positive cells within the indicated gates. Quantification of the numbers of cytokine-positive cells as assessed by flow cytometry for each staining strategy (right). **(E)** ELISA analysis of IL-17, IFNγ and GM-CSF concentration in the supernatants of splenocytes from vehicle- (no dox) or doxycycline- (+ dox) treated WT versus Let-7Tg mice harvested at the peak of disease (day 9-15 post-immunization) and restimulated for 5 days in vitro with 20 µg/mL MOG$_{35-55}$. $*$ $p < 0.05$, $**$ $p < 0.01$; $***$ $p < 0.001$, $****$ $p < 0.0001$ (A, B, C, D, E), employing two-way ANOVA (A) or compared with WT using two-tailed Student's t test (B, C, D, E). Data are from two combined independent experiments (A, B, C; mean ± S.E.M. of each population from all mice), from one experiment representative of two independent experiments (D; mean ± S.E.M. of each population from all mice), or from one experiment (C; mean ± S.E.M. of technical triplicates of each population from all mice).

A EAE

B Mononuclear cells (CNS)

C CD4$^+$ T cells (CNS)

- 2D2Rag2KO WT
- 2D2Rag2KO Let-7Tg
- 2D2Rag2KO Lin28Tg

D Gated on CD4$^+$ T cells (day 9 post-EAE induction)

Isotype control | 2D2Rag2KO WT | 2D2Rag2KO Let-7Tg | 2D2Rag2KO Lin28Tg

63

Figure 2.3 Let-7 miRNAs control the development of active EAE by negatively regulating the pathogenicity of monoclonal CD4$^+$ T cells. (A) Mean clinical scores in 2D2Rag2KO WT (n=4), 2D2Rag2KO Let-7Tg (n=5) and 2D2Rag2KO Lin28Tg (n=3) mice immunized with MOG$_{35-55}$ in complete Freund's adjuvant (CFA) and pertussis toxin (60 ng). **(B)** Number of total mononuclear cells at the peak of the disease (day 9 post-immunization) in the CNS of 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice. **(C)** Number of CNS-infiltrated CD4+ T cells at the peak of the disease (day 9-15 post-immunization) in 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice as analyzed by flow cytometry. **(D)** Intracellular staining of CD4$^+$ T cells from the CNS of 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice (left). Numbers indicate the frequencies of cytokine-positive cells within the indicated gates. * $p < 0.05$, ** $p < 0.01$; *** $p < 0.001$, **** $p < 0.0001$ (A, B, C, D), compared with WT employing two-way ANOVA (A) or using two-tailed Student's t test (B, C, D). Data are from two combined independent experiments (A, B, C; mean ± S.E.M. of each population from all mice) or one experiment representative of two independent experiments (D).

A EAE

B Mononuclear cells (CNS)

C CD4$^+$ T cells (CNS)

● 2D2Rag2KO WT → Rag2KO
● 2D2Rag2KO Let-7Tg → Rag2KO
● 2D2Rag2KO Lin28Tg → Rag2KO

D Gated on donor 2D2Rag2KO CD4$^+$ T cells (day 9 post-EAE induction)

Isotype control | WT | Let-7Tg | Lin28Tg

E Spleen cellularity   CD4$^+$ T cells (Spleen)

● 2D2Rag2KO WT → Rag2KO
● 2D2Rag2KO Let-7Tg → Rag2KO
● 2D2Rag2KO Lin28Tg → Rag2KO

65

Figure 2.4 Let-7 miRNAs negatively regulate CD4$^+$ T cell pathogenicity in a cell-intrinsic manner in EAE. (A) Mean clinical scores in Rag2KO recipient mice that received 2D2Rag2KO WT (n=7), 2D2Rag2KO Let-7Tg (n=7) or 2D2Rag2KO Lin28Tg (n=8) naive CD4$^+$ T cells (2-2.5 x 10^6 cells/recipient) and that were subsequently immunized with MOG$_{35-55}$ in complete Freund's adjuvant (CFA) and pertussis toxin (60 ng). **(B)** Number of total mononuclear cells at the peak of the disease (day 9 post-immunization) in the CNS of Rag2KO recipients that received 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells. **(C)** Number of CNS-infiltrated 2D2Rag2KO CD4+ T cells at the peak of the disease (day 9 post-immunization) in Rag2KO recipients transferred with 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells as analyzed by flow cytometry. **(D)** Intracellular staining of donor CD4$^+$ T cells from the CNS of Rag2KO recipients that received 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells (left). Numbers indicate the frequencies of cytokine-positive cells within the indicated gates. **(E)** Quantification of total cell numbers and CD4$^+$ T cell numbers in the spleens of Rag2KO recipient mice that received 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells. * $p < 0.05$, ** $p < 0.01$; *** $p < 0.001$, **** $p < 0.0001$ (A, B, C, D, E), compared with WT employing two-way ANOVA (A) or using two-tailed Student's t test (B, C, D, E). Data are from two combined independent experiments (A, B, C; mean ± S.E.M. of each population from all mice), from one experiment representative of two independent experiments (D), or from one experiment (E; mean ± S.E.M. of each population from all mice).

Figure 2.5 Let-7 miRNAs control the proliferation of CD4$^+$ T cells by negatively regulating metabolic reprogramming and cell cycle progression. (A) Survival rate of WT, Let-7Tg and Lin28Tg CD4$^+$ T cells activated *in vitro* for 3 days with α-CD3 and α-CD28 mAbs (5 μg/mL each) as analyzed by trypan blue exclusion. **(B)** Proliferation of Cell-Trace Violet-labeled WT, Let-7Tg and Lin28Tg CD4$^+$ T cells activated *in vitro* for 3 days α-CD3 and α-CD28 mAbs (5 μg/mL each) as analyzed by flow cytometry. Numbers indicate the cell frequencies within the indicated gates for each genotype. **(C)** Quantitative RT-PCR analysis of the cell cycle regulators, cyclin D2 (*Ccnd2*), cyclin-dependent kinase 6 (*Cdk6*), cell division cycle 25a phosphatase (*Cdc25a*), and ubiquitin-conjugating enzyme E2 Cdc34 (*Cdc34*) in naive CD4$^+$ T cells activated with plate-bound α-CD3 and α-CD28 mAbs (5 μg/mL each) for increasing time periods as indicated, presented relative to results obtained for the ribosomal protein Rpl13a (control). **(D)** Quantitative RT-PCR analysis of the transcription factors Myc (*Myc*) and AP-4 (*Tfap4*), as well as Myc direct target genes involved in glycolysis and protein synthesis, glucose transporter 3 (*Glut3*), hexokinase 2 (*Hk2*), lactate dehydrogenase A (*Ldha*), glutamyl-tRNA synthetase (*Qars*) and tyrosyl-tRNA synthetase (*Yars*) in naive CD4$^+$ T cells activated with plate-bound α-CD3 mAbs and α-CD28 mAbs (5 μg/mL each) for 48 hours, presented relative to results obtained for the ribosomal protein Rpl13a (control). * $p < 0.05$, ** $p < 0.01$; *** $p < 0.001$, **** $p < 0.0001$ (A, C, D), compared with WT using two-tailed Student's t test. Data are from one experiment representative of two independent experiments (A, C, D; mean ± S.E.M. of technical triplicates of each population from all mice) or from two independent experiments (B).

Figure 2.6 Let-7 miRNAs also get downregulated over time during pathogenic Th17 differentiation. (A) Quantitative RT-PCR analysis of individual let-7 miRNA expression in naive 2D2Rag2KO WT CD4[+] T cells and during *in-vitro*-generation of 2D2RagKO WT pathogenic Th17 cells at the indicated time points, presented relative to results obtained for the small nuclear RNA U6 (control), and normalized to results obtained for naive 2D2Rag2KO WT CD4[+] T cells. **(B)** Quantitative RT-PCR analysis of individual let-7 miRNA expression in naive CD4[+] T cells and day-5 *in-vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg mice, presented relative to results obtained for the small nuclear RNA U6 (control), and normalized to results obtained for naive 2D2Rag2KO WT CD4[+] T cells. **(C)** Quantitative RT-PCR analysis of *Lin28a* and *Lin28b* in naive 2D2Rag2KO WT and 2D2Rag2KO Lin28Tg CD4[+] T cells, as well as during *in-vitro*-generation of 2D2RagKO WT pathogenic Th17 cells at the indicated time points presented relative to results obtained for the small nuclear RNA U6 (control), and normalized to results obtained for naive 2D2Rag2KO WT CD4[+] T cells. . * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$, compared with WT using two-tailed Student's t test. Data are from one experiment representative of at least two experiments (A, B, C; mean ± S.E.M. of technical replicates).

A

Monoclonal (2D2Rag2KO) *in vitro*-directed pathogenic Th17 polarizations

B

Il17a *Csf2* *Il1r1* *Il23r* *Bhlhe40*

Relative expression (normalized to *Rpl13a*)

- 2D2Rag2KO WT
- 2D2Rag2KO Let-7Tg
- 2D2Rag2KO Lin28Tg

C

Mouse *Il1r1* mRNA
Human *IL1R1* mRNA

Mouse *Il23r* mRNA
Human *IL23R* mRNA

5' UTR
CDS
3' UTR
let-7 binding site

D

Il6ra *Il6st* *Stat3* *Irf4* *Rorc*

Relative expression (normalized to *Rpl13a*)

- 2D2Rag2KO WT
- 2D2Rag2KO Let-7Tg
- 2D2Rag2KO Lin28Tg

Figure 2.7 Let-7 miRNAs specifically inhibit the acquisition of the pathogenic Th17 phenotype. (A) Intracellular staining of CD4$^+$ T cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice polarized *in vitro* towards the pathogenic Th17 lineage with IL-6, IL-1β, and IL-23. Numbers indicate the frequencies of cytokine-positive cells within the indicated gates. **(B)** Quantitative RT-PCR analysis of the cytokines IL-17A (*Il17a*) and GM-CSF (*Csf2*), the cytokine receptors IL-1R1 (*Il1r1*) and IL-23R (*Il23r*), and the transcription factor Bhlhe40 (*Bhlhe40*) in *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice from (A), presented relative to results obtained for the ribosomal protein Rpl13a (control). **(C)** Diagram positioning *in silico*-identified let-7 binding sites (black vertical lines) within the mouse and human mRNA sequences of the cytokine receptors IL1-R1 (*Il1r1* and *IL1R1*, respectively) and IL-23R (*Il23r* and *IL-23R*, respectively). **(D)** Quantitative RT-PCR analysis of the IL-6 cytokine receptor components IL-6Rα (*Il6ra*) and IL-6ST (*Il6st*), and the transcription factors STAT3 (*Stat3*), IRF4 (*Irf4*), and RORγt (*Rorc*) in *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice.* $p < 0.05$, *** $p<0.001$, **** $p < 0.0001$ (B, D), compared with WT using two-tailed Student's t test. Data are from one experiment representative of two independent experiments (A) or from two independent experiments (B, D; mean ± S.E.M. of technical triplicates of each population from all mice).

Figure 2.8 Let-7 miRNAs inhibit the differentiation of several helper T cell subsets generated from both polyclonal and monoclonal naive CD4+ T cells *in vitro*. Intracellular staining of CD4+ T cells from polyclonal **(A)** or monoclonal 2D2Rag2KO **(B)** WT, Let-7Tg and Lin28Tg mice polarized *in vitro* towards the Th0, Th1, Th2, non-pathogenic Th17 and iTreg lineages. Numbers indicate the frequencies of cytokine-positive cells within the indicated gates. Data are from one experiment representative of seven (A) or six (B) independent experiments.

Figure 2.9 Let-7 miRNAs negatively regulate the expression of genes controlling the differentiation of Th0, Th1 and Th2 cells generated *in vitro*. Quantitative RT-PCR analysis of the cytokines IFNγ (*Ifng*), GM-CSF (*Csf2*), and IL-4 (*Il4*), the cytokine receptors IL12Rβ2 (*Il12rb2*) and IL4Rα (*Il4ra*), as well as the transcription factors T-bet (*Tbx21*), Bhlhe40 (*Bhlhe40*) and GATA3 (*Gata3*) in naive CD4⁺ T cells and *in vitro*-generated Th0, Th1 and Th2 cells from WT, Let-7Tg and Lin28Tg mice, presented relative to results obtained for the ribosomal protein Rpl13a (control). Data are from one experiment representative of two independent experiments (mean ± S.E.M. of technical triplicates of each population from all mice).

A

Ccr2

Ccr5

- 2D2Rag2KO WT
- 2D2Rag2KO Let-7Tg
- 2D2Rag2KO Lin28Tg

B

Mouse *Ccr2* mRNA

Human *CCR2* mRNA

Mouse *Ccr5* mRNA

Human *CCR5* mRNA

- 5' UTR
- CDS
- 3' UTR
- Non-conserved let-7 binding site
- Conserved let-7 binding site

C

Luciferase reporter assay (NIH/3T3)

D

Pathogenic Th17 cell migration assay (3h)

- 2D2Rag2KO WT
- 2D2Rag2KO Let-7Tg
- 2D2Rag2KO Lin28Tg

E

Ccr2 and *Ccr5* overexpression in *in vitro*-generated pathogenic Th17 cells

Ccr2

- 2D2Rag2KO WT – Empty vector
- 2D2Rag2KO WT – *Ccr2* overexpression
- 2D2Rag2KO WT – *Ccr2* overexpression (no reverse transcriptase)
- 2D2Rag2KO Let-7Tg – Empty vector
- 2D2Rag2KO Let-7Tg – *Ccr2* overexpression
- 2D2Rag2KO Let-7Tg – *Ccr2* overexpression (no reverse transcriptase)

Ccr5

- 2D2Rag2KO WT – Empty vector
- 2D2Rag2KO WT – *Ccr5* overexpression
- 2D2Rag2KO WT – *Ccr5* overexpression (no reverse transcriptase)
- 2D2Rag2KO Let-7Tg – Empty vector
- 2D2Rag2KO Let-7Tg – *Ccr5* overexpression
- 2D2Rag2KO Let-7Tg – *Ccr5* overexpression (no reverse transcriptase)

F

Pathogenic Th17 cell migration assay (3h)
with *Ccr2* or *Ccr5* overexpression

- 2D2Rag2KO WT – Empty vector
- 2D2Rag2KO WT – *Ccr2* overexpression
- 2D2Rag2KO WT – *Ccr5* overexpression
- 2D2Rag2KO Let-7Tg – Empty vector
- 2D2Rag2KO Let-7Tg – *Ccr2* overexpression
- 2D2Rag2KO Let-7Tg – *Ccr5* overexpression

74

Figure 2.10 Let-7 miRNAs prevent the chemokine-dependent migration of *in vitro*-generated pathogenic Th17 cells by suppressing the expression of the chemokine receptors CCR2 and CCR5. (A) Quantitative RT-PCR analysis of the chemokine receptors CCR2 (*Ccr2*) and CCR5 (*Ccr5*) in *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice, presented relative to results obtained for the ribosomal protein Rpl13a (control). **(B)** Diagram positioning *in silico*-identified conserved (red vertical lines) and non-conserved (black vertical lines) let-7 binding sites within the mouse and human mRNA sequences of the chemokine receptors CCR2 (*Ccr2* and *CCR2*, respectively) and CCR5 (*Ccr5* and *CCR5*, respectively). **(C)** Luciferase reporter assay of let-7 targeting *in-silico*-identified let-7-binding sites in mouse *Ccr2* or *Ccr5* mRNA, in NIH/3T3 cells transfected with a luciferase reporter vector containing either the wild-type or mutated variants of these binding sites, or either the wild-type or a mutated variant of the antisense seed sequence of let-7g (controls). Results are presented as relative luminescence units (RLU), calculated by normalization of Firefly luciferase activity to Renilla luciferase activity (control). **(D)** Transwell migration assay of *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice from (A) in response to the chemokines CCL2 (50 ng/mL) and CCL4 (50 ng/mL) alone or in combination (50 ng/mL or 10 ng/mL each). Results are presented as percentage of cell migration in media only control, defined as 100%. **(E)** Quantitative RT-PCR analysis of the chemokine receptors CCR2 (*Ccr2*) and CCR5 (*Ccr5*) in *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT and 2D2Rag2KO Let-7Tg mice, transduced with empty vector (solid bars), *Ccr2*-overexpression vector (horizontally-striped bars), and *Ccr5*-overexpression vector (diagonally-striped bars), presented relative to results obtained for the ribosomal protein Rpl13a (control). **(F)** Transwell migration assay of *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT and 2D2Rag2KO Let-7Tg mice, transduced with empty vector (solid bars), *Ccr2*-overexpression vector (horizontally-striped bars), and *Ccr5*-overexpression vector (diagonally-striped bars) in response to the chemokines CCL2 (50 ng/mL) and CCL4 (50 ng/mL) alone. Results are presented as percentage of cell migration in media only control, defined as 100%. * $p < 0.05$, ** $p < 0.01$; *** $p < 0.001$, **** $p < 0.0001$ (A, C, D, F), compared with WT using two-tailed Student's t test. Data are from one experiment representative two independent experiments (A, C, D, F; mean ± S.E.M. of technical triplicates).

Figure 2.11 Let-7 miRNAs do not control the intrinsic motility of *in vitro*-generated pathogenic Th17 cells. Speed, track length, track straightness, and displacement of migrating CFSE-labeled *in vitro*-generated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice embedded in collagen matrices. * p < 0.05, ** p < 0.01, **** p < 0.0001, compared with WT using two-tailed Student's t test. Data are from one experiment (mean ± S.E.M. of at least 175 analyzed cells of each population from all mice).

CHAPTER 3

COMPUTATIONAL ANALYSES PREDICT THE REGULATORY ROLE OF LET-7 MICRORNAS IN SHAPING THE FATE OF CD8$^+$ T CELLS TOWARDS MEMORY FORMATION WHILE SUPPRESSING TERMINAL EFFECTOR DIFFERENTIATION/EXHAUSTION

3.1 Introduction

Cytotoxic CD8$^+$ T lymphocytes (CTLs) are critical players of the immune response, as they are able to directly contribute to antigen clearance by recognizing and killing cells infected by intracellular pathogens, as wells as tumor cells (Sawamura et al., 1989; Dharakul et al., 1990; Harty et al., 1992; Rodrigues et al., 2003). Upon antigen encounter, antigen-specific CD8$^+$ T cells proliferate and generate a large pool of CTLs that migrate to the inflamed sites and execute their effector function to participate in the resolution of the infection (Butz & Bevan, 1998). After antigen elimination, the majority of CTLs undergo apoptosis during a contraction phase, as they are terminally differentiated, but a small proportion survives and generates long-lived memory CD8$^+$ T cells that will respond faster and more effectively to subsequent challenges with the same antigen (Grayson et al, 2000; Badovinac et al., 2002). This terminal-effector versus memory fate specification depends on the strength of signals 1, 2, and 3, received by CD8$^+$ T cells upon activation, with stronger signals leading to a decrease in memory potential (Stemberger et al., 2007; Gerlach et al., 2010; Angelosanto et al., 2012). These signals also result in the upregulation of co-inhibitory receptors or "immune checkpoints", such as PD-1, TIM-3, LAG-3, 2B4, CD160, and CTLA-4 (Wherry, 2007). During acute

infections, these receptors are only expressed in a transient manner, and contribute to the adjustment of the strength and duration of the CTL response to prevent toxicity towards host tissues (Agata et al., 1996; Monney et al., 2002; Probst et al., 2005). However, when antigen fails to be efficiently cleared, such as during chronic infections and cancer, the persistence of TCR signals on $CD8^+$ T cells results in a more abundant, permanent, and joint expression of these receptors (Blackburn et al., 2009). Following the interaction of these receptors with their specific ligands that are upregulated in immunosuppressive environments, such as the tumor microenvironment, CTLs are diverted towards a dysfunctional state known as exhaustion. Exhausted CTLs are unable to clear the infection and to differentiate into long-lasting memory cells (Moskophidis et al., 1993; Zajac et al., 1998; Wherry et al., 2004).

Although memory $CD8^+$ T cell formation is compromised during chronic inflammation, memory $CD8^+$ T cells introduced under these pathological conditions have the capacity to elicit highly protective responses (Shoukry et al., 2003; Malik et al., 2017). These efficient responses may be due to the high survival capacity of memory cells, coupled to low immune checkpoint expression that may confer resistance to exhaustion (Shoukry et al., 2003; Wirth et al., 2010). In addition, the generation of memory $CD8^+$ T cells by vaccination possess outstanding potential for preventing infectious diseases (Lauvau et al., 2001; Akondy et al., 2017). However, the molecular mechanisms promoting memory formation while inhibiting terminal effector differentiation and restraining exhaustion are still incompletely understood.

RNA interference mediated by miRNAs is a potent and well-conserved post-transcriptional mechanism that regulates gene expression in a sequence-specific manner

(Elbashir et al., 2001; Kim et al., 2008). Many individual miRNAs have been shown to play a role in the control of terminal-effector versus memory CD8$^+$ T cell fate determination. For instance, miR-143, miR-155, and miRNAs of the miR-200 family promote memory CD8$^+$ T cell differentiation (Tsai et al., 2013; Guan et al., 2018; Zhang et al., 2018), while miR-15/16, the miR-17-92 cluster, miR-23a, miR-31, and miR-150, direct terminal-effector specification (Wu et al., 2012; Khan et al., 2013; Lin et al., 2014; Ban et al., 2017; Chen et al., 2017; Moffett et al., 2017; Gagnon et al, 2019).

We previously showed that the let-7 miRNA family is highly expressed in naive CD8$^+$ T cells, thereby keeping these cells in a quiescent state and promoting their survival (Wells et al., 2017; Pobezinskaya et al., 2019). Moreover, we demonstrated that let-7 gets substantially downregulated upon antigen encounter, as these miRNAs negatively regulate CTL differentiation (Wells et al., 2017). Surprisingly, follow-up studies in our lab have found that, even though cytotoxic function is diminished upon let-7 overexpression in *in vitro*-generated CTLs, these cells confer superb anti-cancer protection upon adoptive transfer into tumor-bearing mice. Conversely, although *in vitro*-differentiated let-7-deficient CTLs exhibit enhanced cytotoxic function, these cells failed to control the same tumors, leading to poor recipient survival. Because the CTL response observed *in vitro* is not reflective of the *in-vivo* outcome, the purpose of the research described here was to elucidate this paradox.

RNA sequencing (RNA-Seq) is a well-established quantitative method that measures the expression of all genes in a tissue sample at a given time using next-generation sequencing of the transcriptome (Wang et al., 2009). In addition, bioinformatics has emerged as a powerful tool to understand this type of big biological data by executing *in*

silico analyses that use mathematical and statistical methods embedded in specific analysis pipelines (Van den Berge et al., 2019). Thus, we sought to apply RNA-Seq and bioinformatics analyses in order to explain this *in-vitro* versus *in-vivo* discrepancy in the let-7-mediated regulation of CTL function in an unbiased manner.

We found that the modulation of let-7 expression in CD8$^+$ T cells results in transcriptional changes that shape the terminal-effector versus memory fate. Specifically, we showed that maintaining high let-7 expression during the early stages of CTL differentiation led to the upregulation of a memory-like gene signature, whereas absence of let-7 during the differentiation of CTLs led to the upregulation of a gene signature associated with terminally-differentiated effectors and exhaustion. This was consistent with the identification of multiple early T cell activation-associated pathways inhibited by let-7, including ERK1/2 and Notch. Finally, we identified multiple direct let-7 target genes that were negatively regulated throughout CD8$^+$ T cell differentiation, among which we found that *Hk2* and *Mycn* functionally contribute to the control of terminal-effector versus memory fate. Altogether, this study has solved the paradoxical outcomes in the let-7-regulated CTL function *in-vitro* versus *in-vivo* using an unbiased approach that uncovered a novel regulatory role for let-7 in promoting the generation of memory CD8$^+$ T cells differentiation while preventing terminal-effector differentiation. Thus, let-7 miRNAs exhibit an utmost encouraging therapeutic potential as an innovative treatment against chronic infections and cancer.

3.2 Results

3.2.1 Modulation of let-7 expression in CTLs results in transcriptional changes

To understand the discrepancy between the *in-vitro* and *in-vivo* performance of CTLs expressing different levels of let-7 **(Figure 3.1)**, we isolated naive CD8$^+$ T cells from P14Rag2KO WT, Let-7Tg, and Lin28Tg mice, where P14 is a transgenic TCR which recognizes the gp$_{33-41}$ epitope from the lymphocytic choriomeningitis virus (LCMV) glycoprotein (Pircher et al., 1987). We differentiated these cells into CTLs *in vitro* in the presence of the cytokine IL-2, and we performed RNA-Seq on these CTLs at day 5 of culture to analyze their transcriptome.

To assess whether let-7 regulates the transcriptome of CTLs, we used Principal Component Analysis (PCA) to reduce the complexity of all 35,276 transcripts examined to only ranked 9 variables, or principal components (PCs), which reflect the overall variance between all samples analyzed in a small range of dimensions (Abdi & Williams, 2010). We chose to project our experimental samples along PC1 and PC2, which together accounted for most of the total variance (74% and 13%, respectively). Notably, PCA analysis revealed that WT, Let-7Tg, and Lin28Tg CTLs exhibited transcriptionally distinct gene signatures, as all samples from the same genotype were clustered together, but separated from those with distinct genotypes **(Figure 3.2A)**. This genetic distance was statistically significant between all groups, as represented by the non-overlapping 95% confidence ellipses from each cluster. These results show that let-7 expression alters the transcriptome of CTLs.

To examine the extent to which let-7 modulates the CTL transcriptome, we performed differential gene expression analysis on Let-7Tg-versus-WT, and Lin28Tg-

versus-WT CTLs. The output data showed that, in comparison to WT CTLs, 216 genes were downregulated and 286 genes were upregulated in Let-7Tg CTLs, while in Lin28Tg CTLs 448 genes were downregulated and 428 genes were upregulated, as compared to WT CTLs **(Figures 3.2B)**. Moreover, we found that several genes involved in memory T cell differentiation and terminal-effector differentiation/exhaustion were differentially expressed in a reversed manner in Let-7Tg and Lin28Tg CTLs, when compared to WT CTLs. For instance, memory markers, such as *Ccr7*, *Id3*, *Il7ra*, *Lef1*, *Sell* (CD62L) and *Tcf7* (TCF-1), were upregulated in Let-7Tg CTLs, but downregulated in Lin28Tg CTLs, whereas terminal-effector/exhaustion markers, including *Cd244a* (2B4), *Entpd1* (CD39), *Eomes*, *Havcr2* (TIM-3), *Id2*, and *Pdcd1* (PD-1), were upregulated in Lin28Tg CTLs, but downregulated in Let-7Tg CTLs. These findings suggest that let-7 globally manipulates the transcriptional signature of CTLs.

To identify and compare the expression of all genes that were either positively or negatively regulated by let-7 in CTLs, we used the normalized gene expression reads from WT, Let-7Tg, and Lin28Tg CTL replicate samples to generate a heatmap plot of all the genes that were differentially expressed at least by 30% ($|\log_2(\text{fold change}|= 0.5$) in a statistically significant manner in Let-7Tg and Lin28Tg CTLs, in comparison to WT CTLs. Heatmaps are bi-dimensional matrices that represent, across comparable samples, the differences in the expression level of genes, which are ranked according to the extent of differential expression (Eisen et al., 1998). Under these criteria, we were able to categorize 177 of these genes into 4 distinct clusters **(Figure 3.2C)**. Cluster I was the largest and comprised all genes that were negatively regulated by let-7 (n=98), such as *Cd160*, *Gzmb*, *Havcr2*, and the direct let-7 target *Hk2*, and were thus downregulated in

Let-7Tg CTLs, but upregulated in Lin28Tg CTLs, as compared to WT CTLs. Conversely, cluster II contained all genes that were positively regulated by let-7 (n=70), including *Il7ra*, thereby upregulated in Let-7Tg CTLs, but downregulated in Lin28Tg CTLs, in comparison to WT CTLs. Cluster III and cluster IV were very small and consisted of genes downregulated (n=2) or upregulated (n=7) in both Let-7Tg and Lin28Tg CTLs, when compared to WT CTLs, respectively. These results demonstrate that let-7 has both substantial negative and positive impacts on the CTL transcriptome.

To determine which biological processes the genes significantly downregulated in Let-7Tg CTLs and upregulated in Lin28Tg CTLs (cluster I), as well as the genes significantly upregulated in Let-7Tg CTLs and downregulated in Lin28Tg CTLs (cluster II) belonged to, we performed functional annotation of these genes using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (Huang et al., 2009). This analysis determined that cluster I was enriched for functionally-related gene groups involved in the defense response to viruses and the response to biotic stimulus, whereas in cluster II, genes implicated in the immune response and the apoptotic signaling pathway were over-represented **(Figure 3.2D)**. These data indicate that let-7 expression in CTLs regulates biological processes associated with the immune response and cell survival, which is consistent with our previous reports on the regulatory role of let-7 in CTL differentiation (Wells et al., 2017), as well as the role of let-7 in promoting T cell survival (Pobezinskaya et al., 2019).

3.2.2 Let-7 expression promotes a memory-like gene signature in CTLs, while also repressing genes associated with terminal effector differentiation and exhaustion

Because several memory markers were upregulated in Let-7Tg CTLs and downregulated in Lin28Tg CTLs, as compared to WT CTLs, and multiple terminal-effector/exhaustion markers followed the opposite expression pattern in the same cells, we hypothesized that let-7 may regulate memory versus terminal-effector CD8$^+$ T cell fate determination.

To support our hypothesis that let-7 promotes memory formation in CD8$^+$ T cells, we employed gene set enrichment analysis (GSEA), which determines whether a defined set of genes is differentially expressed in a statistically significant manner between two samples (Subramanian et al., 2005). To do so, we ranked the differential gene expression data from Let-7Tg-versus-WT, and Lin28Tg-versus-WT CTLs by increasing statistical significance using the adjusted p-value. We next ran GSEA by subjecting our ranked gene lists to a memory-associated gene signature (n=56 genes), as well as a terminal-effector/exhaustion-associated gene set (n=62 genes), both of which were generated by gathering well-defined markers from the literature (Yang et al., 2011; Im et al., 2016; Schietinger et al., 2016; Yu et al., 2017; Snell et al., 2018; Miller et al., 2019). In fact, the memory gene signature was significantly enriched in Let-7Tg CTLs (NES=1.458; p-value<0.001), whereas in Lin28Tg CTLs this gene set was significantly depleted (NES=-1.518; p-value<0.001) **(Figure 3.3A)**. In contrast, the terminal-effector/exhaustion gene signature was over-represented in Lin28Tg CTLs (NES=1.431; p-value=0.118), but depleted in Let-7Tg CTLs (NES=-1.153; p-value=0.213), although the statistical

significance threshold was not reached. These findings suggest that let-7 may play a role in the specification of memory versus terminal-effector/exhausted CD8[+] T cell fate.

To define and compare the expression of the genes contained in the gene sets used in GSEA, we used the normalized gene expression reads from WT, Let-7Tg, and Lin28Tg CTL replicate samples and we grouped all genes from both signatures examined into functional categories. We then generated heatmaps of each gene category, namely transcription factors, effector molecules and receptors, chemokines and chemokine receptors, co-stimulatory molecules and receptors, and inhibitory receptors **(Figure 3.3B)**. This analysis revealed that Let-7Tg CTLs upregulated the transcription factors *Foxo1*, *Id3*, *Lef1*, and *Tcf7*, which drive the memory fate of CD8[+] T cells (Zhou et al., 2010; Gattinoni et al., 2011; Yang et al., 2011; Zhou & Xue, 2012; Hess Michelini et al., 2013), but also *Tbx21* (T-bet) and *Zeb2*, which promote cytotoxic activity (Dominguez et al., 2015). Moreover, the secondary lymphoid organ homing receptor *Ccr7*, as well as the cell-adhesion molecule *Sell* (CD62L), which direct the migration of central memory cells to the lymph nodes, also showed increased expression in Let-7Tg CTLs (Kishimoto et al, 1990; Förster et al., 1999; Sallusto et al., 1999). In addition, Let-7Tg CTLs exhibited high expression of the cytokine receptors *Il7ra* (CD127), emblematic of memory precursor effector cells (MPECs), as well as *Il6ra*, which is important for memory CD8[+] T cell survival (Brown et al., 2019). Interestingly, Let-7Tg CTLs also upregulated most co-stimulatory molecules and receptors assessed, including *Cd28*, *Icos*, and *Ox40*, the engagement of which is particularly important for optimal recall responses of memory CD8[+] T cells (Borowski et al., 2007). Most strikingly, Let-7Tg CTLs expressed high levels of T memory stem cell markers, including the transcription factor *Sox4*, the anti-

apoptotic protein *Bcl2*, the secondary lymphoid organ homing receptor *S1pr1*, as well as the Wnt signaling target *Axin2* **(Figure 3.3C)** (Gattinoni et al., 2009; Gattinoni et al., 2011). Thus, these data indicate that let-7 directs the fate of CD8[+] T cells towards memory formation.

On the other hand, Lin28Tg CTLs showed increased expression of the transcription factors *Eomes*, *Id2*, *Ikzf2* (Helios), and *Prdm1* (Blimp-1), which are highly expressed in terminally-differentiated effectors and exhausted CD8[+] T cells (Wherry, 2007; Shin et al., 2009). Besides, *Eomes* and *Ikzf2* are direct let-7 targets (Agarwal et al., 2015; Wells et al., 2017). Moreover, most effector molecules and cytokines, including *GzmA*, *GzmB*, *Prf1*, *Ifng*, *Tnf*, and *Fasl*, were upregulated in Lin28Tg CTLs. In addition, these cells also expressed high levels of the immunosuppressive cytokine *Il10*, which, in addition to being directly targeted by let-7, is also abundantly expressed in exhausted cells CD8[+] T cells (Wilson et al., 2011). Furthermore, numerous pro-inflammatory chemokines, including *Ccl3*, *Ccl4*, *Ccl5*, as well as the chemokine receptors *Cx3cr1* and *Cxcr1*, were highly expressed in Lin28Tg CTLs. In contrast, these cells showed enhanced expression of only a few co-stimulatory molecules and receptors, namely *Tnfrsf9* (4-1BB), its ligand *Tnfsf9* (4-1BBL), and *Tnfrsf8* (CD30). Most remarkably, Lin28Tg CTLs showed upregulation of numerous co-inhibitory receptors, including *Pdcd1* (PD-1), *Havcr2* (TIM-3), *Cd160*, and *Cd244a* (2B4), as well as the short-lived effector cell (SLEC) marker *Klrg1*. Therefore, these results suggest that let-7 deficiency leads to terminal-effector differentiation, which renders CD8[+] T cells susceptible to exhaustion upon engagement with their cognate ligands, which can be found in immunosuppressive conditions such as the tumor microenvironment.

To test whether let-7 expression influences the memory potential of differentiating CD8$^+$ T cells, we injected $2x10^4$ P14Rag2KO WT or P14Rag2KO Lin28Tg naive CD8$^+$ T cells into congenic CD45.1$^+$ recipient mice which were subsequently infected with $6x10^6$ colony-forming units (cfu) of a strain of the bacterium *Listeria monocytogenes*, a well-established model for the study of memory T cell responses (Khan & Badovinac, 2015), that expresses the LCMV gp$_{33-41}$ peptide antigen (Lm-gp33). Strikingly, the frequencies of donor CD8$^+$ T cells in the spleen of mice that received Lin28Tg cells were dramatically diminished, and the proportions of effector-memory (CD44^{hi}CD62L^{lo}) to central-memory cells (CD44^{hi}CD62L^{hi}) were increased, in comparison to mice that received WT cells **(Figure 3.3D)**. These results demonstrate that the formation of memory CD8$^+$ T cells is compromised in the absence of let-7 miRNAs, and that in these conditions the cells that survive contraction preferentially generate effector-memory cells. Overall, our results strongly indicate that let-7 plays a regulatory role in the fate determination of CD8$^+$ T cells into memory and terminally-differentiated cells.

3.2.3 Let-7 expression primes CD8$^+$ T cells towards the memory fate early upon antigen encounter by negatively regulating T-cell receptor signaling pathways

The asymmetric-cell-fate model and the signal-strength model propose that the memory CD8$^+$ T cell fate is specified following antigen encounter (Kaech & Cui, 2012). To determine whether let-7 can direct the fate of CD8$^+$ T cells towards memory formation early during activation, we performed RNA-Seq on P14Rag2KO WT, Let-7Tg, and Lin28Tg naive CD8$^+$ T cells, as well as CD8$^+$ T cells activated *in vitro* for 12 hours.

To examine whether let-7 expression has an impact on the gene signatures of CD8$^+$ T cells at early stages of differentiation, PCA analysis was run on normalized expression reads of naive and 12h-activated CD8$^+$ T cells. Again, the output data demonstrated that the transcriptomes of WT, Let-7Tg, and Lin28Tg CD8$^+$ T cells clustered separately both at the naive and 12h-activated stage, as shown by the shift of samples from different genotypes along PC1 (accounting for 61% and 57% of the total variance in naive and 12h-activated, respectively) and PC2 (accounting for 21% and 22% of the total variance in naive and 12h-activated, respectively), as well as by the grouping of all samples from the same genotype into non-overlapping clusters **(Figure 3.4A and 3.4B)**. These results demonstrate that let-7 expression induces transcriptional changes early during CD8$^+$ T cell differentiation.

To assess the magnitude of let-7 influence on the transcriptome of naive and 12h-activated CD8$^+$ T cells, we analyzed the differential gene expression between WT and Let-7Tg or Lin28Tg CD8$^+$ T cells at these two time points. In naive CD8$^+$ T cells, 220 genes were downregulated and 131 genes were upregulated in Let-7Tg cells, whereas in Lin28Tg cells 1,687 genes were downregulated, and 2,718 genes were upregulated **(Figure 3.4C)**. The same analysis in 12h-activated CD8$^+$ T cells revealed that 357 genes were downregulated and 241 genes were upregulated in Let-7Tg cells, while in Lin28Tg cells 580 genes were downregulated and 1,177 genes were upregulated. These findings demonstrate that let-7 expression already has a substantial impact on the transcriptome of CD8$^+$ T cells at early stages of differentiation **(Figure 3.4D)**.

To determine which genes were significantly controlled by let-7 early during CD8$^+$ T cell differentiation, heatmap clusters representing the same 4 trends as in our

CTL bioinformatics studies were generated using all genes exhibiting at least a 30% change in expression ($|\log_2(\text{fold change})| = 0.5$) in Let-7Tg and Lin28Tg CD8$^+$ T cells, as compared to WT cells, at the naive and 12h-activated stage. In naive cells, 148 of these genes could be incorporated in these 4 clusters (**Figure 3.4E)**, whereas in 12h-activated cells, 224 of these genes could be included **(Figure 3.4F)**. Cluster I, which contained genes repressed by let-7, was again the largest for both time points assessed, especially in 12h-activated cells. In this cluster, there were 63 genes from the naive stage, including the let-7 target genes *Cdc34*, *Efhd2*, *Gng5*, *Hk2*, and *Nme4*, as well as the proliferating cell nuclear antigen *Pcna*. At the 12h-activated time point, cluster I comprised 157 genes, including additional targets of let-7, such as *Arid3a*, *Arid3b*, and *Ero1l*, but also numerous genes involved in cell cycle regulation, including *Ccna2*, *Cdc25a*, and *Mki67*, consistent with the inhibitory role of let-7 in CD8$^+$ T cell proliferation (Wells et al., 2017). Moreover, this cluster contained T cell activation-associated genes, such as *Jund*, and *Notch2*, as well as the effector molecule *Ifng,* the activation marker *Cd44*, and the anti-apoptotic factor *Bcl2l1* (Bcl-xL) (Boise et al., 1993). Cluster II, which contained genes positively regulated by let-7, was once again the second largest cluster at both stages tested, and comprised 41 genes from the naive time point, including the co-stimulatory receptor *Cd28*, which was consistent with the same cluster in CTLs **(Figure 3.2C)**. At the 12h-activated time point, cluster II contained 47 genes, and comprised the transcription factor *Ets1*, which drives the expression of *Il7ra* (CD127) (Grenningloh et al., 2011), as well as *Il6st*, a component of the IL-6 receptor complex, the signaling of which promotes memory CD8$^+$ T cell survival (Nish et al., 2014; Harker et al., 2015). Cluster III and IV, which respectively incorporated genes either upregulated or downregulated in both Let-

89

7Tg and Lin28Tg CTLs when compared to WT CTLs, were once more the least represented at both stages assessed. In naive cells, cluster III comprised 24 genes and cluster IV contained 20 genes while in 12h-activated cells cluster III incorporated 6 genes and cluster IV contained 14 genes. These results reveal that let-7 has a mostly negative impact on the transcriptome of CD8$^+$ T cells that gets established very early during T cell activation.

To identify the biological processes enriched in cluster I in both naive and 12h-activated CD8$^+$ T cells, we ran the DAVID functional gene annotation algorithm. To our surprise, the output data revealed that, in naive CD8$^+$ T cells, many functionally-related gene groups from this cluster belonged to processes associated with T cell activation. These let-7-regulated pathways included signal transduction, protein phosphorylation, gene expression regulation, cell cycle progression, apoptosis, the immune response, as well as signaling pathways downstream of TCR signaling, such as Notch, JNK, MAPK, and ERK1/2 **(Figure 3.5A)**. Consistently, in 12h-activated CD8$^+$ T cells, there was an over-representation of let-7-inhibited processes that resulted from these pathways, such as the regulation of gene expression, protein phosphorylation, and cell cycle progression **(Figure 3.5B)**, which is in agreement with our previously published findings that let-7 represses CD8$^+$ T cell proliferation (Wells et al., 2017). These data indicate that let-7 regulates CD8$^+$ T cell differentiation at early stages of CD8$^+$ T cell activation.

To validate our predictions, we first examined the extent of ERK1/2 phosphorylation (pERK1/2) in 5-minute *in vitro*-activated P14Rag2KO WT, Let-7Tg, and Lin28Tg CD8$^+$ T cells. Outstandingly, the levels of pERK1/2 were diminished in Let-7Tg cells, while in Lin28Tg cells the amount of pERK1/2 was increased, which suggests

that let-7 regulates the strength of TCR signaling in CD8[+] T cells **(Figure 3.5C)**. These findings confirm that let-7 controls the differentiation of CD8[+] T cells during the very first minutes following activation by inhibiting early signaling pathways, including the ERK1/2 pathway.

We next sought to determine whether let-7 controls the fate of CD8[+] T cells through the negative regulation of the Notch signaling pathway, which has already been reported to promote short-lived effector cell (SLEC) over memory precursor effector cell (MPEC) generation (Backer et al., 2014). Notch is a transmembrane receptor which, upon ligand binding on its extracellular portion, undergoes cleavage of its intracellular portion, Notch intracellular domain (NICD) (Artavanis-Tsakonas et al., 1995). NICD is the active form of Notch which can participate both in the transcriptional control of gene expression in the nucleus (canonical Notch signaling) and in signaling pathways in the cytoplasm (non-canonical Notch signaling) (Nam et al., 2003; Kwon et al., 2011; Minter & Osborne, 2012; Dongre et al., 2014; Shin et al., 2014). We overexpressed NICD, containing either a nuclear export signal (NES) or a nuclear localization signal (NLS), in P14Rag2KO CD8[+] T cells by transduction using the pMRX-IRES-GFP retroviral vector that contains a GFP reporter (Saitoh et al., 2002), and assessed their phenotype *in vivo*. We injected $2x10^5$ of these cells into congenic CD45.1[+] recipient mice which were subsequently infected with Lm-gp33. Surprisingly, both NICD-NES and NICD-NLS overexpression in CD8[+] T cells had a dramatic effect on memory formation in the spleen of these mice 30 days post-infection (dpi) **(Figure 3.5D)**. Specifically, the frequencies of NICD-NES and NICD-NLS-overexpressing CD8[+] T cells were substantially reduced in comparison with cells that overexpressed the empty vector, as represented by GFP expression, which

demonstrates that these cells lost their memory potential. Moreover, the percentages of effector-memory cells were increased, while central-memory cell proportions were diminished in NICD-NES- and NICD-NLS-overexpressing CD8$^+$ T cells that persisted at this time point. This was consistent with the diminished frequencies and enhanced effector-memory to central-memory cell identity ratio of donor P14Rag2KO Lin28Tg CD8$^+$ T cells present in the spleen of Lm-gp33-challenged CD45.1$^+$ mice at the same time point **(Figure 3.3D)**. These results suggest that let-7 antagonizes the Notch signaling pathway that promotes terminal-effector CD8$^+$ T cell differentiation over memory formation both by participating in signaling pathways and driving gene transcription.

Since we showed that let-7 negatively regulates early T cell activation signaling pathways, and that we previously demonstrated that let-7 downregulation depends on the strength of TCR signaling upon CD8$^+$ T cell activation (Wells et al., 2017), we next sought to examine whether the generation of SLECs and MPECs depended on strong and weak TCR signals, in accordance with the signal-strength and asymmetric-cell-fate models. To this end, we took advantage of Nur77-GFP mice, which express a GFP reporter under the control of the *Nr41a* (Nur77) promoter, the expression level of which directly correlates with the strength of TCR signaling received by T cells upon activation (Moran et al., 2011). We crossed these mice to P14Rag2KO mice to generate P14Rag2KO Nur77-GFP mice, and we injected 2×10^4 naive CD8$^+$ T cells from these mice into CD45.1$^+$ congenic recipient mice that were subsequently challenged with Lm-gp33. Remarkably, we observed that, at day 9 dpi, SLECs (KLRG1^{hi}CD127^{lo}) expressed higher levels of Nur77 than MPECs (KLRG1^{lo}CD127^{hi}), as reflected by GFP MFI **(Figure 3.5E)**. Of note, intermediate cells (KLRG1^{hi}CD127^{hi}) shared similar Nur77

expression to MPECs. These findings directly validate the signal-strength model of CD8[+] T cell fate determination. Moreover, our data suggest that let-7 promotes the memory CD8[+] T cell fate by suppressing the strength of TCR signaling.

These analyses strongly indicate that let-7 negatively regulates CD8[+] T cell differentiation early on by diminishing the strength of TCR signaling, thereby inhibiting early downstream activation pathways, including ERK1/2 and Notch. These results coincide with the signal-strength and asymmetric-cell-fate models of CD8[+] T cell fate specification, and thus provide a mechanism for the let-7-mediated regulation of memory versus terminal-effector CD8[+] T cell fate determination.

3.2.4 Let-7 consistently regulates target genes throughout CD8[+] T cell differentiation

To deepen our understanding of the let-7-regulated molecular mechanisms controlling the fate of CD8[+] T cells, we compared all the let-7 target genes contained in cluster I at all stages of CD8[+] T cell differentiation assessed (naive, 12h-activated, and CTLs). Remarkably, this analysis revealed that multiple genes were negatively regulated by let-7 throughout CD8[+] T cell differentiation **(Figure 3.6A)**. For instance, the ubiquitin-conjugating enzyme *Cdc34*, which is involved in the regulation of the cell cycle, as well as in the NF-κB and Wnt signaling pathways, was negatively regulated by let-7 in both naive and 12h-activated CD8[+] T cells (Semplici et al., 2002 ; Legesse-Miller et al., 2010; Wu et al., 2010). Moreover, the expression of the transcription factor *Mycn*, which promotes hematopoietic stem cell proliferation, differentiation, survival, was inhibited by let-7 at both the 12h-activated and CTLs stage of CD8[+] T cell differentiation (Laurenti et al., 2008). Most interestingly, let-7 consistently repressed several target genes at all time

points tested, namely *Efhd2*, *Gng5*, and *Hk2*. *Efhd2*, or EF Hand Domain Family Member D2, is a calcium-binding adapter protein which has been shown to promote CD8$^+$ T cell cytotoxicity and contribute to PD-1 inhibitory activity (Peled et al., 2018). *Gng5* is a G protein-coupled receptor gamma subunit that participates in chemokine receptor signaling, which regulates the migration of T cells (Griffith et al., 2014). *Hk2* is the glycolytic enzyme hexokinase 2, which catalyzes the rate-limiting step of glucose phosphorylation into glucose-6-phosphate, and is highly upregulated in T cells upon activation as well as in terminal effectors, but gets downregulated in memory CD8$^+$ T cells (Tan et al., 2017; Sukumar et al., 2013). These results provide candidate let-7 target genes that may play a role in the regulation of CD8$^+$ T cell fate determination.

To test whether the candidate let-7 target genes identified above contribute to the regulation of terminal-effector versus memory CD8$^+$ T cell fate specification, we overexpressed the open reading frame (ORF) of *Cdc34*, *Efhd2*, *Gng5*, *Hk2*, and *Mycn* in CD8$^+$ T cells by transduction using the pMRX-IRES-GFP retroviral vector. Overexpression of *Cdc34* in *in vitro*-generated Let-7Tg CTLs resulted in a slight increase in PD-1 expression, and, unexpectedly, in enhanced frequencies of central memory-like (CD44^{hi}CD62L^{hi}) cells over effector memory-like (CD44^{hi}CD62L^{lo}) cells **(Figure 3.6B)**. However, this effect was also observed in cells that were not transduced (GFP$^-$), making these results inconclusive. To test the biological relevance of the remaining candidate genes in the fate of CD8$^+$ T cells, P14Rag2KO CD8$^+$ T cells overexpressing the ORF of *Efhd2*, *Gng5*, *Hk2*, or *Mycn* were injected into CD45.1$^+$ congenic host mice that were subsequently infected with Lm-gp33. At 30 dpi, only overexpression of *Hk2* and *Mycn* had substantial effects on the formation of memory CD8$^+$ T cells in the spleen of these

mice **(Figure 3.6C and 3.6D)**. In fact, the percentages of *Hk2*- and *Mycn*-overexpressing CD8$^+$ T cells were significantly diminished when compared to cells that overexpressed the empty vector. Moreover, the frequencies of effector-memory cells were increased, while central-memory cell proportions were diminished in *Hk2*- or *Mycn*- overexpressing cells that persisted at this time point. These findings are consistent with the phenotype observed upon Notch NICD overexpression **(Figure 3.5D)**, and are in agreement with previous reports describing Notch as a positive regulator of glycolysis, and *Mycn* as a positive regulator of Notch (Landor et al., 2011; Tong et al., 2019). Thus, these data demonstrate that *Hk2* and *Mycn* are let-7 target genes that play a role in establishing the terminal-effector differentiation program and repressing memory formation in CD8$^+$ T cells.

Taken together, our results demonstrate that let-7 miRNA expression specifies the fate of CD8$^+$ T cells following antigen encounter towards memory formation while preventing terminal-effector differentiation, and thus the susceptibility to exhaustion, thereby solving the *in-vitro* versus *in-vivo* paradox of let-7-regulated CTL function. Specifically, absence of let-7 leads to the upregulation of co-inhibitory receptors that induce exhaustion upon engagement with their cognate ligands, which are abundantly expressed in immunosuppressive environments encountered during chronic infections and cancer. In fact, we show that let-7 alters the CD8$^+$ T cell transcriptome, reduces TCR signaling strength, and inhibits downstream signaling pathways during early stages of activation, including ERK1/2 and Notch. Finally, we identified multiple let-7 target genes that were continuously dysregulated during CD8$^+$ T cell differentiation, and among these we found that *Hk2* and *Mycn* drive the terminal-effector CD8$^+$ T cell fate, while inhibiting

the generation of memory cells. Consequently, our discovery that let-7 skews CD8$^+$ T cell fate towards memory cell generation may lead to the development of novel therapeutic strategies contributing to substantial advances in the treatment of cancer and chronic infections.

3.3 Discussion

Our study uncovered a novel post-transcriptional mechanism regulating the fate of CD8$^+$ T cells towards memory and terminally-differentiated effector cell formation, using RNA-Seq and bioinformatics analyses as an unbiased approach. Particularly, we identified let-7 miRNAs as central regulators of this dichotomy, promoting the generation of memory CD8$^+$ T cells while restraining the terminal effector program early during CD8$^+$ T cell differentiation, thereby preventing exhaustion in chronic inflammatory conditions. This discovery elucidates the paradoxical CTL performance *in-vitro* and *in-vivo*, as let-7 deficiency resulted in high expression of co-inhibitory receptors that can induce exhaustion upon interaction with their cognate ligands, which are upregulated in immunosuppressive conditions, such as the tumor microenvironment. Most importantly, our findings directly establishes let-7 has a promising innovative therapeutic means to treat chronic pathologies such as cancer.

Analysis of the CTL transcriptome showed that let-7 expression significantly altered the phenotype of these cells, in which many genes were negatively regulated by let-7. Consistently with the *in-vitro* phenotype of CTLs, Let-7Tg CTLs upregulated genes involved in the immune response and the regulation of apoptosis, whereas processes such as the defense response to viruses and the response to biotic stimuli were over-represented

in let-7 deficient CTLs. Moreover, let-7 overexpression contributed to the enrichment of a memory-associated gene signature, whereas in the absence of let-7 a gene set characteristic of terminally-differentiated CD8$^+$ T cells was over-represented. Specifically, we found that Let-7Tg CTLs expressed high levels of the well-defined memory markers *Ccr7*, *Sell* (CD62L), *Il7ra*, *Bcl2*, *Foxo1*, *Id3*, *Tcf7*, and *Lef1*, as well as T stem cell memory markers, including *Axin2*, *S1pr1* and *Sox4*, but also transcription factors involved in CTL differentiation, such as *Tbx21* (T-bet) and *Zeb2* (Gattinoni et al., 2009; Gattinoni et al., 2011; Dominguez et al., 2015). Additionally, these cells expressed high levels of co-stimulatory receptors, such as *Cd28*, *Icos*, and *Ox40*, the signaling of which contributes to efficient memory responses (Borowski et al., 2007). Based on these results, we could infer that, although they exhibit reduced cytotoxicity *in vitro*, Let-7Tg CTLs maintain a central/stem cell-like memory potential and are thus able to elicit the robust, long-lasting anti-tumor immunity observed *in vivo*. This is in accordance with our previously published findings that let-7 preserves the quiescence of naive T cells, as memory cells are characterized by a return to the quiescent state (Kalia et al., 2015; Wells et al., 2017). Our predictions are also consistent with another publication in which we demonstrated that let-7 expression is required for the survival of naive T cells, as Let-7Tg CTLs had increased expression of the anti-apoptotic genes *Bcl2* and *Bcl11b* (Bcl-xL) (Pobezinskaya et al., 2019). Thus, let-7 may contribute to the resistance of memory precursors to the contraction phase and prolonged survival of memory cells through enhanced *Bcl2* expression (Akbar et al., 1993; Grayson et al., 2000; Pobezinskaya et al., 2019). In contrast, Lin28Tg CTLs preferentially expressed the transcription factors *Eomes*, *Id2*, *Ikzf2* (Helios), and *Prdm1* (Blimp-1), the co-inhibitory receptors *Pdcd1* (PD-

1), *Havcr2* (TIM-3), *Cd160*, and *Cd244a* (2B4), effector molecules and cytokines *GzmA*, *GzmB*, *Prf1*, *Ifng*, *Tnf*, and *Fasl*, as well as the immunosuppressive cytokine *Il10*, all of which are highly expressed in terminally-differentiated and exhausted CD8$^+$ T cells (Wherry, 2007; Blackburn et al., 2009; Shin et al., 2009). These cells also had increased expression of the co-stimulatory receptor *Tnfrsf9* (4-1BB), which has been described as an exhaustion marker in CD8$^+$ T cells (Williams et al., 2017). Several of these genes were also direct targets of let-7, namely *Eomes*, which we previously reported, as well as *Ikzf2* and *Il10* (Swaminathan et al., 2012; Agarwal et al., 2015; Wells et al., 2017). Our data indicate that, despite their superior *in-vitro* cytotoxic activity, Lin28Tg CTLs fail to control tumor growth *in vivo* due to the high expression of these co-inhibitory receptors, which likely interacted with their cognate ligands in the tumor microenvironment, inducing exhaustion in these cells. We further show experimentally that Lin28Tg CD8$^+$ T cell have a poor memory potential, as only few of these cells persisted after Lm-gp33 clearance, which are skewed towards the effector-memory phenotype. Thus, these results suggest that absence of let-7 leads to the terminal differentiation of CD8$^+$ T cells, which renders these cells prone to exhaustion.

In fact, we show that this let-7-mediated-regulation of CD8$^+$ T cell fate determination occurs soon after antigen encounter, which is consistent with previous work in our lab that recapitulated the phenotype of Let-7Tg CTLs by inducing the let-7g transgene only during the first 48h following CD8$^+$ T cell activation *in vitro* **(Figure 3.7)**. Specifically, transcriptome analysis of naive CD8$^+$ T cells predicted that numerous signaling pathways downstream of TCR signaling were negatively regulated by let-7, including ERK1/2 and Notch, which we experimentally validated. Interestingly, both the

cytoplasmic (NICD-NES) and nuclear (NICD-NLS) active forms of Notch inhibited memory CD8[+] T cell formation and skewed the persisting memory cells towards effector-memory cell formation at the expense of central-memory cell generation, thereby showing that both canonical and non-canonical Notch signaling contribute to the regulation of CD8[+] T cell fate. These results indicate that let-7 expression diminishes the strength of TCR signaling in these cells, thereby specifying the memory CD8[+] T cell fate minutes following antigen encounter. In fact, we show, using P14Rag2KO donor CD8[+] T cells that express the Nur77-GFP reporter of TCR signal strength, that SLECs exhibit a stronger TCR signaling history than MPECs. These data are consistent with previous work in our lab demonstrating that let-7 inhibits TCR signal strength in *in vitro*-activated P14Rag2KO WT, Let-7Tg, and Lin28Tg CD8[+] T cells expressing Nur77-GFP **(Figure 3.8)**. Our data are in accordance with the signal-strength and asymmetric-cell-fate models of CD8[+] T cell fate determination, both of which propose that the strength of TCR signaling received upon T cell activation inversely correlates with the extent of memory potential (Kaech & Cui, 2012). Our predictions are also consistent with a previously published report in which we showed that the magnitude of let-7 downregulation upon CD8[+] T cell activation depends on the strength and duration of TCR signaling, where high let-7 expression negatively regulates CTL differentiation (Wells et al., 2017). Moreover, examination of the CD8[+] T cell transcriptome at both the naive and 12h-activated stage revealed that let-7 inhibited cell cycle progression, which we had already shown before (Wells et al., 2017). Thus, reduced proliferation, in addition to the enhanced survival promoted by let-7 in CD8[+] T cells, may also contribute to the maintenance of the quiescent state in these cells, thereby preserving the memory cell pool.

Even though our study provides strong evidence that let-7 miRNAs promote the fate of CD8$^+$ T cells towards memory CD8$^+$ T cells while restraining terminal-effector differentiation and exhaustion, the relative expression of let-7 at these different stages of CD8$^+$ T cell differentiation *in vivo* remains to be examined. It would be reasonable to hypothesize that, because weak TCR signaling induces the retention of let-7 expression, these cells would adopt the memory fate, while CD8$^+$ T cells receiving strong TCR signals downregulate let-7 to a greater extent will become terminally-differentiated, and thus more susceptible to exhaustion. Along these lines, recurrent TCR stimulation during chronic inflammation due to persisting antigen may gradually cause the loss of let-7 expression in CD8$^+$ T cells, which would progressively direct these cells towards the exhausted state. In fact, we confirmed, using CD8$^+$ T cells expressing the Nur77-GFP reporter of TCR signal strength, that SLECs do receive stronger TCR signals than MPECs, which is in agreement with our hypothesis. In addition, it would be interesting to test the memory versus terminal-effector differentiation potential of CD8$^+$ T cells activated *in vitro* with different strengths of TCR stimulation at the phenotypic and functional levels.

We also identified multiple direct target genes of let-7 that were consistently dysregulated throughout CD8$^+$ T cell differentiation, which provided candidates to study the let-7-mediated mechanisms that inhibit terminal effector differentiation and exhaustion. The ubiquitin-conjugating enzyme *Cdc34* was common to the naive and 12h-activated time points, the oncogenic transcription factor *Mycn* was found at both the 12h-activated and CTL stages, and the calcium-binding adapter protein *Efhd2*, the G-protein gamma subunit *Gng5*, as well as the rate-limiting glycolytic enzyme *Hk2* were negatively

regulated by let-7 at all stages of CD8$^+$ T cell differentiation examined. Among these, the rate-limiting glycolytic enzyme *Hk2* and the oncogenic transcription factor *Mycn* were confirmed to prevent memory CD8$^+$ T cell formation and enhance the effector- to central-memory cell ratios using the Lm infection model. Since *Hk2* and *Mycn* overexpression recapitulated the phenotype observed upon overexpression of Notch, and given that Notch signaling induces glycolysis and is regulated by *Mycn*, additional overexpression studies in Let-7Tg CD8$^+$ T cells or knockdown in Lin28Tg cells would determine whether these factors have redundant or distinct roles in CD8$^+$ T cell fate regulation (Landor et al., 2011; Tong et al., 2019). Although they were not investigated in this study, we do not rule out the possibility that genes which are regulated by let-7 at a single stage of CD8$^+$ T cell differentiation may play a role in the regulation of terminal effector differentiation and memory formation. In fact, previous work in our lab has identified such a role for the transcription factor *Arid3a*, the expression of which is inhibited by let-7 at the 12h-activated stage, as well as the transcription factors *Eomes* and *Hmga1*, which are both negatively regulated by let-7 at the CTL stage **(Figure 3.9)**. Thus, together with the early T cell activation signaling pathways we had identified above, assessing the function of these genes will advance our knowledge of the molecular mechanisms through which let-7 controls the fate of CD8$^+$ T cells.

Although the present study offers significant insights into the let-7-mediated mechanisms regulating terminal effector versus memory CD8$^+$ T cell differentiation, it only examined the role of let-7 miRNAs in the fate of CD8$^+$ T cells at the transcriptional level, and thus provides an incomplete perspective in this regard. Therefore, validating whether let-7 shapes the proteome of differentiating CD8$^+$ T cells consistently with our

transcriptomic study will be important. Moreover, because the memory and terminal-effector fates are also regulated at the epigenetic level, whether let-7 performs its regulatory function by modeling the chromatin state of differentiating CD8$^+$ T cells remains to be examined (Araki et al., 2009; Crompton et al., 2016; Kakaradov et al., 2017; Henning et al., 2018). Furthermore, since it is well understood that terminally-differentiated and memory T cells rely on distinct metabolic processes, investigating whether let-7 plays a role in modulating these metabolic pathways will be interesting, especially since we already showed that the expression of glycolytic genes, including *Glut1*, *Glut3*, *Hk2*, *Pfk1*, *Pkm*, and *Tpi*, were repressed by let-7 (Wells et al., 2017). Moreover, previous work in our lab showed that, when compared to WT CTLs, Let-7Tg CTLs exhibit a lower glycolytic rate, while in Lin28Tg CTLs glycolysis is increased **(Figure 3.10)**, which is in agreement with studies describing that memory CD8$^+$ T cells preferentially use fatty acid metabolism, whereas glycolysis is used to a higher extent in terminally-differentiated cells (Araki et al., 2009; Pearce et al., 2009; Michalek & Rathmell, 2010; Sukumar et al., 2013; Pollizzi et al., 2016). This is also consistent with our results showing that *Hk2*-overexpressing CD8$^+$ T cells fail to form memory cells.

Our data emphasize a strong potential for the translation of the let-7-mediated control of memory CD8$^+$ T cell formation into novel therapies for the treatment of chronic pathologies such as cancer and persistent infections. Such innovative medical solutions could consist of let-7 miRNA delivery to CD8$^+$ T cells during the *ex vivo* T cell expansion phase of CAR-T cell production for adoptive T cell therapy, during which these cells would be directed towards the memory fate, and thus would not be as prone to exhaustion (Ho et al., 2003; Rosenberg et al., 2011). Besides, in the case of anti-cancer therapy,

delivering let-7 miRNAs directly to tumor cells could also be performed, since let-7 is a well-known tumor suppressor, and thus may have at least an additive effect on the outcome of tumor control. Moreover, the combination of these let-7-based therapies with checkpoint blockade immunotherapy may elicit a superior anti-tumor response. Furthermore, our study may substantially contribute to advances in vaccine development, since effective vaccination relies on the generation of memory cells (Lauvau et al., 2001; Akondy et al., 2017). Finally, although it remains to be tested experimentally, inhibiting let-7 expression in CD8[+] T cells may constitute a promising healthcare solution to treat CD8[+] T cell-driven autoimmune disorders, such as type-1 diabetes, by inducing exhaustion in these self-reactive cells (McKinney et al., 2015).

Altogether, our study elucidated the paradoxical outcome of let-7 expression on the *in-vitro* versus *in-vivo* activity of CTLs by predicting that let-7 expression regulates CD8[+] T cell differentiation towards the generation of memory cells, while inhibiting the differentiation of terminal effectors. Additionally, our data establish let-7 miRNA as novel therapeutic tool for the manipulation of CD8[+] T cell function in the contexts of cancer, persistent infections, and autoimmune diseases.

A Cytotoxicity assay of *in vitro*-generated P14Rag2KO CTLs (4h)

Data by Alexandria Wells, Ph.D.

B

Data by Elena Pobezinskaya, Ph.D., and Alexandria Wells, Ph.D.

Figure 3.1 Let-7 expression in CTLs results in paradoxical functional outcomes *in vitro* and *in vivo*. (A) Cytotoxicity assay of *in vitro*-differentiated CTLs from P14Rag2KO WT, P14Rag2KO Let-7Tg, and P14Rag2KO Lin28Tg mice co-cultured for 4h at the indicated ratios with splenocytes pulsed with either LCMV gp$_{33-41}$ peptide (cognate P14 epitope) or LCMV np396 peptide (non-specific epitope). **(B)** Tumor growth curves in mice inoculated subcutaneously with 0.25×10^6 B16^{gp33} tumor cells. Tumor-bearing mice received adoptive transfer of 1.5×10^6 CTLs generated *in vitro* from either P14Rag2KO WT (n=5), P14Rag2KO Let-7Tg (n=5), P14Rag2KO Lin28Tg (n=5) mice. Some mice did not receive CTLs (n=5). * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$, compared with WT using two-tailed Student's t-test. Data are from one experiment representative of three experiments (A; mean and S.E.M of technical triplicates), or from one experiment representative of two experiments (B; mean and S.E.M. of 5 biological replicates).

A — PCA on P14Rag2KO CTLs

B — Differential gene expression analysis on P14Rag2KO CTLs

Lin28Tg vs WT · Let-7Tg vs WT

● Upregulated   ● Downregulated

C — Differentially-expressed genes with |log2FoldChange| ≥ 0.5
P14Rag2KO CTLs

D — DAVID GO Biological process enrichment analysis on genes
from Cluster I and Cluster II in P14Rag2KO CTLs

Figure 3.2 Let-7 miRNAs significantly alter the CTL transcriptome. (A) Principal component analysis (PCA) on normalized expression read counts from the RNA-Seq data obtained from *in vitro*-generated CTLs from P14Rag2KO WT, P14Rag2KO Let-7, and P14Rag2KO Lin28Tg mice, separated by PC1 (y axis) and PC2 (x axis), which explain 74% and 13% of the total variance between samples, respectively. All replicate samples from each genotype were clustered by applying 95% confidence ellipses (p <0.05). **(B)** Volcano plots displaying differential gene expression in *in vitro*-differentiated P14Rag2KO Lin28Tg (left panel) and P14Rag2KO Let-7Tg (right panel) CTLs, as compared with P14Rag2KO WT CTLs, by the mean expression value of $-\log_{10}$(p-value) (y axis) and the $\log_2$ value of the expression fold change (Log2(Fold Change), x axis). Each differentially-expressed gene is represented by a gray solid circle, and examples of upregulated (red solid circles) and downregulated (blue solid circles) associated with CTL differentiation are indicated in each plot. **(C)** Heatmap clusters of normalized expression read counts from the RNA-Seq data showing all genes differentially expressed by $|\log_2$(Fold Change)$| \geq 0.5$ in a statistically-significant manner (p<0.05) in *in vitro*-generated CTLs from P14Rag2KO WT (center), P14Rag2KO Let-7 (right), and P14Rag2KO Lin28Tg (left) mice. Downregulated genes are indicated in blue and upregulated genes are represented in red. Cluster I shows genes downregulated in Let-7Tg CTLs and upregulated in Lin28Tg CTLs, cluster II indicates genes upregulated in Let-7Tg CTLs and downregulated in Lin28Tg CTLs, cluster III represents genes downregulated in both Let-7Tg and Lin28Tg CTLs, and cluster IV shows genes upregulated in both Let-7Tg and Lin28Tg CTLs, in comparison with WT CTLs. Examples of differentially-expressed genes important for CTL differentiation are indicated. **(D)** Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis of gene ontology (GO) biological processes significantly enriched (p <0.05) in cluster I (red bubbles) and cluster II (blue bubbles) from (C), based on the over-representation of functionally-related gene groups. Data is presented relative to the $-\log_{10}$ of the false discovery rate ($-\log_{10}$(FDR), x axis). The size of the bubbles indicates the percentage of genes from each cluster contributing to the enriched biological process.

A

GSEA on P14Rag2KO CTLs

Enrichment plot: Memory-associated genes

NES = 1.458
p < 0.001

NES = -1.518
p < 0.001

Let-7Tg ← → WT

Lin28Tg ← → WT

Enrichment plot: Terminal effector-associated genes

NES = -1.153
p = 0.213

NES = 1.431
p = 0.118

Let-7Tg ← → WT

Lin28Tg ← → WT

B

Heatmap clustering of the genes contained in the P14Rag2KO CTL GSEA signatures

Transcription factors

Prdm1
Eomes
Id2
Tcf7
Lef1
Id3
Foxo1

Lin28Tg   WT   Let-7Tg

Effector molecules and receptors

GzmB
GzmA
Tnf
TRAIL
Fasl
Il10
Ifng
Prf1
Il6ra
Il7r

Lin28Tg   WT   Let-7Tg

Chemokines and chemokine receptors

Ccl5
Ccl4
Csf1
Ccl3
Xcl1
Cx3cr1
Cxcr1
Cxcl11
Ccr7
Cxcr6
Cxcl10

Lin28Tg   WT   Let-7Tg

Costimulatory molecules and receptors

Tnfrsf9 (4-1BB)
Tnfrsf8 (CD30)
Tnfsf9 (4-1BBL)
Klrg1
Cd27
Cd28
Sell (CD62L)
Icos
Tnfrsf4 (OX40)
Tnfsf8 (CD30L)
Tnfsf14 (LIGHT)
Tnfsf4 (OX40L)

Lin28Tg   WT   Let-7Tg

Inhibitory receptors

Entpd1 (CD39)
Havcr2 (TIM-3)
Cd160
Pdcd1 (PD-1)
Cd244a (2B4)
Pdcd1lg2 (PD-L2)
Mt1
Lag3
Ctla4
Mt2
Tigit
Mt3
Cd101

Lin28Tg   WT   Let-7Tg

Expression level

Min.   Max.

C

T stem cell memory (Tscm) markers

P14Rag2KO CTLs

Ly6a
Kit
Bcl2
Lef1
Bcl11b
S1pr1
Axin2
Slamf1
Sox4

Lin28Tg   WT   Let-7Tg

Expression level

Min.   Max.

D

Day 30 post-Lm-gp33 infection

Gated on live singlets

WT   0.37

Lin28Tg   0.04

Gated on CD45.2⁺ donor CD8⁺ T cells

7.1   92.7

29.5   68.9

Donor CD8⁺ T cells

CD44hiCD62Llo donor CD8⁺ T cells

CD44hiCD62Lhi donor CD8⁺ T cells

● P14Rag2KO WT
● P14Rag2KO Lin28Tg

Figure 3.3 Let-7 miRNA expression promotes a memory gene signature in CTLs, while let-7 deficiency is characterized by am enrichment in genes associated with terminal effectors. (A) Gene set enrichment analysis (GSEA) using the adjusted p-value-ranked normalized expression read counts from the RNA-Seq data obtained from *in vitro*-generated P14Rag2KO Let-7 and P14Rag2KO Lin28Tg CTLs scored against gene sets containing memory-associated genes (n=56; left panel) and terminal effector-associated genes (n=62; right panel), and compared to the transcriptome of P14Rag2KO WT CTLs. Gene signatures were created by gathering well-characterized genes from the literature (see Materials and methods). Normalized enrichment score (NES), as well as adjusted p-values, are shown for each analysis. Positive NES values indicate gene signature enrichment, while negative NES values show gene set under-representation. **(B)** Heatmap clusters of normalized expression read counts from the RNA-Seq data showing differential expression by P14Rag2KO WT (center), Let-7Tg (right), and Lin28Tg (left) CTLs of the genes used for GSEA in (A) that were classified into heatmap categories. Downregulated genes are indicated in blue and upregulated genes are represented in red. Examples of differentially-expressed genes important for memory and terminal effector differentiation are indicated. **(C)** Heatmap showing differential expression of T stem cell memory (Tscm) markers in P14Rag2KO WT (center), Let-7Tg (right), and Lin28Tg (left) CTLs. Downregulated genes are indicated in blue and upregulated genes are represented in red. **(D)** Staining of CD45.2$^+$ donor P14Rag2KO WT (n=3) and P14Rag2KO Lin28Tg (n=3) CD8$^+$ T cells in the spleen of CD45.1$^+$ host mice for CD44 and CD62L at day 30 post-infection with Lm-gp33. Numbers represent the frequencies of each population on the indicated gates (left). Quantification of the frequencies of total, effector memory (CD44^{hi}CD62L^{lo}), and central memory (CD44^{hi}CD62L^{hi}) CD45.2$^+$ donor P14Rag2KO CD8$^+$ T cells for each genotype as assessed by flow cytometry (right) * p <0.05, ** p < 0.01, compared with P14Rag2KO WT CD8$^+$ T cells using two-tailed Student's t-test (D). Data are from one experiment representative of two experiments (D, mean ± S.E.M. of each population from all mice).

A PCA on naive P14RagKO CD8⁺ T cells

B PCA on 12h-activated P14RagKO CD8⁺ T cells

C Differential gene expression analysis on P14Rag2KO naïve CD8⁺ T cells

Lin28Tg vs WT

Let-7Tg vs WT

D Differential gene expression analysis on P14Rag2KO 12h-activated CD8⁺ T cells

Lin28Tg vs WT

Let-7Tg vs WT

E Differentially-expressed genes with |log2FoldChange| ≥ 0.5 Naive P14RagKO CD8⁺ T cells

F Differentially-expressed genes with |log2FoldChange| ≥ 0.5 12h-activated P14Rag2KO CD8⁺ T cells

Figure 3.4 Let-miRNAs substantially modify the transcriptome of naive and 12h-activated CD8$^+$ T cells. (A and B) Principal component analysis (PCA) on normalized expression read counts from the RNA-Seq data obtained from P14Rag2KO WT, P14Rag2KO Let-7, and P14Rag2KO Lin28Tg naive **(A)** or 12h-activated **(B)** CD8$^+$ T cells, separated by PC1 (y axis) and PC2 (x axis), which explain 61% and 21% (naive) or 57% and 22% (12h-activated) of the total variance between samples, respectively. All replicate samples from each genotype were clustered by applying 95% confidence ellipses (p<0.05). **(C and D)** Volcano plots displaying differential gene expression in naive **(C)** and 12h-activated **(D)** P14Rag2KO Lin28Tg (left panel) and P14Rag2KO Let-7Tg (right panel) CD8$^+$ T cells, as compared with P14Rag2KO WT CD8$^+$ T cells, by the mean expression value of -log$_{10}$(p-value) (y axis) and the log$_2$ value of the expression fold change (Log2(Fold Change), x axis). Each differentially-expressed gene is represented by a gray solid circle, and significantly upregulated and downregulated genes are indicated in red and blue, respectively. **(E and F)** Heatmap clusters of normalized expression read counts from the RNA-Seq data showing all genes differentially expressed by |log$_2$(Fold Change)| ≥ 0.5 in a statistically-significant manner (p<0.05) in naive **(E)** and 12h-activated **(F)** P14Rag2KO WT (center), P14Rag2KO Let-7 (right), and P14Rag2KO Lin28Tg (left) mice. Downregulated genes are indicated in blue and upregulated genes are represented in red. Cluster I shows genes downregulated in Let-7Tg CD8$^+$ T cells and upregulated in Lin28Tg cells, cluster II indicates genes upregulated in Let-7Tg CD8$^+$ T cells and downregulated in Lin28Tg cells, cluster III represents genes downregulated in both Let-7Tg and Lin28Tg CD8$^+$ T cells, and cluster IV shows genes upregulated in both Let-7Tg and Lin28Tg cells, in comparison with WT CD8$^+$ T cells. Examples of differentially-expressed genes important for CD8$^+$ T cell differentiation are indicated.

A DAVID GO Biological process enrichment analysis on genes from Cluster I in naive P14Rag2KO CD8$^+$ T cells

% Genes: 1, 3, 6, 12

Apoptotic process
Positive regulation of Notch signaling pathway
Cell differentiation
Positive regulation of gene expression
Signal transduction
Activation of MAPK activity
Positive regulation of JUN kinase activity
Positive regulation of ERK1 and ERK2 cascade
Cell adhesion
Protein phosphorylation
Chemotaxis
Inflammatory response
Immune system process
Cell cycle

-Log10(FDR)

B DAVID GO Biological process enrichment analysis on genes from Cluster I in 12h-activated P14Rag2KO CD8$^+$ T cells

% Genes: 10, 20, 30, 40

Negative regulation of transcription from RNA polymerase II promoter
Protein phosphorylation
Microtubule-based movement
Cell cycle

-Log10(FDR)

C pERK1/2 expression in P14Rag2KO activated CD8$^+$ T cells (5 minutes)

Normalized MFI (relative to WT)

WT
Let-7Tg
Lin28Tg

E Nurr77-GFP expression in P14Rag2KO Nurr77-GFP CD8$^+$ T cells (Day 9 post-Lm-gp33 infection)

MFI (GFP)

SLECs
MPECs
Intermediates

D Day 30 post-Lm-gp33 infection

Gated on CD45.2$^+$ donor CD8$^+$ T cells

Gated on GFP$^+$ CD45.2$^+$ donor CD8$^+$ T cells

Empty vector — 17.9 — 20.0 / 80.0
NES — 3.1 — 40.7 / 58.1
NLS — 2.0 — 54.2 / 45.8

CD8 / GFP
CD44 / CD62L

Donor CD8$^+$ T cells
Cell frequency

CD44^{hi}CD62L^{lo} donor CD8$^+$ T cells
Cell frequency

CD44^{hi}CD62L^{hi} donor CD8$^+$ T cells
Cell frequency

● Empty vector
● NES
● NLS

Figure 3.5 Let-7 miRNAs controls the fate of differentiating CD8$^+$ T cells by suppressing the strength of TCR signaling, thereby inhibiting early signaling pathways, including ERK1/2 and Notch. Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis of gene ontology (GO) biological processes significantly enriched (p <0.05) in cluster I of naive **(A)** and 12h-activated **(B)** CD8$^+$ T cells, based on the over-representation of functionally-related gene groups. Data is presented relative to the -$\log_{10}$ of the false discovery rate (-Log_{10}(FDR), x axis). The size of the bubbles indicates the percentage of genes from each cluster contributing to the enriched biological process. **(C)** Normalized MFI of phosphor-ERK1/2 (pERK1/2) in P14Rag2KO WT, P14Rag2KO Let-7Tg, and P14Rag2KO Lin28Tg CD8$^+$ T cells activated *in vitro* for 5 minutes with plate-bound anti-CD3e (1 µg/mL) and anti-CD28 mAbs (5 µg/mL). Data is presented relative to results obtained for 5-minute activated P14Rag2KO WT CD8$^+$ T cells. **(D)** Staining of CD45.2$^+$ donor P14Rag2KO WT CD8$^+$ T cells transduced with GFP reporter-containing empty retroviral vector (n=3), or retrovirus expressing Notch intracellular domain (NICD) fused to either a nuclear export signal (NES, n=3) or a nuclear localization signal (NLS, n=3) in the spleen of CD45.1$^+$ host mice for CD44 and CD62L at day 30 post-infection with Lm-gp33. Numbers represent the frequencies of each population on the indicated gates (left). Quantification of the frequencies of total, effector memory (CD44^{hi}CD62L^{lo}), and central memory (CD44^{hi}CD62L^{hi}) CD45.2$^+$ donor P14Rag2KO CD8$^+$ T cells for each condition as assessed by flow cytometry (right). **(E)** MFI of GFP of P14Rag2KO Nur77-GFP donor CD8$^+$ SLECs (KLGR1^{hi}CD62L^{lo}) and MPECs (KLRG1^{lo}CD127^{hi}) in the blood of CD45.1$^+$ host mice at day 9 post-infection with Lm-gp33. Data is presented relative to MFI obtained for control P14Rag2KO WT CD8$^+$ SLECs and MPECs. * p < 0.05; ** p <0.01, *** p < 0.001, compared with WT using two-tailed Student's t-test. Data are from one experiment representative of two experiments (C; mean and S.E.M. of technical triplicates), or from one experiment (D, E; mean and S.E.M. of each cell population).

A

Distribution of let-7 target genes differentially expressed in Cluster I at all time points tested

CTLs

9

0   3   5

Naive   8   3   20   12h-activated

B

In vitro-generated P14Rag2KO Let-7Tg CTLs

Gated on CD8+ T cells | Gated on GFP^{hi} CD8+ T cells | Gated on GFP^{hi} CD8+ T cells

Empty vector

23.7

30.7   68.1

Cdc34

20.5

6.2   93.4

5.02
137
209

— Isotype control
— Empty vector
— Cdc34

PD-1

C

Day 30 post-Lm-gp33 infection

Gated on CD45.2+ donor CD8+ T cells | Gated on GFP+ CD45.2+ donor CD8+ T cells

Empty vector

18.6

29.7   70.3

Hk2

6.0

47.9   52.1

Donor CD8+ T cells

**

CD44^{hi}CD62L^{lo} donor CD8+ T cells

*

CD44^{hi}CD62L^{hi} donor CD8+ T cells

*

● Empty vector
● Hk2

D

Day 30 post-Lm-gp33 infection

Gated on CD45.2+ donor CD8+ T cells | Gated on GFP+ CD45.2+ donor CD8+ T cells

Empty vector

36.3

23.7   75.8

Mycn

8.7

9.1   72.7

113

Figure 3.6 Let-7 miRNAs consistently represses the expression of multiple target genes throughout CD8$^+$ T cell differentiation, and restrain terminal effector differentiation through inhibiting *Hk2* and *Mycn* expression. (A) Diagram representing the numbers of let-7 direct targets that are differentially expressed in cluster I a statistically significant manner at all stages of CD8$^+$ T cell differentiation examined. **(B)** Staining of P14Rag2KO Let-7Tg CD8$^+$ T cells transduced with GFP reporter-containing empty retroviral vector or retrovirus expressing Cdc34 and differentiated *in vitro* into CTLs for CD44 and CD62L. Numbers represent the frequencies of each population on the indicated gates (left). Histogram of PD-1 expression in GFP^{hi} cells from each condition, as assessed by flow cytometry. Numbers represent the MFI of PD-1 for each condition (right). **(C)** Staining of CD45.2$^+$ donor P14Rag2KO WT CD8$^+$ T cells transduced with GFP reporter-containing empty retroviral vector (n=2), or retrovirus expressing Hk2 (n=3) in the spleen of CD45.1$^+$ host mice for CD44 and CD62L at day 30 post-infection with Lm-gp33. Numbers represent the frequencies of each population on the indicated gates (left). Quantification of the frequencies of total, effector memory (CD44^{hi}CD62L^{lo}), and central memory (CD44^{hi}CD62L^{hi}) CD45.2$^+$ donor P14Rag2KO CD8$^+$ T cells for each condition as assessed by flow cytometry (right). **(D)** Staining of CD45.2$^+$ donor P14Rag2KO WT CD8$^+$ T cells transduced with GFP reporter-containing empty retroviral vector (n=1), or retrovirus expressing Mycn (n=3) in the spleen of CD45.1$^+$ host mice for CD44 and CD62L at day 30 post-infection with Lm-gp33. Numbers represent the frequencies of each population on the indicated gates. * p < 0.05; ** p <0.01, compared with WT using two-tailed Student's t-test. Data are from one experiment representative of two experiments (C; mean and S.E.M. of each cell population), or from one experiment (B, D).

Figure 3.7 Maintenance of let-7 expression during the first 48h of CTL differentiation is sufficient to recapitulate the memory phenotype of Let-7Tg CTLs *in vitro*. Quantitative RT-PCR analysis of mRNA expression in: *Tcf7* (TCF-1), *Sell* (CD62L), *Ccr7*, *Id2, Havcr2* (TIM-3), and *Cd244* (2B4) in *in vitro*-differentiated P14Rag2KO CTLs WT and Let-7Tg CTLs which received doxycycline either prior to stimulation or during the culture, as indicated (left, blue boxes), presented relative to the expression of the ribosomal protein *Rpl13a*. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.001$ compared with WT cells from matched culture conditions using two-tailed Student's t-test. Data are from one experiment representative of two experiments (mean ± S.E.M. of technical triplicates).

115

Nurr77-GFP expression in P14Rag2KO Nurr77-GFP CD8$^+$ T cells (12h)

Data by Elena Pobezinskaya, Ph.D.

Figure 3.8 Let-7 miRNAs negatively regulate the strength of TCR signaling in CD8$^+$ T cells. MFI of GFP in P14Rag2KO Nur77-GFP WT, P14Rag2KO Nur77-GFP Let-7Tg, and P14Rag2KO Nur77-GFP Lin28Tg CD8$^+$ T cells activated *in vitro* for 12h with plate-bound anti-CD3e and anti-CD28 mAbs (5 µg/mL each). **** $p < 0.0001$, compared with WT using two-tailed Student's t-test. Data are from one experiment representative of two experiments (mean and S.E.M. of technical triplicates).

Data (A, B, C) by Alexandria Wells, Ph.D.

Figure 3.9 Let-7 miRNAs inhibit terminal effector differentiation through a complex transcriptional mechanism involving *Arid3a*, *Eomes*, and *Hmga1*. Staining of P14Rag2KO Let-7Tg CD8$^+$ T cells transduced with GFP reporter-containing empty retroviral vector or retrovirus expressing Arid3a **(A)**, Eomes **(B)**, or Hmga1 **(C)** and differentiated *in vitro* into CTLs for TIM-3, 2B4, CD160, PD-1, and CD62L and intracellular staining of IFNγ on P14Rag2KO Let-7Tg CD8 T cells transduced with either GFP-expressing empty vector or Hmga1. Numbers represent either the frequencies of positive cells (GFP, TIM-3, 2B4, CD160, CD62L), negative cells (CD62L), or mean fluorescence intensities of protein expression (MFI, PD-1, IFNγ) of each population on the indicated gates.

117

Glycolytic rate assay of *in vitro*-generated P14Rag2KO CTLs

Data by Elena Pobezinskaya, Ph.D., and Alexandria Wells, Ph.D.

Figure 3.10 Let-7 miRNAs regulate glycolysis in CTLs. Glycolytic rate assay of *in vitro*-generated P14Rag2KO WT, P14Rag2KO Let-7Tg, and P14Rag2KO Lin28Tg CTLs. Arrows indicate the times of rotenone/antimycin A (Rot/AA, inhibitor of mitochondrial activity) and 2-deoxyglucose (2-DG, inhibitor of glycolysis) treatments. Data from one experiment representative of two experiments (mean ± S.E.M. of technical triplicates.

CHAPTER 4

CONCLUSIONS AND FUTURE DIRECTIONS

4.1 Conclusions

Overall, the data presented in this thesis show that let-7 miRNAs are global regulators of T cell differentiation. We first investigated the role of let-7 in CD4$^+$ T cell differentiation in the context of autoimmunity, and demonstrated that, as observed in CD8$^+$ T cells, the expression level of let-7 miRNAs is high in naive CD4$^+$ T cells, but gets downregulated upon activation, proportionally to both the strength and duration of TCR signaling. Moreover, we show that this reduction in let-7 expression is required for the differentiation of pathogenic Th17 cells in EAE, the mouse model of the autoimmune disease MS. Specifically, maintenance of high levels of let-7 during the differentiation of these cells resulted in almost complete protection from disease, while absence of let-7 in pathogenic Th17 cells led to aggravated EAE. In fact, we demonstrated that let-7 negatively regulated the proliferation, IL-1β/IL-23-dependent acquisition of function, and CCR2/CCR5-dependent migration of these cells to the CNS. This first study thus established a protective role for let-7 miRNAs in EAE, which has promising therapeutic implications for the treatment of MS and related autoimmune diseases.

We further predicted a regulatory role of let-7 miRNAs in the fate determination of CD8$^+$ T cells towards memory cell formation and terminal-effector differentiation using RNA-Seq and bioinformatics analyses as an unbiased approach, which we validated through *in-vitro* and *in-vivo* experiments. Specifically, we elucidated the paradoxical outcomes of let-7-mediated regulation of CTL function *in-vitro* versus *in-vivo*, during which we had observed that let-7-deficient CTLs that exhibited superior cytolytic

function *in vitro* failed to control tumor growth *in vivo*. Conversely, overexpression of let-7 in CTLs *in vitro* resulted in diminished cytotoxic activity, whereas the same cells elicited outstanding tumor control *in vivo*. Transcriptomic analyses of these cells uncovered that let-7 promoted memory CD8$^+$ T cell differentiation, while inhibiting the differentiation of terminally-differentiated effectors. Conversely, absence of let-7 resulted in the activation of the terminal-effector differentiation program, characterized, among others, by the upregulation of co-inhibitory receptors. These receptors may render let-7-deficient CD8$^+$ T cells susceptible to exhaustion upon engagement with their cognate ligands, which are upregulated in immunosuppressive conditions, such as the tumor microenvironment. In fact, we showed that the influence of let-7 miRNAs on CD8$^+$ T cell fate gets established early upon activation, as let-7 dampened the strength of TCR signaling, which resulted in the inhibition of signaling pathways associated with T cell activation, including ERK1/2 and Notch. Moreover, we identified direct let-7 target genes that were dysregulated throughout CD8$^+$ T cell differentiation, among which we validated the rate-limiting glycolytic enzyme *Hk2* and the transcription factor *Mycn* as drivers of the terminally-differentiated state *in vivo*. Thus, we have identified specific genes that are functionally repressed by let-7 to prevent terminal effector differentiation and maintain the memory potential of CD8$^+$ T cells.

4.2 Future directions

Even though the discoveries described in this dissertation significantly advance our knowledge of the let-7-mediated mechanisms regulating T cell differentiation, they also raise many other questions that remain to be investigated, such as: (1) uncovering the molecular mechanisms governing let-7 expression in T cells (2) determining the

common let-7-mediated regulatory mechanisms of T cell differentiation, (3) assessing the possible role of let-7 in the control of Treg activity, (4) deepening our understanding of the role of let-7 in the induction of memory T cells, and (5) identifying the function of *Hk2* and *Mycn* in the differentiation of terminal effector CD8$^+$ T cells.

4.2.1 Determine the molecular mechanisms controlling let-7 expression in T cells

An outstanding question remaining from our studies on the role of let-7 miRNAs in T cell differentiation is to identify the molecular mechanisms regulating the expression of let-7 in T cells, especially given the therapeutic potential of modulating let-7 expression in these cells to control T cell responses. We previously demonstrated that let-7 miRNAs are abundantly expressed in both naive CD4$^+$ and CD8$^+$ T cells, but get dramatically downregulated over time upon T cell activation (Wells et al., 2017; Angelou et al., 2020). Moreover, we showed that the extent of let-7 downregulation following antigen encounter depends on the strength and duration of TCR signaling, both in CD4$^+$ and CD8$^+$ T cells. Because mature miRNAs are encoded in genes and generated following a sequence of transcriptional and post-transcriptional steps during biogenesis, it would be interesting to examine whether the TCR-mediated regulatory mechanisms of let-7 expression are of epigenetic, transcriptional and/or post-transcriptional nature.

To test whether let-7 is regulated at the epigenetic level, the chromatin state at the distinct let-7 miRNA loci can first be analyzed in naive and activated T cells using methods such as ATAQ-Seq and bisulfite sequencing. ATAQ-Seq, or assay for transposase-accessible chromatin with high-throughput sequencing, enables the analysis of global epigenetic profiles through the construction of a sequencing library using the hyperactive transposase Tn5, which integrates the Tn5 transposon modified with flanking

sequencing adapters, at accessible chromatin regions of the genome (Buenrostro et al., 2013), which can be identified by sequencing. Bisulfite sequencing consists of treating DNA with bisulfite before sequencing to uncover methylation profiles, particularly of cytosine residues at the carbon-5 position of CpG dinucleotides, which are found at high frequencies at gene promoters, and where methylation represses transcriptional activity (Frommer et al., 1992). The predicted outcomes of such experiments would be that the genomic loci of let-7 miRNAs in naive T cells consist of open chromatin, and would therefore be enriched following ATAQ-Seq, but become less accessible to the transcriptional machinery in activated T cells, in which these loci would not be detected, or at very low levels, by ATAQ-Seq. Conversely, CpG dinucleotides at let-7 miRNA promoters in naive T cells would not be marked by methylation, as they are transcriptionally active, while in activated T cells CpG methylation at these sites would be increased, as let-7 miRNA transcription is repressed.

To identify the potential transcriptional mechanisms regulating let-7 miRNA expression in T cells, proteomics of isolated chromatin segments (PICh), can be run on naive and activated T cells. This technique employs DNA probes that hybridize to genomic loci of interest and pull these down together with associated proteins, which can be subsequently identified using mass spectrometry (Déjardin & Kingston, 2009). Proteins bound to let-7 loci in activated, but not naive T cells, may be responsible for the negative regulation of let-7 expression following antigen encounter. These candidates can first be validated by overexpression, where the open-reading frame (ORF) of their respective genes is cloned into a retroviral vector containing a GFP reporter that gets transduced in NIH/3T3 fibroblasts, in which let-7 miRNAs are abundantly expressed.

Candidates that induce a reduction in let-7 expression in this system can then be tested functionally by transducing activated T cells with specific shRNAs targeting these genes. Recovery of high let-7 expression upon silencing of these candidates in activated T cells will confirm their role in the TCR-mediated control of let-7 expression.

Previous work in our lab showed that, while mature let-7 miRNAs, including let-7b, let-7c, and let-7g, are depleted in activated T cells, their respective pre-let-7 miRNAs accumulate, suggesting that a post-transcriptional mechanism controls let-7 expression. Subsequent mass spectrometry experiments using pre-let-7b pull-down have identified numerous candidate proteins that bind to pre-let-7b during T cell activation. We have already tested the potential role of some candidates in the regulation of let-7 expression by overexpression in NIH/3T3 fibroblasts, using the gain-of-function strategy described above. Although none of the candidates assessed so far were found to control let-7 expression in this system, more candidates remain to be examined. Once candidates are validated in NIH/3T3 fibroblasts, their potential role in the regulation of let-7 expression in T cells can be assessed by silencing the expression of these genes using shRNAs, as mentioned before. Maintenance of high let-7 miRNA expression upon silencing of these genes will confirm their role in controlling let-7 expression in T cells.

To further understand how let-7 is regulated at different stages of T cell differentiation, the experimental approaches proposed above can also be expanded to SLECs, MPECs, memory, and exhausted T cells. To this end, donor $CD8^+$ T cells adoptively transferred into congenic recipient mice challenged with Lm or cancer can be electronically sorted at these differentiation stages. In addition to offering important insights into the molecular mechanisms regulating the expression of let-7 miRNAs in T

cells, these findings will provide a therapeutic strategy to modulate let-7 expression to enhance T cell responses against infections and cancer, and suppress the activity of autoreactive T cells.

4.2.2 Identify the common let-7-mediated mechanisms regulating T cell differentiation

We show, in accordance with previous publications (Polikepahad et al., 2010; Kumar et al., 2011; Swaminathan et al., 2012), that the let-7-mediated suppression of effector CD4$^+$ T cell differentiation is not limited to the pathogenic Th17 cell subset and extends to the Th0, Th1, and Th2 lineages. Together with our published data on the suppressive function of let-7 in the differentiation of effector CD8$^+$ T cells (Wells et al., 2017), our findings indicate that let-7 plays a global regulatory role in T cell differentiation, and suggest that common let-7-mediated regulatory mechanisms are involved in the control of both CD4$^+$ and CD8$^+$ T cell differentiation. Because let-7, initially highly expressed in naive T cells, is downregulated in both subsets within the first 48 hours following TCR stimulation, and since both CD4$^+$ and CD8$^+$ T cells undergo shared early activation signaling pathways downstream of TCR signaling, a major point to address will be to determine the common genes within these pathways that are regulated by let-7 during T cell differentiation. A first step in answering this question would be to perform RNA-Seq on monoclonal WT, Let-7Tg, and Lin28Tg CD4$^+$ and CD8$^+$ T cells at the naive and early-activated stage, followed by bioinformatics analyses. Such analyses that will be relevant in identifying the shared signaling pathways regulated by let-7 in both CD4$^+$ and CD8$^+$ T cells are contained within pathway analysis softwares, which interact with pathways collections and protein interaction networks databases. The

algorithm of such softwares will calculate the number of genes from the RNA-Seq data that are differentially expressed in the pathway collection databases between WT versus Let-7Tg, and WT versus Lin28Tg activated CD4$^+$ and CD8$^+$ T cells, and generate a list of predicted let-7-regulated pathways ranked according to the statistical significance of the overlap between the list of differentially expressed genes and the genes contained in a given pathway. The pathways that are most probably regulated by let-7 will be the ones that are shared between the WT-versus-Let-7Tg and WT-versus-Lin28Tg hits in both the CD4$^+$ and CD8$^+$ T cell samples.

Upon identification of these predicted shared let-7-regulated pathways, and following validation of these *in silico* predictions by quantifying the transcript and protein expression of the direct let-7 target genes contained in the identified pathways in WT, Let-7Tg, and Lin28Tg activated CD4$^+$ and CD8$^+$ T cells, whether these factors promote T cell differentiation will be tested using both gain-of-function and loss-of-function approaches. Gain-of-function can be achieved through transduction of early-activated T cells with a retroviral overexpression vector containing the open reading frame of these candidate genes, as well as a reporter such as GFP, upon which cells overexpressing these factors can be identified through GFP expression. Similarly, loss-of-function can be accomplished by designing shRNAs capable of inhibiting the expression of the candidate genes. Implementing these approaches in both *in vitro* and *in vivo* experimental strategies, using the outcome on effector T cell differentiaton as a readout, will enable us to directly test the hypothesis that let-7 miRNAs negatively regulate both CD4$^+$ and CD8$^+$ T cell differentiation by mechanistically targeting our candidate genes.

In vitro, when compared with the same cells overexpressing the empty vector, recovery of effector T cell phenotype upon overexpression of these genes in Let-7Tg CD4$^+$ and CD8$^+$ T cells, as well as diminished effector T cell phenotype in WT and Lin28Tg CD4$^+$ and CD8$^+$ T cells expressing shRNAs targeting these factors, will confirm that the candidate genes are regulated by let-7, and functionally relevant in both CD4$^+$ and CD8$^+$ T cell differentiation. *In vivo* models of infection, autoimmunity, and cancer, can also be used to determine whether these candidate genes control T cell differentiation, thereby establishing their biological significance. To investigate the potential regulatory role of these genes in T cell differentiation during acute infection, transduced OT-I Rag2KO CD8$^+$ T cells, which specifically recognize the OVA$_{257-264}$ epitope from the chicken ovalbumin (OVA), or OT-II Rag2KO CD4$^+$ cells, which specifically recognize the OVA$_{323-339}$ epitope, can be transferred into congenically-marked recipient mice which are subsequently challenged with an OVA-expressing Lm strain (Lm-OVA). In comparison with T cells expressing the empty vector, shRNA-expressing donor WT and Lin28Tg T cells will become more MPEC-like, resulting in enhanced memory T cell formation.

To investigate the function of the candidate genes in T cell differentiation during the anti-cancer immune response, transduced OT-I Rag2KO CD8$^+$ T cells or OT-II Rag2KO CD4$^+$ cells can be adoptively transferred into recipient mice challenged with subcutaneous OVA-expressing B16 melanoma tumors (B16-OVA). In the case of CD8$^+$ T cells, it would be predicted that, when compared to the same cells expressing the empty vector, Let-7Tg T cells overexpressing the candidate genes would divert towards the terminal-effector state and thus would not be able to control tumor growth, while shRNA-

expressing donor WT and Lin28Tg T cells would control the tumors more efficaciously, as they would adopt a memory-like phenotype. For CD4$^+$ T cells, in comparison to empty vector-expressing cells, donor Let-7Tg T cells overexpressing the candidate genes would become better helpers and contribute to effective tumor control, while donor WT and Lin28Tg T cells that express shRNAs would be detrimental to the anti-tumor response, as their helper capacity would be compromised.

To assess whether the predicted let-7 target genes regulate the differentiation of both T cell subsets in the context of autoimmunity, T cell transfers in EAE and the RIP-mOVA model of diabetes, in which membrane-OVA is expressed under the control of the rat insulin promoter, can be respectively used as CD4$^+$ and CD8$^+$ T cell-driven autoimmunity *in vivo* experimental methods. 2D2Rag2KO donor CD4$^+$ T cells can be used in EAE, while OT-IRag2KO donor CD8$^+$ T cells can be employed in the diabetes model. In comparison with T cells expressing the empty vector, Let-7Tg T cells overexpressing the candidate genes are expected to exhibit enhanced pathogenicity, while the autoreactive phenotype of shRNA-expressing donor WT and Lin28Tg T cells would be diminished.

If some candidate genes, in addition to meet our predictions following the above-mentioned gain-of-function and loss-of function *in vitro* and *in vivo* studies, are not well characterized in regards to their role in T cell differentiation, it would be interesting to generate conditional overexpression and knock-out mouse models, in which these factors are specifically overexpressed or deleted in T cells, respectively. Further crossing of these mice with TCR-transgenic mice on a Rag2KO background would provide powerful tools

for the study of the function of these genes in T cell differentiation *in vitro* and *in vivo* using the disease models mentioned before.

4.2.3 Investigating the potential role of let-7 in Treg function

Although we observed substantial suppression of monoclonal 2D2Rag2KO iTreg differentiation *in vitro* in Chapter 2, we showed that mice which received 2D2Rag2KO Let-7Tg CD4$^+$ T cells upon EAE induction did not develop autoimmunity, due to the let-7-mediated inhibition of pathogenic effector CD4$^+$ T cells. This global let-7-mediated inhibition of effector CD4$^+$ T cell differentiation may have masked a potential role of let-7 in the regulation of Treg activity, which will be important to determine given that Tregs are critical regulators of immune responses and are very different from other effector CD4$^+$ T cell lineages. To study the potential role of let-7 in the regulation of Treg activity, we could acquire FOXP3-GFP mice, in which only Tregs express the GFP reporter that is constitutively expressed under the control of the Treg-specific FOXP3 promoter, and can thus be electronically sorted by gating on GFP$^+$ cells. Breeding FOXP3-GFP mice to Let-7Tg and Lin28Tg mice will enable the direct investigation of the potential regulatory role of let-7 miRNAs in the immunosuppressive function of Tregs both *in vitro* and *in vivo*.

To test whether let-7 suppresses Treg activity, an *in-vitro* suppression assay can be performed using FACS-sorted FOXP3-GFP (GFP$^+$) WT, Let-7Tg, and Lin28Tg Tregs co-cultured with CTV-labeled electronically-sorted GFP$^-$ naive WT CD4$^+$ T cells activated *in vitro* with anti-CD3e mAbs and CD4 T cell-depleted irradiated splenocytes. In this assay, the extent of GFP$^-$ CD4$^+$ T cell proliferation, represented by CTV dilution, is inversely correlated with the potential of Treg immunosuppressive function. The

predicted outcome of this assay would be, in comparison to WT Tregs, a diminished suppressive capacity in Let-7Tg Tregs, whereas in Lin28Tg Tregs the immunosuppressive potential would be increased.

To confirm the biological significance of let-7 in the negative regulation of Treg-mediated immunosuppression *in vivo*, the T cell transfer model of colitis can be employed, in which FACS-sorted FOXP3-GFP WT, Let-7Tg, and Lin28Tg Tregs are co-transferred with electronically-sorted GFP$^-$ CD45RB^{hi} naive WT CD4$^+$ T cells, which are pathogenic and induce the disease, into Rag2KO recipient mice. In this model, weight loss and colon inflammation are inversely correlated with Treg immunosuppressive capacity and disease control. When compared to WT Tregs, Let-7Tg Tregs would be expected to show reduced suppressive activity, while Lin28Tg Tregs would exhibit enhanced disease control.

To investigate the let-7-mediated molecular mechanisms regulating Treg function, FACS-sorted FOXP3-GFP WT, Let-7Tg, and Lin28Tg Tregs can be subjected to RNA-Seq, and the transcriptome of these cells can be subsequently analyzed by bioinformatics analyses. The potential mechanistic role in Treg function of genes that are negatively regulated by let-7 in Tregs and that are also predicted direct let-7 targets can be tested by gain-of-function and loss-of-function approaches described before, using *in-vitro* suppression assays and colitis.

If the hypothesis that let-7 inhibits Treg-mediated immunosuppression is validated through the experiments proposed above, let-7 miRNAs may be established as a novel therapeutic target that could be artificially deleted in Tregs from patients suffering from autoimmune disorders such as inflammatory bowel disease, transplant rejection, and

graft-versus-host disease to enhance Treg-mediated immunosuppression of autoimmunity. On the other hand, let-7 miRNAs could be specifically delivered to Tregs that populate the the tumor microenvironment of cancer patients to inhibit their immunosuppressive activity towards the anti-tumor response.

4.2.4 *In-vivo* assessment of the memory-promoting role of let-7 in T cells

Although we demonstrated in Chapter 3 that the memory potential of let-7-deficient CD8$^+$ T cells is compromised *in vivo* by the adoptive transfer of P14Rag2KO Lin28Tg naive CD8$^+$ T cells in congenic host mice subsequently challenged with Lm-gp33, we did not show that CD8$^+$ memory T cell formation is enhanced when high let-7 expression is maintained by adoptive transfer of Let-7Tg CD8$^+$ T cells in this system. Despite the fact that this experiment is conceptually feasible, previous work in our lab revealed that adoptively transferred Let-7Tg cells could not be retrieved from the spleen of Lm-gp33-challenged host mice at 30 dpi. Because we previously showed that let-7 inhibits CD8$^+$ T cell clonal expansion (Wells et al., 2017), this phenotype could be explained by impaired proliferation. It was also described that central-memory T cells, the memory subset which Let-7Tg CTLs shares the most phenotypic attributes with, can give rise to tissue-resident memory T cells that populate non-lymphoid organs, including the skin (Osborn et al., 2019). Thus, it will be interesting to test whether the preferential location of memory Let-7Tg CD8$^+$ T cells is in peripheral tissues, which would provide an explanation for their absence in lymphoid organs. Moreover, minor differences in the genetic background of Let-7Tg and host mice exist and could therefore cause allogeneic rejection of donor Let-7Tg cells. Therefore, whether complete genetic background matching of Let-7Tg mice with host mice through backcrossing can rescue this technical

difficulty would be interesting to assess. A direct solution to this issue that would avoid the lengthy process of backcrossing would be to clone let-7g into a retroviral vector containing a GFP reporter, and use this method to overexpress let-7 to the same extent as in Let-7Tg CD8$^+$ T cells in donor WT CD8$^+$ T cells of the same genetic background as host mice, which prevents any risk of allogeneic rejection. Using this approach, the role of let-7 in the formation of memory CD8$^+$ T cells *in vivo* can be assessed using the Lm-gp33 model of infection and compared in the same host mice between let-7g-overexpressing (GFP$^+$) and WT (GFP$^-$) donor P14Rag2KO CD8$^+$ T cells. Potential differences in the preferential anatomical location between these populations can also be examined by comparing the ratios of GFP$^+$ versus GFP$^-$ frequencies in lymphoid and non-lymphoid organs.

The same approach can be used to investigate the potential role of let7 miRNAs in the control of memory CD4$^+$ T cell generation, which was not addressed in this dissertation, with the hypothesis that, similarly to CD8$^+$ T cells, let-7 directs the fate of CD4$^+$ T cells towards memory formation. In fact, we have generated a strain of Lm that expresses the gp$_{66-81}$ epitope of LCMV (Lm-gp66), which is specifically recognized by TCR-transgenic SMARTA CD4$^+$ T cells. Thus, crossing SMARTA mice to WT and Lin28Tg mice on a Rag2KO background will enable the study of the potential regulatory role of let-7 miRNA in memory CD4$^+$ T cell generation *in vivo* by adoptive transfer of transduced SMARTARag2KO WT CD4$^+$ T cells into congenically-marked host mice subsequently challenged with Lm-gp66. To investigate the effect of let-7 deficiency on memory CD4$^+$ T cell formation, donor naive SMARTARag2KO Lin28Tg CD4$^+$ T cells can be adoptively transferred into congenic recipient mice subsequently infected with

Lm-gp66 . In comparison with WT (GFP$^-$) CD4$^+$ T cells, let-7-overexpressing (GFP$^+$) CD4$^+$ T cells would be predicted to show enhanced memory cell formation, while absence of let-7 would be expected, as in CD8$^+$ T cells, to result in compromised generation of memory CD4$^+$ T cells.

4.2.5 Determine the function of *Hk2* and *Mycn* in terminal effector CD8$^+$ T cell differentiation

In Chapter 3, we identified *Hk2* and *Mycn* as let-7 direct targets that functionally promote the terminal effector fate in CD8$^+$ T cells, using retroviral transduction to overexpress these genes as a gain-of-function approach. To test whether absence of these genes results in the specification of CD8$^+$ T cells towards the memory fate, conditional genetic knock-out mouse models in which these genes would be specifically deleted in CD8$^+$ T cells could be generated. In fact, Hk2$^{fl/fl}$ and Mycn$^{fl/fl}$ mice were already produced by other groups (Knoepfler et al., 2002; Patra et al., 2013). Thus, breeding these mice to mice that express the Cre recombinase under the control of a T cell-specific promoter, such as CD4 or CD2, will result in the deletion of *Hk2* and *Mycn* only in T cells. These mouse model will enable the study of the role of these genes in terminal effector CD8$^+$ T cell differentiation using *in-vitro* CTL differentiation and the *in vivo* model of Lm infection used throughout Chapter 3. It would be expected that, consistently with our overexpression studies, the generation of memory T cells would be enhanced in CD8$^+$ T cells deficient in either gene.

Altogether, this dissertation establishes a central role for let-7 miRNAs in the regulation of T cell differentiation, and highlights the very promising medical potential

of using let-7 miRNA delivery as a novel therapeutic mean to modulate T cell-mediated

responses for the treatment of pathological conditions, such as autoimmunity and cancer.

CHAPTER 5

MATERIALS AND METHODS

5.1 Mice

C57BL/6J (WT CD45.2$^+$, stock no. 000664), B6.SJL- *Ptprc^{a}Pepc^b*/ BoyJ (WT CD45.1$^+$, stock no. 002014), B6(Cg)-Rag2$^{tm1.1Cgn}$/J (Rag2KO, stock no. 008449), B6.Cg-Col1a1$^{tm3(tetO-Mirlet7g/Mir21)Gqda}$/J (let-7g, stock no. 023912), B6.Cg- Gt(ROSA)26 Sor$^{tm1(rtTA*M2)Jae}$/J (M2rtTA, stock no. 006965), and C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J (Nur77-GFP, stock no. 016617) mice were acquired from the Jackson Laboratory. let-7g and M2rtTA mice were bred to generate Let-7Tg mice. Mice with a human CD2 promoter-driven Lin28B transgene (Lin28Tg) (Pobezinsky et al., 2015), as well as B6 Tg(TcrLCMV)327Sdz/JDvs/J (P14) mice were generously provided by Alfred Singer (NCI, NIH) and C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (2D2) mice were a kind gift from Barbara Osborne (UMass Amherst, VASCI). 2D2 mice were crossed on a Rag2KO background to produce 2D2Rag2KO WT mice. Let-7Tg and 2D2 mice were bred on a Rag2KO background to generate 2D2Rag2KO Let-7Tg mice. Lin28Tg and 2D2 mice were crossed on a Rag2KO background to produce 2D2Rag2KO Lin28Tg mice. P14 mice were crossed on a Rag2KO background to produce P14Rag2KO WT mice. Let-7Tg and P14 mice were bred on a Rag2KO background to generate P14Rag2KO Let-7Tg mice. Lin28Tg and P14 mice were crossed on a Rag2KO background to produce P14Rag2KO Lin28Tg mice. Control mice used were either littermates or age and sex-matched mice. All breedings were maintained at the University of Massachusetts, Amherst. All experiments were executed according to the recommendations in the Guide for the Care and Use of Laboratory Animals of the

National Institutes of Health. All mice were handled in accordance with reviewed and approved institutional animal care and use committee (IACUC) protocols (#2017-0041, #2017-0053) of the University of Massachusetts.

5.2 Doxycycline treatment for the induction of let-7 transgene expression

All experimental mice (including controls) were fed with 2 mg/mL doxycycline hyclate (Sigma) and 10 mg/mL sucrose in drinking water that was replaced once over the course of 4 days before the start of experiments to induce maximal let-7g expression. For EAE experiments, doxycycline treatment was maintained throughout disease course analysis, during which doxycycline-containing water was replaced every other day. For *in-vitro* lymphocyte cultures, lymphocyte culture media (see cell sorting and *in-vitro* culture below) was complemented with 2 µg/mL doxycycline hyclate.

5.3 Cell sorting and *in-vitro* culture

Lymph nodes were collected and gently dissociated using sharp-ended forceps to release lymphocytes. Naive CD4$^+$CD44^{lo}CD25$^-$CD8$^-$ T cells were either purified using electronic sorting after removal of B cells from whole-lymphocyte suspensions using α-mouse IgG-coated magnetic beads (BioMAg, Qiagen) or directly isolated from whole-lymphocyte suspensions using the EasySep^{TM} Mouse Naive CD4+ T Cell Isolation kit (Stem Cell Technologies) according to the manufacturer's instructions. Cells were cultured in RPMI media supplemented with 10% fetal bovine serum, 1% penicillin/streptavidin, 1% L-glutamine, 1% non-essential amino-acids, 1% sodium pyruvate, 1% HEPES and 0.3% β-mercaptoethanol. Culture media was supplemented with 2 µg/mL doxycycline, and 100

μg/mL gentamicin when necessary. Unless otherwise indicated, cells were activated with plate-bound α-CD3 (clone 2C11, 1 or 5 µg/mL) and α-CD28 (clone 37.51, 5 µg/mL).

5.4 Induction of EAE and disease analysis

EAE was induced by subcutaneous immunization with the MOG_{35-55} peptide in complete Freund's adjuvant (Hooke Laboratories EK-2110) according to the manufacturer's instructions. Intraperitoneal injection of 60 ng pertussis toxin (Hooke Laboratories BT-0105) was performed 2-4 hours and 26-28 hours post-immunization. For adoptive-transfer experiments, intravenous injection of $2-2.5x10^6$ WT, Let-7Tg or Lin28Tg 2D2Rag2KO naive $CD4^+$ T cells was performed 12 hours prior to immunization with MOG_{35-55}. EAE symptoms were scored according to standard criteria: 0, asymptomatic; 1, limp tail; 2, hindlimb weakness; 3, hindlimb paralysis; 4, complete hindlimb and partial frontlimb paralysis; 5, moribund or death.

5.5 Isolation of CNS-infiltrating cells

Experimental mice were sacrificed at the peak of EAE and perfused through the left cardiac ventricle with PBS containing 1% fetal bovine serum. Brain and spinal cord tissues were dissociated and digested with 1 mg/mL DNaseI (Roche) and 2.5 mg/mL collagenase D (Roche) for 30 minutes at 37°C using a gentleMACS dissociator (Miltenyi), filtered through 100-µm mesh strainers, and centrifuged through a Percoll density gradient (37% and 70%). Mononuclear cells in the interphase were collected, washed twice with PBS and resuspended in lymphocyte culture media prior to *in-vitro* restimulation.

5.6 Enzyme-linked immunosorbent assay (ELISA)

Spleens from experimental mice were harvested at the peak of EAE and splenocytes were released by gentle organ dissociation using sharp-ended forceps. After erythrocyte lysis, duplicates of 2×10^7 splenocytes from each mouse were restimulated in lymphocyte culture media supplemented with either 2.5, 5 or 10 µg/mL MOG$_{35-55}$ (Hooke Laboratories DS-0111) in the presence of 2 µg/mL doxycycline hyclate. Cytokine concentrations were measured in supernatants collected from restimulated cells after 5 days in culture. Concentrations of secreted IL-17, GM-CSF and IFNγ were measured using matching capture and biotinylated detection mAbs (BD Pharmingen) in a sandwich ELISA. HRP-conjugated streptavidin and HRP substrate from the TMB ELISA kit (Pierce) were applied for the quantification of HRP activity at 450 nm using a Synergy™ 2 Multi-Mode Microplate Reader (Biotek).

5.7 CTV and CFSE labeling

Naive CD4$^+$ T cells were labeled at 1×10^6 cells/mL in PBS containing 2.5 µM CTV or 1 µM CFSE, both obtained from Invitrogen, for 15 minutes at 37°C. The labeling reaction was stopped by washing the cells with lymphocyte culture media prior to use in experiments.

5.8 In-vitro proliferation assay

CTV-labeled WT, Let-7Tg and Lin28Tg cells were activated with plate-bound α-CD3e (clone 2C11, 5 µg/mL) and α-CD28 (clone 37.51, 5 µg/mL). Cells were cultured for 3 days prior to CTV dilution profile analysis by flow cytometry.

5.9 *In-vitro* differentiation of CD4$^+$ T helper (Th) cells

Naive CD4$^+$ T cells (1x10^6) were activated with soluble α-CD3 (clone 2C11, 2 µg/mL) in the presence of irradiated WT splenocytes (5x10^6) and cultured for 5 days in lymphocyte culture media. In some experiments, whole-splenocyte suspensions were depleted of CD4$^+$ and CD8$^+$ T cells using α-mouse CD4 (clone L3T4) and α-mouse CD8 (clone Ly-2) microbeads (Miltenyi) followed by magnetic-activated cell sorting. For pathogenic Th17 differentiation, culture media was further supplemented with 20 ng/mL IL-6 (Miltneyi), 10 ng/mL IL-1β (Miltenyi), 10 ng/mL IL-23 (R&D Systems), 10 µg α-IFNγ mAbs (clone XMG1.2, BioXCell) and 10 µg/mL α-IL-4 mAbs (clone 11B11, BioXCell). For Th0 differentiation, culture media was further supplemented with 200 U/mL IL-2 (Peprotech). For Th1 differentiation, culture media was further supplemented with 200 U/mL IL-2, 10 ng/mL IL-12 (Peprotech) and 10 µg/mL α-IL-4 mAbs (clone 11B11, BioXCell). For Th2 differentiation, culture media was further supplemented with 200 U/mL IL-2, 10 ng/mL IL-4 (Peprotech) and 10 µg/mL α-IFNγ mAbs (clone XMG1.2, BioXCell). For non-pathogenic Th17 cell differentiation, culture media was further supplemented with 20 ng/mL IL-6 (Miltenyi), 2 ng/mL TGF-β (Miltenyi), 10 µg/mL α-IFNγ mAbs (clone XMG1.2, BioXCell) and 10 µg/mL α-IL-4 mAbs(clone 11B11, BioXCell). For iTreg differentiation, naive CD4$^+$ T cells were stimulated with 10 µg/mL soluble α-CD3 (clone 2C11, BD Pharmingen) and culture media was further supplemented with 100 U/mL IL-2 (Peprotech) and 5 ng/mL TGF-β (Miltenyi).

5.10 In-vitro differentiation of cytotoxic CD8$^+$ T lymphocytes (CTLs)

Naive CD8$^+$ T cells were stimulated either with irradiated splenocytes loaded with anti-CD3e mAbs (10 µg/mL), or plate-bound anti-CD3e mAbs (10 µg/mL) and anti-CD28

mAbs (5 µg/mL), then differentiated for 5 days in lymphocyte culture media supplemented with 100 U/mL IL-2 (Peprotech). Culture media was further supplemented with 2µg/mL doxycycline when necessary.

5.11 Overexpression and retroviral transduction of candidate genes

The open reading frame (ORF) of *Ccr2*, *Ccr5*, *Cdc34*, *Hk2*, *Mycn*, *NICD-NES*, and *NICD-NLS* were cloned into the pMRX-IRES-GFP plasmid, which contain a green fluorescent protein (GFP) reporter (Saitoh et al., 2002). Empty pMRX-IRES-GFP plasmids were used as controls. Retrovirus supernatants were produced by transfecting Platinum-E (Plate-E) retroviral packaging cells (Morita et al., 2000) using Transporter 5 transfection reagent (Polysciences). Retrovirus supernatants were concentrated 10x in lymphocyte culture media with PEG-it™ virus concentration reagent (System Biosciences) prior to cell transduction. T cells were retrovirally transduced 24h after activation with 10x-concentrated retrovirus supernatants by spin-infection (660 xg for 90 minutes at 37°C) in the presence of polybrene (4 µg/mL). Transduction media was replaced with lymphocyte culture media appropriately supplemented 4h after spin-infection. Analysis of transduced cells was performed by gating on the GFP$^+$ cell population.

5.12 Flow cytometry

For analysis of surface markers, live cells were treated with α-CD16/32 Fc block (2.4G2, BD Pharmingen, RRID:AB_394657) prior to staining with antibodies against surface markers for 30 minutes at 4°C. For intracellular cytokine staining, cell suspensions were restimulated *in vitro* for a total of 4 hours with 50 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma) and 1 µM Ionomycin (Sigma) with addition of 2 µM monensin

(eBioscience) in the last 2 hours of restimulation to inhibit secretion. After surface marker staining, cells were stained with the Live/Dead fixable Aqua Dead Cell Stain Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Before intracellular staining, cells were fixed and permeabilized for 30 minutes at 4°C using the Cytofix/Cytoperm solution kit (BD Biosciences) for cytokine staining or the Foxp3/ Transcription factor staining buffer set (eBioscience) for transcription factor staining according to the manufacturer's instructions. Samples were acquired on a BD LSR Fortessa flow cytometer (BD Biosciences) and data analysis was performed using FlowJo software (TreeStar).

5.13 Antibodies

The following monoclonal antibodies were used for flow cytometry: 2B4 (m2B4, Biolegend), CD4 (RM4-5, Biolegend), CD8a (53-6.7, eBioscience; 5H10, Invitrogen), CD25 (PC61, Biolegend), CD45.2 (104, BD Pharmingen), CD44 (IM7, BD Pharmingen), CD62L (MEL-14, Biolegend), CD127 (A7R34, Biolegend), CD160 (CNX46-3, eBioscience), FOXP3 (FJK-16S, eBioscience), GFP (FM264G, Biolegend), GM-CSF (MP1-22E9, Biolegend), IFNγ (XMG1.2, Biolegend), IL-4 (11B11, BD Pharmingen), IL-17A (17B7, eBioscience), KLRG1 (2F1, BD Pharmingen), PD-1 (29F.A12, Biolegend), PE-Streptavidin (Biolegend), APC-Streptavidin (Biolegend), TIM-3 (RMT3-23, Biolegend).

5.14 RNA isolation and quantitative RT-PCR

RNA was isolated using the QIAGEN miRNeasy (QIAGEN) or the Total RNA Purification kit (Norgen Biotek) according to the manufacturer's instructions. Genomic

140

DNA was eliminated using the DNA-free DNA removal kit (Invitrogen). cDNA of mRNA-encoded genes was synthesized using the SuperScript III Reverse Transcriptase kit (Invitrogen) or the SensiFast^{TM} cDNA synthesis kit (Bioline). cDNA of miRNAs was synthesized using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). SYBR Green or TaqMan quantitative RT-PCR were executed using the SensiFast^{TM} SYBR Lo-Rox kit (Bioline) or the SensiFast ^{TM} Probe Lo-Rox kit (Bioline), respectively. The list of specific SYBR Green amplification primers (Integrated DNA Technologies), TaqMan gene (Integrated DNA Technologies or Thermo Fisher Scientific) and TaqMan microRNA assays (Thermo Fisher Scientific) used can be found in **Table 5.1**. Quantitative RT-PCR data was acquired using a QuantStudio 6 Flex Real-Time PCR system and analyzed using QuantStudio Real-Time PCR software (Applied Biosystems).

5.15 *In-silico* prediction of let-7 binding sites

Let-7 binding sites were identified by searching for complete or partial continuous matches to the extended let-7 seed sequence "TACTACCTCA" in the complete mRNA sequences of the indicated mouse and human genes, and are available in **Table 5.2**. A 6 bp-long perfect match was considered as minimum requirement for a potential binding site. Conservation was assessed according to the retention of the binding site position within corresponding mouse and human mRNA sequences upon optimal GLOBAL pairwise alignment using BioEdit software (Tom Hall, Ibis Therapeutics).

5.16 Luciferase reporter assays

NIH/3T3 cells (ATCC) were transfected with the pmirGLO vector (Promega) containing either the wild-type *in-silico* predicted let-7-binding sites within *Ccr2* and *Ccr5* mouse mRNA, or mutated variants of these binding sites, or either the wild-type or a mutated variant of the antisense seed sequence of let-7g, using Lipofectamine and Plus Reagent (Invitrogen). Firefly luciferase activity was measured 48h post-transfection and was normalized to Renilla luciferase activity, using the Dual-Luciferase Assay Reporter kit (Promega), on a POLARstar Omega 96-well plate reader (BMG Labtech).

5.17 Motility in collagen matrices

In vitro-differentiated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice were harvested at day 5, labeled with CFSE, and resuspended in RPMI/10% FBS. PureCol EZ Gel (Advanced BioMatrix) was added to cells in RPMI/10% FBS to obtain a final collagen gel concentration of 1.6 mg/mL with a final cell concentration of 1.25×10^6 cells/mL. Collagen gels were allowed to fully polymerize for 1 hour at 37°C prior to imaging the cells for 20 minutes at 10-second intervals with a modified inverted epi-fluorescence microscope (Axio Observer.Z1, Carl Zeiss). Data was analyzed using Imaris software (Bitplane).

5.18 Transwell assay

In vitro-differentiated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice were harvested at day 5, washed in RPMI/10% FBS and resuspended at 5×10^6 cells/mL in RPMI/10% FBS. Chemotaxis towards 600 µL control media, Ccl2 and Ccl4 alone (50 ng/mL) or in combination (50 ng/mL or 10 ng/mL

each) in the lower chamber of a 24-well plate was assessed by incubating 100 µL cell suspension in the upper chamber of 24-well 6.5 mm transwell inserts with a 5-µm pore polycarbonate membrane (Corning) at 37°C for 3 hours. Percent chemotaxis was measured by manually counting the number of cells present in the lower chamber and normalized to cell counts obtained in control media for each condition.

5.19 *Listeria monocytogenes-gp33* (Lm-gp33) infection and adoptive CD8[+] T cell transfer

$2x10^4$ CD45.2[+] P14Rag2KO donor cells, or $2x10^5$ transduced CD45.2[+] P14Rag2KO donor cells from the indicated mice were transferred intravenously (i.v.) into CD45.1[+] congenic hosts. Mice were challenged i.v. with $6x10^6$ colony-forming units (cfu) Lm-gp33 grown to log phase in TSB with 50 µg/mL streptomycin the next day, or 1h later, respectively.

5.20 RNA Sequencing (RNA-Seq) and bioinformatics analyses

$20x10^6$ *in vitro*-generated CTLs were sent out for RNA-Seq. Unless specified, the R scripting language was used for bioinformatics analyses.

5.20.1 Reads mapping to the reference genome

Reference genome and gene model annotation files were downloaded from genome website browser (NCBI/UCSC/Ensembl) directly. Indexes of the reference genome were built using Bowtie v2.0.6 and paired-end clean reads were aligned to the reference genome using TopHat v2.0.9. Bowtie uses a BWT(Burrows-Wheeler Transformer) algorithm for mapping reads to the genome and Tophat can generate a database of splice

143

junctions based on the gene model annotation file and thus achieve a better mapping result than other nonsplice mapping tools.

5.20.2 Quantification of gene expression level

HTSeq v0.6.1 was used to count the read numbers mapped of each gene. Reads Per Kilobase of exon model per Million mapped reads (RPKM), which considers the effect of sequencing depth and gene length for the reads count at the same time, was calculated for each gene based on the length of the gene and reads count mapped to this gene.

5.20.3 Differential gene expression analysis

Differential expression analysis between two conditions/groups (three biological replicates per condition) was performed using the DESeq2 R package (2_1.6.3). DESeq2 provide statistical routines for determining differential expression in digital gene expression data using a model based on the negative binomial distribution. The resulting p-values were adjusted using the Benjamini and Hochberg's approach for controlling the False Discovery Rate (FDR). Genes with an adjusted p-value <0.05 found by DESeq2 were assigned as differentially expressed.

5.20.4 Plot generation for data visualization

Principal component analysis (PCA) was performed with normalized expression read counts using the "PCAtools", "car", "RColorBrewer", and "ggplots2" R packages. Volcano plots were generated with differential gene expression analysis output data using the "ggplots2" R package. Heatmaps were generated with normalized expression read

counts using the "ggplots2" and "RColorBrewer" R packages. Bubble plots were generated using the "ggplots2" R package.

5.20.5 Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis of gene ontology (GO) biological processes

Lists of genes of interest were subjected to the gene ontology (GO) Functional Annotation Tool of the Database for Annotation, Visualization and Integrated Discovery (DAVID) database, which finds functionally-related groups of genes that belong to biological processes that are enriched in the submitted gene list (Huang et al., 2009). GO terms with p-value < 0.05 were considered significantly enriched.

5.20.6 Gene set enrichment analysis

The differential gene expression data output was ranked according to the adjusted p-value. Gene signatures were generated by compiling well-defined memory and terminal-effector/exhaustion markers from the literature (Yang et al., 2011; Im et al., 2016; Schietinger et al., 2016; Yu et al., 2017; Snell et al., 2018; Miller et al., 2019). The GSEA software (Broad Institute) was used for data analysis (Mootha et al., 2003; Subramanian et al., 2005).

5.20.7 Venn diagram

Genes contained in Cluster I at all time points tested were analyzed for predicted let-7 miRNA target genes using the TargetScan database (Agarwal et al., 2015). A Venn diagram representing the let-7 target genes dysregulated at all stages of CD8$^+$ T cell differentiation tested was generated using the "ggplots2" R package.

5.21 Statistics

Data statistical analysis was performed with Prism 7 (GraphPad software) or RStudio software (RStudio Team). P-values were determined using a two-tailed Student's t test or a two-way ANOVA, as indicated on the figure legends. A p value < 0.05 was considered significant (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

Table 5.1: Primers and probes used for quantitative RT-PCR

SYBR primers		
Gene	Forward primer (5'-3')	Reverse primer (5'-3')
Bhlhe40	ACGGAGACCTGTCAGGGATG	GGCAGTTTGTAAGTTTCCTTGC
Ccnd2	GAGTGGGAACTGGTAGTGTTG	CGCACAGAGCGATGAAGGT
Ccr2	ATCCACGGCATACTATCAACATC	CAAGGCTCACCATCATCGTAG
Ccr5	TTTTCAAGGGTCAGTTCCGAC	GGAAGACCATCATGTTACCCAC
Cdc25a	ACAGCAGTCTACAGAGAATGGG	GATGAGGTGAAAGGTGTCTTGG
Cdc34	CCCCAACACCTACTATGAGGG	ACATCTTGGTGAACCGGA
Cdk6	GGCGTACCCACAGAAACCATA	AGGTAAGGGCCATCTGAAAACT
Csf2	TGGAAGCATGTAGAGGCCATCA	GCGCCCTTGAGTTTGGTGAAAT
Gata3	CGAGATGGTACCGGGCACTA	GACAGTTCGCGCAGGATGT
Glut3	ATGGGGACAACGAAGGTGAC	GTCTCAGGTGCATTGATGACTC
Hk2	TGATCGCCTGCTTATTCACGG	AACCGCCTAGAAATCTCCAGA
Il1r1	GTGCTACTGGGGCTCATTTGT	GGAGTAAGAGGACACTTGCGAAT
Il4	GGTCTCAACCCCCAGCTAGT	GCCGATGATCTCTCTCAAGTGAT
Il4ra	TCTGCATCCCGTTGTTTTGC	GCACCTGTGCATCCTGAATG
Il6ra	CCTGAGACTCAAGCAGAAATGG	AGAAGGAAGGTCGGCTTCAGT
Il6st	CCGTGTGGTTACATCTACCCT	CGTGGTTCTGTTGATGACAGTG
Il12rb2	AGAGAATGCTCATTGGCACTTC	AACTGGGATAATGTGAACAGCC
Il17a	TTTAACTCCCTTGGCGCAAAA	CTTTCCCTCCGCATTGACAC
Il23r	TTCAGATGGGCATGAATGTTTCT	CCAAATCCGAGCTGTTGTTCTAT
Irf4	TCCGACAGTGGTTGATCGAC	CCTCACGATTGTAGTCCTGCTT
Myc	AGTGCTGCATGAGGAGACAC	GGTTTGCCTCTTCTCCACAG
Qars	CCTTGGCCTTAGCGAGAACAA	TGTCGATGGTAGAACCCAGAATC
Rorc	GACCCACACCTCACAAATTGA	AGTAGGCCACATTACACTGCT
Rpl13a	CGAGGCATGCTGCCCCACAA	AGCAGGGACCACCATCCGCT
Stat3	AGCTGGACACACGCTACCT	AGGAATCGGCTATATTGCTGGT
Tfap4	GGAGAAGCTAGAGCGGGAAC	TTTTGCCGGGATGTAGAGAC
TaqMan probes		
Gene	Assay ID	Source
Ifng	Mm.PT.58.30096391	Integrated DNA Technologies
Rpl13a	Mm.PT.58.43547045.g	Integrated DNA Technologies
Ldha	Mm01612132_g1	Thermo Fisher Scientific
TaqMan microRNA assays		
microRNA	Assay ID	Source
hsa-let-7a	00377	Thermo Fisher Scientific
hsa-let-7b	00378	Thermo Fisher Scientific
hsa-let-7c	00379	Thermo Fisher Scientific
hsa-let-7d	02283	Thermo Fisher Scientific
hsa-let-7e	02406	Thermo Fisher Scientific
hsa-let-7f	00382	Thermo Fisher Scientific
hsa-let-7g	02282	Thermo Fisher Scientific
hsa-let-7i	02221	Thermo Fisher Scientific
U6	01973	Thermo Fisher Scientific

Table 5.2: Let-7-binding sites identified in mouse and human Ccr2 and Ccr5 mRNA sequences

Species	Receptor	Accession number	Binding site	Sequence	Positon
Mouse	*Ccr2*	NM_009915.2	1	TACCTCA	153-159
			2	ACCTCA	2025-2030
	Ccr5	NM_009917.5	1	CTACCT	311-316
			2	ACTACC	356-361
Human	*CCR2*	NM_001123396.2	1	ACCTCA	211-216
			2	CTACCTC	360-366
			3	ACCTCA	1679-1684
	CCR5	NM_000579.3	1	CTACCT	558-563
			2	ACTACCTC	1274-1281

BIBLIOGRAPHY

Abbott AL, Alvarez-Saavedra E, Miska EA, Lau NC, Bartel DP, Horvitz HR, Ambros V. 2005. The let-7 MicroRNA family members mir-48, mir-84, and mir-241 function together to regulate developmental timing in Caenorhabditis elegans. Dev Cell 9(3):403-14. doi: 10.1016/j.devcel.2005.07.009, PMID 16139228

Abdi H, Williams LJ. 2010. Principal component analysis. Wiley Interdisciplinary Reviews: Computational Statistics. 2(4):433–59. doi:10.1002/wics.101

Adrain C, Murphy BM, Martin SJ. 2005. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J Biol Chem 280(6):4663-73. doi: 10.1074/jbc.M410915200, PMID 15569669

Agarwal V, Bell GW2, Nam JW1, Bartel DP1. 2015. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4 doi: 10.7554/eLife.05005, PMID 26267216

Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910–14. doi: 10.1074/jbc.M207577200, PMID 12417590

Akbar AN, Salmon M, Savill J, Janossy G. 1993. A possible role for bcl-2 in regulating T-cell memory--a 'balancing act' between cell death and survival. Immunol Today 14(11):526-32. doi: 10.1016/0167-5699(93)90181-J, PMID 8274194

Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124(4):783-801. doi: 10.1016/j.cell.2006.02.015, PMID 16497588

Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA, Abdelsamed HA, McGuire DJ, Cohen KW, Alexe G, Nagar S, McCausland MM, Gupta S, Tata P, Haining WN, McElrath MJ, Zhang D, Hu B, Greenleaf WJ, Goronzy JJ, Mulligan MJ, Hellerstein M, Ahmed R. 2017. Origin and differentiation of human memory CD8 T cells after vaccination. Nature 552(7685):362-367. doi: 10.1038/nature24633, PMID 29236685

Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765-72. doi: 10.1093/intimm/8.5.765, PMID 8671665

Ahmadzadeh M, Hussain SF, Farber DL. 2001. Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells. J Immunol 166(2):926-35. doi: 10.4049/jimmunol.166.2.926, PMID 11145669

Allie N, Grivennikov SI, Keeton R, Hsu NJ, Bourigault ML, Court N, Fremond C, Yeremeev V, Shebzukhov Y, Ryffel B, Nedospasov SA, Quesniaux VF, Jacobs M. 2013. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci Rep 3:1809. doi: 10.1038/srep01809. doi: 10.1038/srep01809, PMID 23657146

Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H. 2005. Clustering and conservation patterns of human microRNAs. Nucleic Acid Res 33(8):2697-706. doi: 10.1093/nar/gki567, PMID 15891114

Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T. 2003. A uniform system for microRNA annotation. RNA 9(3):277-9. doi: 10.1261/rna.2183803, PMID 12592000

Ameres SL, Martinez J, Schroeder R. 2007. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130(1):101-12. doi: 10.1016/j.cell.2007.04.037, PMID 17632058

Anderson G, Moore NC, Owen JJ, Jenkinson EJ. 1996. Cellular interactions in thymocyte development. Annu Rev Immunol 14:73-99. doi: 10.1146/annurev.immunol.14.1.73, PMID 8717508

Andrus L, Granelli-Piperno A, Reich E. 1984. Cytotoxic T cells both produce and respond to interleukin 2. J Exp Med 159(2):647-52. doi: 10.1084/jem.159.2.647, PMID 6607316

Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ. 2012. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol 6(15):8161-70. doi: 10.1128/JVI.00889-12, PMID 22623779

Angelou CC, Wells AC, Vijayaraghavan J, Dougan CE, Lawlor R, Iverson E, Lazarevic V, Kimura MY, Peyton SR, Minter LM, Osborne BA., Pobezinskaya EL, Pobezinsky LA. 2020. Differentiation of Pathogenic Th17 Cells Is Negatively Regulated by Let-7 MicroRNAs in a Mouse Model of Multiple Sclerosis. Front Immunol 10: 3125. doi: 10.3389/fimmu.2019.03125, PMID 32010153

Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460(7251):108-12. doi: 10.1038/nature08155, PMID 19543266

Araki Y, Wang Z, Zang C, Wood WH 3rd, Schones D, Cui K, Roh TY, Lhotsky B, Wersto RP, Peng W, Becker KG, Zhao K, Weng NP. 2009. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and

function of memory CD8+ T cells. Immunity 30(6):912-25. doi: 10.1016/j.immuni.2009.05.006, PMID 19523850

Arsenio J, Kakaradov B, Metz PJ, Kim SH, Yeo GW, Chang JT. 2014. Early specification of CD8+ T lymphocyte fates during adaptive immunity revealed by single-cell gene-expression analyses. Nat Immunol 15(4):365-372. doi: 10.1038/ni.2842, PMID 24584088

Artavanis-Tsakonas S, Matsuno K, Fortini ME. 1995. Notch signaling. Science 268(5208):225-32. doi: 10.1126/science.7716513, PMID 7716513

Artyomov MN, Lis M, Devadas S, Davis MM, Chakraborty AK. 2010. CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery. Proc Natl Acad Sci U S A 107(39):16916-21. doi: 10.1073/pnas.1010568107, PMID 20837541

Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher HP, Zinkernagel RM, Tonegawa S. 1994. Evidence for a differential avidity model of T cell selection in the thymus. Cell 76(4):651-63. doi: 10.1016/0092-8674(94)90505-3, PMID 8124708

Backer RA, Helbig C, Gentek R, Kent A, Laidlaw BJ, Dominguez CX, de Souza YS, van Trierum SE, van Beek R, Rimmelzwaan GF, ten Brinke A, Willemsen AM, van Kampen AH, Kaech SM, Blander JM, van Gisbergen K, Amsen D. 2014. A central role for Notch in effector CD8(+) T cell differentiation. Nat Immunol 15(12):1143-51. doi: 10.1038/ni.3027, PMID 25344724

Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. Nature 455(7209):64-71. doi: 10.1038/nature07242, PMID 18668037

Badovinac VP, Porter BB, Harty JT. 2002. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 3(7):619-26. doi: 10.1038/ni804, PMID 12055624

Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122(4):553-63. doi: 10.1016/j.cell.2005.07.031, PMID 16122423

Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, Auffray C, Triebel F, Piatier-Tonneau D. 1992. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 176(2):327-37. doi: 10.1084/jem.176.2.327, PMID 1380059

Ban YH, Oh SC, Seo SH, Kim SM, Choi IP, Greenberg PD, Chang J, Kim TD, Ha SJ. 2017. miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation. Cell Rep 20(11):2598-2611. doi: 10.1016/j.celrep.2017.08.065, PMID 28903041

Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER. 1989. Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol 143(1):127-30. PMID 2499625

Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL. 2010. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol 40(1):225-31. doi: 10.1002/eji.200939381, PMID 19877012

Bankovich AJ, Shiow LR, Cyster JG. 2010. CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4. J Biol Chem 285(29):22328-37. doi: 10.1074/jbc.M110.123299, PMID 20463015

Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-7. doi: 10.1038/nature04444, PMID 16382236

Barrett LW, Fletcher S, Wilton SD. 2012. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci 69(21):3613-34. doi: 10.1007/s00018-012-0990-9, PMID 22538991

Bartel, DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136(2), 215-233. doi: 10.1016/j.cell.2009.01.002, PMID 19167326

Bartel, DP. 2018. Metazoan MicroRNAs. Cell 173(1):20-51. doi: 10.1016/j.cell.2018.03.006, PMID 29570994

Baskerville S, Bartel DP. 2005. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11(3):241-7. doi: 10.1261/rna.7240905, PMID 15701730

Baumjohann D, Ansel KM. 2013. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol 13(9):666-78. doi: 10.1038/nri3494, PMID 23907446

Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, Ahmed R. 2002. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195(12):1541-8. doi: 10.1084/jem.20020369, PMID 12070282

Beltra JC, Decaluwe H. 2016. Cytokines and persistent viral infections. Cytokine 82:4-15. doi: 10.1016/j.cyto.2016.02.006, PMID 26907634

Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197(9):1073-81. doi: 10.1084/jem.20021603, PMID 12732654

Beura LK, Wijeyesinghe S, Thompson EA, Macchietto MG, Rosato PC, Pierson MJ, Schenkel JM, Mitchell JS, Vezys V, Fife BT, Shen S, Masopust D. 2018. T Cells in Nonlymphoid Tissues Give Rise to Lymph-Node-Resident Memory T Cells. Immunity 48(2):327-338.e5. doi: 10.1016/j.immuni.2018.01.015., PMID 29466758

Beura LK, Fares-Frederickson NJ, Steinert EM, Scott MC, Thompson EA, Fraser KA, Schenkel JM, Vezys V, Masopust D. 2019. CD4+ resident memory T cells dominate immunosurveillance and orchestrate local recall responses. J Exp Med 216(5):1214-1229. doi: 10.1084/jem.20181365, PMID 30923043

Bhat P, Leggatt G, Waterhouse N, Frazer IH. 2017. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis 8(6):e2836. doi: 10.1038/cddis.2017.67, PMID 28569770

Bird L. 2018. Innate immunity: Sensing bacterial messages. Nat Rev Immunol 18(2):78. doi: 10.1038/nri.2018.5, PMID 29379188

Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. 2009. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10(1):29-37. doi: 10.1038/ni.1679. doi: 10.1038/ni.1679, PMID 19043418

Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74(4):597-608. doi: 10.1016/0092-8674(93)90508-n, PMID 8358789

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3(1):87-98. doi: 10.1016/1074-7613(95)90161-2, PMID 7621080

Borchert GM, Lanier W, Davidson BL. 2006. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13(12):1097-101. doi: 10.1038/nsmb1167, PMID 17099701

Borowski A.B., Boesteanu A.C., Mueller Y.M., Carafides C., Topham D.J., Altman J.D., Jennings S.R., Katsikis P.D. 2007. Memory CD8+ T cells require CD28 costimulation. J. Immunol. 179:6494–6503.

Bousso P. 2008. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat Rev Immunol 8(9):675-84. doi: 10.1038/nri2379, PMID 19172690

Brancati G, Großhans H. 2018. An interplay of miRNA abundance and target site architecture determines miRNA activity and specificity. Nucleic Acids Res. 46(7):3259-3269. doi: 10.1093/nar/gky201, PMID 29897601

Brehm MA, Daniels KA, Welsh RM. 2005. Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol 175(8):5043-9. doi: 10.4049/jimmunol.175.8.5043, PMID 16210607

Bromley SK, Yan S, Tomura M, Kanagawa O, Luster AD. 2013. Recirculating memory T cells are a unique subset of CD4+ T cells with a distinct phenotype and migratory pattern. J Immunol 190(3):970-6. doi: 10.4049/jimmunol.1202805, PMID 23255361

Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12(11):1301-9, PMID 17041596

Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 1998. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 188(11):2083-90. doi: 10.1084/jem.188.11.2083, PMID 9841922

Brown FD, Sen DR, LaFleur MW, Godec J, Lukacs-Kornek V, Schildberg FA, Kim HJ, Yates KB, Ricoult SJH, Bi K, Trombley JD, Kapoor VN, Stanley IA, Cremasco V, Danial NN, Manning BD, Sharpe AH, Haining WN, Turley SJ. 2019. Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling. Nat Immunol 20(12):1668-1680. doi: 10.1038/s41590-019-0515-x, PMID 31636464

Brugnera E, Bhandoola A, Cibotti R, Yu Q, Guinter TI, Yamashita Y, Sharrow SO, Singer A. 2000. Coreceptor reversal in the thymus: signaled CD4+8+ thymocytes initially terminate CD8 transcription even when differentiating into CD8+ T cells. Immunity 13(1):59-71. doi: 10.1016/s1074-7613(00)00008-x, PMID 10933395

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. 1987. A new member of the immunoglobulin superfamily--CTLA-4. Nature 328(6127):267-70. doi: 10.1038/328267a0, PMID 3496540

Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Gräf P, Verschoor A, Schiemann M, Höfer T, Busch DH. 2013. Disparate individual fates compose robust CD8+ T cell immunity. Science 340(6132):630-5. doi: 10.1126/science.1235454, PMID 23493420

Bucks CM, Norton JA, Boesteanu AC, Mueller YM, Katsikis PD. 2009. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol 182(11):6697-708. doi: 10.4049/jimmunol.0800997, PMID 19454664

Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. 2013. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods10(12):1213-8. doi: 10.1038/nmeth.2688, PMID 24097267

Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaëlsson J, Lund O, Hejdeman B, Jansson M, Sönnerborg A, Koup RA, Betts MR, Karlsson AC. 2014. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog 10(7):e1004251. doi: 10.1371/journal.ppat.1004251, PMID 25032686

Burnet MF. 1959. The Clonal Selection Theory of Acquired Immunity. Cambridge, Cambridge University Press.

Büssing I, Slack FJ, Grosshans H. 2008. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 14(9):400-9. doi: 10.1016/j.molmed.2008.07.001, PMID 18674967

Butz EA, Bevan MJ. 1998. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8(2):167-75. doi: 10.1016/s1074-7613(00)80469-0, PMID 9491998

Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. 2008. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 9(2):176-85. doi: 10.1038/ni1554, PMID 18193050

Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW, Ohashi PS. 2007. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 117(12):3833-45. doi: 10.1172/JCI32567, PMID 17992258

Cannarile MA, Lind NA, Rivera R, Sheridan AD, Camfield KA, Wu BB, Cheung KP, Ding Z, Goldrath AW. 2006. Transcriptional regulator Id2 mediates CD8+ T cell immunity. Nat Immunol 7(12):1317-25. doi: 10.1038/ni1403, PMID 17086188

Casciola-Rosen L, Garcia-Calvo M, Bull HG, Becker JW, Hines T, Thornberry NA, Rosen A. 2007. Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem 282(7):4545-52. doi: 10.1074/jbc.M606564200, PMID 17179148

Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. 1998. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol 20(3):373-82. doi: 10.3109/08923979809034820, PMID 9736442

Chang DW, Claassen GF, Hann SR, Cole MD. 2000. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 20(12):4309-19. doi: 10.1128/mcb.20.12.4309-4319.2000, PMID 10825194

Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, Banerjee A, Longworth SA, Vinup KE, Mrass P, Oliaro J, Killeen N, Orange JS, Russell SM, Weninger W, Reiner SL. 2007. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315(5819):1687-91. doi: 10.1126/science.1139393, PMID 17332376

Chang JT, Ciocca ML, Kinjyo I, Palanivel VR, McClurkin CE, Dejong CS, Mooney EC, Kim JS, Steinel NC, Oliaro J, Yin CC, Florea BI, Overkleeft HS, Berg LJ, Russell SM, Koretzky GA, Jordan MS, Reiner SL. 2011. Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. Immunity 34(4):492-504. doi: 10.1016/j.immuni.2011.03.017, PMID 21497118

Chang HM, Triboulet R, Thornton JE, Gregory RI. 2013. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. Nature 497(7448):244-8. doi: 10.1038/nature12119, PMID 23594738

Chapman NM, Boothby MR, Chi H. 2020. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol 20(1):55-70. doi: 10.1038/s41577-019-0203-y, PMID 31406325

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. 2003. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198: 1875–1886. doi: 10.1084/jem.20030152, PMID 14676299

Chen CZ1, Li L, Lodish HF, Bartel DP. 2004. MicroRNAs modulate hematopoietic lineage differentiation. Science 303(5654):83-6. doi: 10.1126/science.1091903, PMID 14657504

Chen Z, Stelekati E, Kurachi M, Yu S, Cai Z, Manne S, Khan O, Yang X, Wherry EJ. 2017. miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep 20(11):2584-2597. doi: 10.1016/j.celrep.2017.08.060, PMID 28903040

Cho OH, Shin HM, Miele L, Golde TE, Fauq A, Minter LM, Osborne BA. 2009. Notch regulates cytolytic effector function in CD8+ T cells. J Immunol 182(6):3380-9. doi: 10.4049/jimmunol.0802598, PMID 19265115

Chong MM, Rasmussen JP, Rudensky AY, Littman DR. 2008. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med 205(9):2005-17. doi: 10.1084/jem.20081219, PMID 18725527

Chou C, Pinto AK, Curtis JD, Persaud SP, Cella M, Lin CC, Edelson BT, Allen PM, Colonna M, Pearce EL, Diamond MS, Egawa T. 2014. c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ T cells. Nat Immunol 15(9):884-93. doi: 10.1038/ni.2943, PMID 25029552

Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. 2009. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009 Apr 17;30(4):576-87. doi: 10.1016/j.immuni.2009.02.007, PMID 19362022

Cobb BS, Nesterova TB, Thompson E, Hertweck A, O'Connor E, Godwin J, Wilson CB, Brockdorff N, Fisher AG, Smale ST, Merkenschlager M. 2005. T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med 201(9):1367-73. doi: 10.1084/jem.20050572, PMID 15867090

Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T, Smale ST, Sakaguchi S, Livesey FJ, Fisher AG, Merkenschlager M. 2006. A role for Dicer in immune regulation. J Exp Med 203(11):2519-27. doi: 10.1084/jem.20061692, PMID 17060477

Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6):560-7. doi: 10.1038/ni.2027, PMID 21516112

Compston A, Coles A. 2008. Multiple sclerosis. Lancet 372(9648), 1502-1517. doi: 10.1016/S0140-6736(08)61620-7, PMID 18970977

Cone RE. 1981. Molecular basis for T lymphocyte recognition of antigens. Prog Allergy 29:182-221. PMID 7036180

Cooper MD, Alder MN. 2006. The evolution of adaptive immune systems. Cell 124(4): 815-822. doi: 10.1016/j.cell.2006.02.001, PMID 16497590

Cooper MD. 2015. The early history of B cells. Nat Rev Immunol 15(3):191-7. doi: 10.1038/nri3801, PMID 25656707

Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. 2001. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 166(7):4312-8. doi: 10.4049/jimmunol.166.7.4312, PMID 11254683

Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ, Broadley S, Scott RJ, Booth DR, Lechner-Scott J; ANZgene Multiple Sclerosis Genetics Consortium. 2010. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed

in MS whole blood. PLoS One. 2010 Aug 11;5(8):e12132. doi: 10.1371/journal.pone.0012132, PMID 20711463

Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, Wherry EJ. 2014. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity 40(2):289-302. doi: 10.1016/j.immuni.2014.01.005, PMID 24530057

Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP. 2016. Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. Cell Mol Immunol 13(4):502-13. doi: 10.1038/cmi.2015.32, PMID 25914936

Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A. 2009. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 206(1):51-9. doi: 10.1084/jem.20081242, PMID 19139168

Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421(6924):744-8. doi: 10.1084/jem.20171352, PMID 12610626

Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF. 1999. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 162:3256–62. PMID 10092777

Davis MM, Bjorkman PJ. 1988. T-cell antigen receptor genes and T-cell recognition. Nature 334(6181):395-402. doi: 10.1038/334395a0, PMID 3043226

Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350-4. doi: 10.1038/nature05115, PMID 16921384

De Boer RJ, Homann D, Perelson AS. 2003. Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol 171(8):3928-35. doi: 10.4049/jimmunol.171.8.3928, PMID 14530309

DeGrendele HC, Estess P, Picker LJ, Siegelman MH. 1996. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 183(3):1119-30. doi: 10.1084/jem.183.3.1119, PMID 8642254

Déjardin J, Kingston RE. 2009. Purification of proteins associated with specific genomic Loci. Cell 136(1):175-86. doi: 10.1016/j.cell.2008.11.045, PMID 19135898

Dharakul T, Rott L, Greenberg HB. 1990. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes. J Virol 64(9):4375-82. PMID 1974652

DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. 2007. Autoantigen-specific TGFβ-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol. 179:4685–93. doi: 10.4049/jimmunol.179.7.4685, PMID 17878367

Dominguez CX, Amezquita RA, Guan T, Marshall HD, Joshi NS, Kleinstein SH, Kaech SM. 2015. The transcription factors ZEB2 and T-bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. J Exp Med 212(12):2041-56. doi: 10.1084/jem.20150186, PMID 26503446

Dongre A, Surampudi L, Lawlor RG, Fauq AH, Miele L, Golde TE, Minter LM, Osborne BA. 2014. Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral CD4(+) T Cells. Front Immunol 5:54. doi: 10.3389/fimmu.2014.00054, PMID 24611064

Donnadieu E, Bismuth G, Trautmann A. 1994. Antigen recognition by helper T cells elicits a sequence of distinct changes of their shape and intracellular calcium. Curr Biol 4(7):584–595. doi:10.1016/s0960-9822(00)00130-5, PMID 7953532

Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei G. 2009. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 10(12):1252-9. doi: 10.1038/ni.1798, PMID 19838199

Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. 2006. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461-3. doi: 10.1126/science.1135245, PMID 17068223

Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95(25):14863-8. doi: 10.1073/pnas.95.25.14863, PMID 9843981

Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG. 2006. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203(11):2461-72. doi: 10.1084/jem.20061462, PMID 17030951

Elbashir SM, Lendeckel W, Tuschl T. 2001. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15(2):188-200. doi: 10.1101/gad.862301, PMID 11157775

El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12(6):568-75. doi: 10.1038/ni.2031, PMID 21516111

Engel I, Hedrick SM. 1988. Site-directed mutations in the VDJ junctional region of a T cell receptor beta chain cause changes in antigenic peptide recognition. Cell 54(4):473-84. doi: 10.1016/0092-8674(88)90068-2, PMID 2456856

Fallarino F, Fields PE, Gajewski TF. 1998. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med 188(1):205-10. doi: 10.1084/jem.188.1.205, PMID 9653097

Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. 2005. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310(5755):1817-21. doi: 10.1126/science.1121158, PMID 16308420

Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. 2000. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 192(6):899-905. doi: 10.1084/jem.192.6.899, PMID 10993920

Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336. doi: 10.1038/ni904, PMID 12612578

Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, Lipp M. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1):23-33. doi: 10.1016/s0092-8674(00)80059-8, PMID 10520991

Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. 2002. The CD28 signaling pathway regulates glucose metabolism. Immunity 16(6):769-77. doi: 10.1016/s1074-7613(02)00323-0, PMID 12121659

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027-34. doi: 10.1084/jem.192.7.1027, PMID 11015443

Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009 Jan;19(1):92-105. doi: 10.1101/gr.082701.108, PMID 18955434

Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A89(5):1827-31, PMID 1542678

Frost RJ, Olson EN. 2011. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci U S A 108(52):21075-80. doi: 10.1073/pnas.1118922109, PMID 22160727

Früh K, Yang Y. 1999. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11(1):76-81. doi: 10.1016/s0952-7915(99)80014-4, PMID 10047537

Fuller MJ, Zajac AJ. 2003. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 170(1):477-86. doi: 10.4049/jimmunol.170.1.477, PMID 12496434

Gagnon JD, Ansel KM1. 2019. MicroRNA regulation of CD8+ T cell responses. Noncoding RNA Investig 3. pii: 24. doi: 10.21037/ncri.2019.07.02, PMID 31844841

Gagnon JD, Kageyama R, Shehata HM, Fassett MS, Mar DJ, Wigton EJ, Johansson K, Litterman AJ, Odorizzi P, Simeonov D, Laidlaw BJ, Panduro M, Patel S, Jeker LT, Feeney ME, McManus MT, Marson A, Matloubian M, Sanjabi S, Ansel KM. 2019. miR-15/16 Restrain Memory T Cell Differentiation, Cell Cycle, and Survival. Cell Rep 28(8):2169-2181.e4. doi: 10.1016/j.celrep.2019.07.064, PMID 31433990

Galaktionov K, Chen X, Beach D. 1996. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382(6591):511-7. doi: 10.1038/382511a0, PMID 8700224

Gao GF, Rao Z, Bell JI. 2002. Molecular coordination of αβ T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. Trends Immunol 23: 408–413. PMID 12133804

Garidou L, Heydari S, Gossa S, McGavern DB. 2012. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J Virol 86(13):7060-71. doi: 10.1128/JVI.00164-12, PMID 22553324

Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP. 2009. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15(7):808-13. doi: 10.1038/nm.1982, PMID 19525962

Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. 2011. A human memory T cell subset with stem cell-like properties. Nat Med 17(10):1290-7. doi: 10.1038/nm.2446, PMID 21926977

Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB. 1993. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci U S A 90(21):9944-8. doi: 10.1073/pnas.90.21.9944, PMID 8234339

Gerlach C, van Heijst JW, Swart E, Sie D, Armstrong N, Kerkhoven RM, Zehn D, Bevan MJ, Schepers K, Schumacher TN. 2010. One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med 207(6):1235-46. doi: 10.1084/jem.20091175, PMID 20479114

Glaichenhaus N, Shastri N, Littman DR, Turner JM. 1991. Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells. Cell 64: 511–520. doi: 10.1016/0092-8674(91)90235-q, PMID 1671341

Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature 467(7318):967-71. doi: 10.1038/nature09447, PMID 20962846

Goodnow CC. 2007. Multistep pathogenesis of autoimmune disease. Cell 130(1):25-35. doi: 10.1016/j.cell.2007.06.033, PMID 17632054

Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD. 2013. The microRNA miR-155 controls

CD8(+) T cell responses by regulating interferon signaling. Nat Immunol 14(6):593-602. doi: 10.1038/ni.2576, PMID 23603793

Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, Drexler I, Höfer T, Riddell SR, Busch DH. 2014. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 41(1):116-26. doi: 10.1016/j.immuni.2014.05.018, PMID 25035956

Grandori C, Eisenman RN. 1997. Myc target genes. Trends Biochem Sci 22(5):177-81. doi: 10.1016/s0968-0004(97)01025-6, PMID 9175477

Grayson JM, Zajac AJ, Altman JD, Ahmed R. 2000. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J Exp Med 164(8):3950-4. doi: 10.4049/jimmunol.164.8.3950, PMID 10754284

Grenningloh R, Tai TS, Frahm N, Hongo TC, Chicoine AT, Brander C, Kaufmann DE, Ho IC. 2011. Ets-1 maintains IL-7 receptor expression in peripheral T cells. J Immunol 186(2):969-76. doi: 10.4049/jimmunol.1002099, PMID 21148801

Griffith JW, Sokol CL, Luster AD. 2014. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32:659-702. doi: 10.1146/annurev-immunol-032713-120145, PMID 24655300

Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. 2007. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27(1):91-105. doi: 10.1016/j.molcel.2007.06.017, PMID 17612493

Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG. 2007. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117(11):3383-92. doi: 10.1172/JCI31184, PMID 17932562

Gu SM, Park MH, Yun HM, Han SB, Oh KW, Son DJ, Yun JS, Hong JT. 2016. CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice. Oncotarget 15382-93. doi: 10.18632/oncotarget.8097, PMID 26985768

Guan H, Fan D, Mrelashvili D, Hao H, Singh NP, Singh UP, Nagarkatti PS, Nagarkatti M. 2013. MicroRNA let-7e is associated with the pathogenesis of experimental autoimmune encephalomyelitis. Eur J Immunol 43(1):104-14. doi: 10.1002/eji.201242702, PMID 23079871

Guan T, Dominguez CX, Amezquita RA, Laidlaw BJ, Cheng J, Henao-Mejia J, Williams A, Flavell RA, Lu J, Kaech SM. 2018. ZEB1, ZEB2, and the miR-200 family form a

counterregulatory network to regulate CD8+ T cell fates. J Exp Med 215(4):1153-1168. doi: 10.1084/jem.20171352, PMID 29449309

Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE. 2011. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 134(Pt 12):3578-89. doi: 10.1093/brain/awr262, PMID 22088562

Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. 1998. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 95(1):258-63. doi: 10.1073/pnas.95.1.258, PMID 9419363

Hagan JP, Piskounova E, Gregory RI. 2009. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol 16(10):1021-5. doi: 10.1038/nsmb.1676, PMID 19713958

Hamilton SE, Jameson SC. 2012. CD8 T cell quiescence revisited. Trends Immunol 33(5):224-30. doi: 10.1016/j.it.2012.01.007, PMID 22361353

Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK. 2003. Duration of antiviral immunity after smallpox vaccination. Nat Med 9(9):1131-7. doi: 10.1038/nm917, PMID 12925846

Harbertson J, Biederman E, Bennett KE, Kondrack RM, Bradley LM. 2002. Withdrawal of stimulation may initiate the transition of effector to memory CD4 cells. J Immunol 168(3):1095-102. doi: 10.4049/jimmunol.168.3.1095, PMID 11801643

Harding F, McArthur J, Gross J, Raulet D, Allison J. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607–609. doi: 10.1038/356607a0, PMID 1313950

Hargadon KM, Johnson CE2, Williams CJ2. 2018. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29-39. doi: 10.1016/j.intimp.2018.06.001, PMID 29990692

Harker JA, Wong KA, Dolgoter A, Zuniga EI. 2015. Cell-Intrinsic gp130 Signaling on CD4+ T Cells Shapes Long-Lasting Antiviral Immunity. J Immunol 195(3):1071-81. doi: 10.4049/jimmunol.1402402, PMID 26085685

Harty JT, Schreiber RD, Bevan MJ. 1992. CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. Proc Natl Acad Sci U S A. 89(23):11612-6. doi: 10.1073/pnas.89.23.11612, PMID 1360672

He X, He X, Dave VP, Zhang Y, Hua X, Nicolas E, Xu W, Roe BA, Kappes DJ. 2005. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 433(7028):826-33. doi: 10.1038/nature03338, PMID 15729333

Henning AN, Roychoudhuri R, Restifo NP. 2018. Epigenetic control of CD8+ T cell differentiation. Nat Rev Immunol 18(5):340-356. doi: 10.1038/nri.2017.146, PMID 29379213

Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. 2008. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 32(2):276-84. doi: 10.1016/j.molcel.2008.09.014, PMID 18951094

Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, Yeom KH, Han J, Kim VN. 2009. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 138(4):696-708. doi: 10.1016/j.cell.2009.08.002, PMID 19703396

Hertel J, Bartschat S, Wintsche A, Otto C; Students of the Bioinformatics Computer Lab, Stadler PF. 2012. Evolution of the let-7 microRNA family. RNA Biol 9(3):231-41. doi: 10.4161/rna.18974, PMID 22617875

Hess Michelini R1, Doedens AL, Goldrath AW, Hedrick SM. 2013. Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med 210(6):1189-200. doi: 10.1084/jem.20130392, PMID 23712431

Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3(5):431-7. doi: 10.1016/s1535-6108(03)00113-2, PMID 12781360

Hoffman B, Liebermann DA. 2008. Apoptotic signaling by c-MYC. Oncogene 27(50):6462-72. doi: 10.1038/onc.2008.312, PMID 18955973

Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. 1993. Development of TH1 CD4+ T cells through IL-12 produced by *Listeria*-induced macrophages. Science 260:547–49. doi: 10.1126/science.8097338, PMID 8097338

Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57. doi: 10.1038/nprot.2008.211, PMID 19131956

Hutcheson J, Scatizzi JC, Siddiqui AM, Haines GK 3rd, Wu T, Li QZ, Davis LS, Mohan C, Perlman H. 2008. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity 28(2):206-17. doi: 10.1016/j.immuni.2007.12.015, PMID 18275831

Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH, Ahmed R. 2016. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537(7620):417-421. doi: 10.1038/nature19330, PMID 27501248

International Multiple Sclerosis Genetics Consortium1, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357(9):851-62. doi: 10.1056/NEJMoa073493, PMID 17660530

Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. 2017. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356(6337):513-519. doi: 10.1126/science.aal3535, PMID 28473584

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99(19):12293-7. doi: 10.1073/pnas.192461099, PMID 12218188

Iwasaki A, Medzhitov R. 2015. Control of adaptive immunity by the innate immune system. Nat Immunol 16(4):343-53. doi: 10.1038/ni.3123, PMID 25789684

Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran T, Rao A. 1993. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365(6444):352-5. doi: 10.1038/365352a0, PMID 8397339

Janeway, CA. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today, 13(1), 11–16. doi:10.1016/0167-5699(92)90198-g, PMID 1739426

Janeway CA, Murphy KM, Weaver CT. 2017. 'Part I'-'Part III' in Garland Science (Ed.) *Janeway's Immunobiology*. 9th edition. New York, NY: Garland Science/Taylor & Francis. 1-231.

Janas ML, Groves P, Kienzle N, Kelso A. 2005. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J Immunol 175(12):8003-10. doi: 10.4049/jimmunol.175.12.8003, PMID 16339537

Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA. 2012. MicroRNA 10a marks regulatory T cells. PLoS One 7(5):e36684. doi: 10.1371/journal.pone.0036684, PMID 22629323

Jiang S, Li C, Olive V, Lykken E, Feng F, Sevilla J, Wan Y, He L, Li QJ. 2011. Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118(20):5487-97. doi: 10.1182/blood-2011-05-355644, PMID 21972292

Jiang S, Yan W, Wang SE, Baltimore D. 2018. Let-7 Suppresses B Cell Activation through Restricting the Availability of Necessary Nutrients. Cell Metab 27(2):393-403.e4. doi: 10.1016/j.cmet.2017.12.007, PMID 29337138

Johnson SM, Lin SY, Slack FJ. 2003. The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Dev Biol 259(2):364-79. doi: 10.1016/s0012-1606(03)00202-1, PMID 12871707

Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. 2007. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67(16):7713-22. doi: 10.1084/jem.20171352, PMID 17699775

Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA. 2008. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205(12):2763-79. doi: 10.1084/jem.20081398.

Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM. 2007. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27(2):281-95. doi: 10.1016/j.immuni.2007.07.010, PMID 17723218

Jung P, Menssen A, Mayr D, Hermeking H. 2008. AP4 encodes a c-MYC-inducible repressor of p21. Proc Natl Acad Sci U S A 105(39):15046-51. doi: 10.1073/pnas.0801773105, PMID 18818310

Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, Lassmann H, Wekerle H, Hohlfeld R, Meinl E. 2009. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132(Pt 12):3342-52. doi: 10.1093/brain/awp300, PMID 19952055

Kaech SM, Ahmed R. 2001. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2(5):415-22. doi: 10.1038/87720, PMID 11323695

Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4(12):1191-8. doi: 10.1038/ni1009, PMID 14625547

Kagnoff MF, Eckmann L. 1997. Epithelial cells as sensors for microbial infection. J Clin Invest 100(1):6-10. doi: 10.1172/JCI119522, PMID 9202050

Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. 2010. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32(1):91-103. doi: 10.1016/j.immuni.2009.11.010, PMID 20096608

Kalia V, Penny LA, Yuzefpolskiy Y, Baumann FM, Sarkar S. 2015. Quiescence of Memory CD8(+) T Cells Is Mediated by Regulatory T Cells through Inhibitory Receptor CTLA-4. Immunity 42(6):1116-29. doi: 10.1016/j.immuni.2015.05.023, PMID 26084026

Kaech SM, Cui W. 2012. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 12(11):749-61. doi: 10.1038/nri3307, PMID 23080391

Kakaradov B, Arsenio J, Widjaja CE, He Z, Aigner S, Metz PJ, Yu B, Wehrens EJ, Lopez J, Kim SH, Zuniga EI, Goldrath AW, Chang JT, Yeo GW. 2017. Early transcriptional and epigenetic regulation of CD8+ T cell differentiation revealed by single-cell RNA sequencing. Nat Immunol 18(4):422-432. doi: 10.1038/ni.3688, PMID 28218746

Kallies A, Xin A, Belz GT, Nutt SL. 2009. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 31(2):283-95. doi: 10.1016/j.immuni.2009.06.021. PMID 19664942

Kara EE, McKenzie DR, Bastow CR, Gregor CE, Fenix KA, Ogunniyi AD, Paton JC, Mack M, Pombal DR, Seillet C, Dubois B, Liston A, MacDonald KPA, Belz GT, Smyth MJ, Hill GR, Comerford I, McColl SR. 2015. CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. Nat Comm 6:8644. doi: 10.1038/ncomms9644, PMID 26511769

Kariv I, Hardy RR, Hayakawa K. 1993. Selective enrichment of major histocompatibility complex class II-specific autoreactive T cells in the thymic Thy0 subset. J Exp Med 177(5):1429-37. doi: 10.1084/jem.177.5.1429, PMID 8097523

Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1(3):167-78. doi: 10.1016/1074-7613(94)90095-7, 7534202

Khan AA, Penny LA, Yuzefpolskiy Y, Sarkar S, Kalia V. 2013. MicroRNA-17~92 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections. Blood 121(22):4473-83. doi: 10.1182/blood-2012-06-435412, PMID 23596046

Khan SH, Badovinac VP. 2015. Listeria monocytogenes: a model pathogen to study antigen-specific memory CD8 T cell responses. Semin Immunopathol 37(3):301-10. doi: 10.1007/s00281-015-0477-5, PMID 25860798

Kim JM, Rasmussen JP, Rudensky AY. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:191–197. doi: 10.1038/ni1428, PMID 17136045

Kim YK, Kim VN. 2007. Processing of intronic microRNAs. EMBO J 26(3):775-83. doi: 10.1038/sj.emboj.7601512, PMID 17255951

Kim DH1, Saetrom P, Snøve O Jr, Rossi JJ. 2008. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16230-5. doi: 10.1073/pnas.0808830105, PMID 18852463

Kimura K, Hohjoh H, Fukuoka M, Sato W, Oki S, Tomi C, Yamaguchi H, Kondo T, Takahashi R, Yamamura T. 2018. Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. Nat Comm 9(1):17. doi: 10.1038/s41467-017-02406-2, PMID 29295981

Kishikawa H, Sun J, Choi A, Miaw SC, Ho IC. 2001. The cell type-specific expression of the murine IL-13 gene is regulated by GATA-3. J. Immunol. 167:4414–20. doi: 10.4049/jimmunol.167.8.4414, PMID 11591766

Kishimoto TK, Jutila MA, Butcher EC. 1990. Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule. Proc Natl Acad Sci U S A 87(6):2244-8. doi: 10.1073/pnas.87.6.2244, PMID 2179952

Klein L, Kyewski B, Allen PM, Hogguist KA. 2014. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol 14(6): 377-391. doi: 10.1038/nri3667, PMID 24830344

Kloosterman WP, Wienholds E, Ketting RF, Plasterk RH. 2004. Substrate requirements for let-7 function in the developing zebrafish embryo. Nucleic Acid Res 32(21):6284-91. doi: 10.1093/nar/gkh968, PMID 15585662

Knight SW, Bass BL. 2001. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 293(5538):2269-71. doi: 10.1126/science.1062039, PMID 11486053

Knoepfler PS, Cheng PF, Eisenman RN. 2002. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16(20):2699-712. doi: 10.1101/gad.1021202, PMID 12381668

Komuczki J, Tuzlak S, Friebel E, Hartwig T, Spath S, Rosenstiel P, Waisman A, Opitz L, Oukka M, Schreiner B, Pelczar P, Becher B. 2019. Fate-Mapping of GM-CSF Expression Identifies a Discrete Subset of Inflammation-Driving T Helper Cells Regulated by Cytokines IL-23 and IL-1β. Immunity 50(5):1289-1304.e6. doi: 10.1016/j.immuni.2019.04.006, PMID 31079916

Kondo M, Weissman IL, Akashi K. 1997. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91(5):661-72. doi: 10.1016/s0092-8674(00)80453-5, PMID 9393859

Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. 2003. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 198(12):1797-806. doi: 10.1084/jem.20030735, PMID 14662907

Krummel MF, Bartumeus F, Gérard A. 2016. T cell migration, search strategies and mechanisms. Nat Rev Immunol 16(3):193-201. doi: 10.1038/nri.2015.16. 16(3):193-201. doi: 10.1038/nri.2015.16, PMID 26852928

Kuchen S, Resch W, Yamane A, Kuo N, Li Z, Chakraborty T, Wei L, Laurence A, Yasuda T, Peng S, Hu-Li J, Lu K, Dubois W, Kitamura Y, Charles N, Sun HW, Muljo S, Schwartzberg PL, Paul WE, O'Shea J, Rajewsky K, Casellas R. 2010. Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 32(6):828-39. doi: 10.1016/j.immuni.2010.05.009, PMID 20605486

Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75(2):263-74. doi: 10.1016/0092-8674(93)80068-p, PMID 8402911

Kumar M, Ahmad T, Sharma A, Mabalirajan U, Kulshreshtha A, Agrawal A, Ghosh B. 2011. J Allergy Clin Immunol 128(5):1077-85.e1-10. doi: 10.1016/j.jaci.2011.04.034, PMID 21616524

Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, Srivastava D. 2011. Notch post-translationally regulates β-catenin protein in stem and progenitor cells. Nat Cell Biol 13(10):1244-51. doi: 10.1038/ncb2313, PMID 21841793

Kwong B, Rua R, Gao Y, Flickinger J Jr, Wang Y, Kruhlak MJ, Zhu J, Vivier E, McGavern DB, Lazarevic V. 2017. T-bet-dependent NKp46+ innate lymphoid cells

regulate the onset of TH17-induced neuroinflammation. Nat Immunol 18(10):1117-1127. doi: 10.1038/ni.3816, PMID 28805812

Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. 2001. Identification of novel genes coding for small expressed RNAs. Science 294(5543):853-8. doi: 10.1126/science.1064921, PMID 11679670

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 2002. Identification of tissue-specific microRNAs from mouse. Curr Biol 12(9):735-9. doi: 10.1016/s0960-9822(02)00809-6, PMID 12007417

Lai EC. 2002. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30(4):363-4. doi: 10.1038/ng865, PMID 11896390

Landor SK, Mutvei AP, Mamaeva V, Jin S, Busk M, Borra R, Grönroos TJ, Kronqvist P, Lendahl U, Sahlgren CM. 2011. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc Natl Acad Sci U S A 108(46):18814-9. doi: 10.1073/pnas.1104943108, PMID 22065781

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. 2014. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185. doi: 10.1155/2014/149185, PMID 24901008

Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201(2):233-40. doi: 10.1084/jem.20041257, PMID 15657292

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. 2015. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(1):23-34. doi: 10.1056/NEJMoa1504030, PMID 26027431

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261-8. doi: 10.1038/85330, PMID 11224527

Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, Knoepfler PS, Cheng PF, MacDonald HR, Eisenman RN, Bernstein ID, Trumpp A. 2008. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 3(6):611-24. doi: 10.1016/j.stem.2008.09.005, PMID 19041778

Lauvau G, Vijh S, Kong P, Horng T, Kerksiek K, Serbina N, Tuma RA, Pamer EG. 2001. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294(5547):1735-9. doi: 10.1126/science.1064571, PMID 11721060

Leach DR, Krummel MF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-6. doi: 10.1126/science.271.5256.1734, PMID 8596936

Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843-54. doi: 10.1016/0092-8674(93)90529-y, PMID 8252621

Lee YJ, Han Y, Lu HT, Nguyen V, Qin H, Howe PH, Hocevar BA, Boss JM, Ransohoff RM, Benveniste EN. 1997. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 158(5):2065-75. PMID 9036950

Lee RC, Ambros V. 2001. An extensive class of small RNAs in Caenorhabditis elegans. Science 294(5543):862-4. doi: 10.1126/science.1065329, PMID 11679672

Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, Kim VN. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956):415-9. doi: 10.1038/nature01957, PMID 14508493

Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. 2004. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23(20):4051-60. doi: 10.1038/sj.emboj.7600385, PMID 15372072

Legesse-Miller A, Elemento O, Pfau SJ, Forman JJ, Tavazoie S, Coller HA. 2010. let-7 Overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. J Biol Chem 284(11):6605-9. doi: 10.1074/jbc.C900002200, PMID 19126550

Lenz DC, Kurz SK, Lemmens E, Schoenberger SP, Sprent J, Oldstone MB, Homann D. 2004. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci U S A 101(25):9357-62. doi: 10.1073/pnas.0400640101, PMID 15197277

Leuschner PJ, Ameres SL, Kueng S, Martinez J. 2006. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 7(3):314-20. doi: 10.1038/sj.embor.7400637, PMID 16439995

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115(7):787-98. doi: 10.1016/s0092-8674(03)01018-3, PMID 14697198

Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15-20. doi: 10.1016/j.cell.2004.12.035, PMID 15652477

Li Z, Wu F, Brant SR, Kwon JH. 2011. IL-23 receptor regulation by Let-7f in human CD4+ memory T cells. J Immunol 186(11):6182-90. doi: 10.4049/jimmunol.1000917, PMID 21508257

Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33(10):2706-16. doi: 10.1002/eji.200324228, PMID 14515254

Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M, Hao J, Alekseev A, Khong H, Chen T, Huang R, Wu J, Zhao Q, Wu Q, Xu S, Wang X, Jin W, Yu S, Wang Y, Wei L, Wang A, Zhong B, Ni L, Liu X, Nurieva R, Ye L, Tian Q, Bian XW, Dong C. 2019. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature 67(7749):525-529. doi: 10.1038/s41586-019-0979-8, PMID 30814730

Lieberman J. 2010. Granzyme A activates another way to die. Immunol Rev 235(1):93-104. doi: 10.1111/j.0105-2896.2010.00902.x, PMID 20536557

Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, O'Shea JJ. 2001. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A. 98(26):15137-15142. doi: 10.1073/pnas.261570598, PMID 11752460

Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433(7027):769-73. doi: 10.1038/nature03315, PMID 15685193

Lin CC, Bradstreet TR, Schwarzkopf EA, Sim J, Carrero JA, Chou C, Cook LE, Egawa T, Taneja R, Murphy TL, Russell JH, Edelson BT. 2014. Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation. Nat Commun 5:3551. doi: 10.1038/ncomms4551, PMID 24699451

Lin CC, Bradstreet TR, Schwarzkopf EA, Jarjour NN, Chou C, Archambault AS, Sim J, Zinselmeyer BH, Carrero JA, Wu GF, Taneja R, Artyomov MN, Russell JH, Edelson BT. 2016. IL-1-induced Bhlhe40 identifies pathogenic T helper cells in a model of autoimmune neuroinflammation. J Exp Med. 2016 Feb 8;213(2):251-71. doi: 10.1084/jem.20150568, PMID 26834156

Lin R, Chen L, Chen G, Hu C, Jiang S, Sevilla J, Wan Y, Sampson JH, Zhu B, Li QJ. 2014. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest 124(12):5352-67. doi: 10.1172/JCI76561, PMID 25347474

Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8(5):500-8. doi: 10.1038/nm0502-500, PMID 11984595

Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, Rudensky AY. 2009. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30(1):80-91. doi: 10.1016/j.immuni.2008.11.010, PMID 19144316

Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142(6):914-29. doi: 10.1016/j.cell.2010.08.012, PMID 20850013

Luckey MA, Kimura MY, Waickman AT, Feigenbaum L, Singer A, Park JH. 2014. The transcription factor ThPOK suppresses Runx3 and imposes CD4(+) lineage fate by inducing the SOCS suppressors of cytokine signaling. Nat Immunol 17(7): 638-645. doi: 10.1038/ni.2917, PMID 24880459

Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M. Superior T memory stem cell persistence supports long-lived T cell memory. 2013. J Clin Invest 123(2):594-9. doi: 10.1172/JCI66327, PMID 23281401

Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG. 2000. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci U S A. 97(23):12694-9. doi: 10.1073/pnas.97.23.12694, PMID 11070085

Lytle JR, Yario TA, Steitz JA. 2007. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 104(23):9667-72. doi: 10.1073/pnas.0703820104, PMID 17535905

Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, Hua M, Li N, Yao H, Cao X. 2011. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol 12(9):861-9. doi: 10.1038/ni.2073, PMID 21785411

Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y, Singh N, Nagarkatti M, Nagarkatti P. 2014. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci 11(8):810-8. doi: 10.7150/ijms.8647, PMID 24936144

Macián F, López-Rodríguez C, Rao A. 2001. Partners in transcription: NFAT and AP-1. Oncogene 20(19):2476-89. doi: 10.1038/sj.onc.1204386, PMID 11402342

Macián F1. 2005. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5(6):472-84. doi: 10.1038/nri1632, PMID 15928679

MacRae IJ, Ma E, Zhou M, Robinson CV, Doudna JA. 2008. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci U S A 105(2):512-7. doi: 10.1073/pnas.0710869105, PMID 18178619

Maïza H, Leca G, Mansur IG, Schiavon V, Boumsell L, Bensussan A. 1993. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 178(3):1121-6. doi: 10.1084/jem.178.3.1121, PMID 7688788

Majoros WH, Ohler U. 2007. Spatial preferences of microRNA targets in 3' untranslated regions. BMC Genomics 8:152. doi: 10.1186/1471-2164-8-152, PMID 17555584

Malik BT, Byrne KT, Vella JL, Zhang P, Shabaneh TB, Steinberg SM, Molodtsov AK, Bowers JS, Angeles CV, Paulos CM, Huang YH, Turk MJ. 2017. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol 2(10). pii: eaam6346. doi: 10.1126/sciimmunol.aam6346, PMID 28738020

Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D. 2019. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. Oncoimmunology 8(12):e1665976. doi: 10.1080/2162402X.2019.1665976, PMID 31741766

Man K, Gabriel SS, Liao Y, Gloury R, Preston S, Henstridge DC, Pellegrini M, Zehn D, Berberich-Siebelt F, Febbraio MA, Shi W, Kallies A. 2017. Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells

during Chronic Infection. Immunity 47(6):1129-1141.e5. doi: 10.1016/j.immuni.2017.11.021, PMID 29246443

Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. 2006. Transforming growth factor-β induces development of the TH17 lineage. Nature 441: 231–234. doi: 10.1038/nature04754, PMID16648837

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. 2018. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544-548. doi: 10.1038/nature25501, PMID 29443960

Martinelli-Boneschi F, Esposito F, Brambilla P, Lindström E, Lavorgna G, Stankovich J, Rodegher M, Capra R, Ghezzi A, Coniglio G, Colombo B, Sorosina M, Martinelli V, Booth D, Oturai AB, Stewart G, Harbo HF, Kilpatrick TJ, Hillert J, Rubio JP, Abderrahim H, Wojcik J, Comi G. 2012. A genome-wide association study in progressive multiple sclerosis. Mult Scler 18(10):1384-94. doi: 10.1177/1352458512439118, PMID 22457343

Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, Togher S, Heissmeyer V, Zhang YC, Crotty S, Lamperti ED, Ansel KM, Mempel TR, Lähdesmäki H, Hogan PG, Rao A. 2015. The transcription factor NFAT promotes exhaustion of activated CD8$^+$ T cells. Immunity 42(2):265-278. doi: 10.1016/j.immuni.2015.01.006, PMID 25680272

Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. 2013. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med 210(8):1603-19. doi: 10.1084/jem.20122387, PMID 23878307

Martinvalet D, Dykxhoorn DM, Ferrini R, Lieberman J. 2008. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell 133(4):681-92. doi: 10.1016/j.cell.2008.03.032, PMID 18485875

Masopust D, Vezys V, Marzo AL, Lefrançois L. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291(5512):2413-7. doi: 10.1126/science.1058867, PMID 11264538

Masson D, Tschopp J. 1985. Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem 260(16):9069-72. PMID 3874868

Matloubian M1, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355-60. doi: 10.1038/nature02284, PMID 14737169

Matsuki T, Nakae S, Sudo K, Horai R, Iwakura Y. 2006. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol 18(2):399-407. doi: 10.1093/intimm/dxh379, PMID 16415102

Mattes J, Collison A, Plank M, Phipps S, Foster PS. 2009. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A 106(44):18704-9. doi: 10.1073/pnas.0905063106, PMID 19843690

Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315(5818):1576-9. doi: 10.1126/science.1137999, PMID 17322030

Mazanet MM, Hughes CC. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169(7):3581-8. doi: 10.4049/jimmunol.169.7.3581, PMID 12244148

McCaughtry TM, Wilken MS, Hogquist KA. 2007. Thymic emigration revisited. J Exp Med 204(11):2513-20. doi: 10.1084/jem.20070601, PMID 17908937

McCaughtry TM, Etzensperger R, Alag A, Tai X, Kurtulus S, Park JH, Grinberg A, Love P, Feigenbaum L, Erman B, Singer A. 2012. Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus. J Exp Med 209(12): 2263-2276. doi: 10.1084/jem.20121505, PMID 23109710

McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ. 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390–1397. doi:10.1038/ni1539, PMID 17994024

McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ. 2009. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10(3):314-24. doi: 10.1038/ni.1698, PMID 19182808

McKenzie MD, Dudek NL, Mariana L, Chong MM, Trapani JA, Kay TW, Thomas HE. 2006. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. Int Immunol 18(6):837-46. doi: 10.1093/intimm/dxl020, PMID 16574667

McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. 2015. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015 Jul 30;523(7562):612-6. doi: 10.1038/nature14468, PMID 26123020

McKinstry KK, Strutt TM, Swain SL. 2010. Regulation of CD4+ T-cell contraction during pathogen challenge. Immunol Rev 236:110-24. doi: 10.1111/j.1600-065X.2010.00921.x, PMID 20636812

McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, Bernard CC. 2001. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 194(7):873-82. doi: 10.1084/jem.194.7.873, PMID 11581310

Melamed Z, Levy A, Ashwal-Fluss R, Lev-Maor G, Mekahel K, Atias N, Gilad S, Sharan R, Levy C, Kadener S, Ast G. 2013. Alternative splicing regulates biogenesis of miRNAs located across exon-intron junctions. Mol Cell 50(6):869-81. doi: 10.1016/j.molcel.2013.05.007, PMID 23747012

Meneely PM, Herman RK. 1984. Lethals, steriles and deficiencies in a region of the X chromosome of Caenorhabditis elegans. Genetics 92(1):99-115. PMID 574105

Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449(7164):819-26. doi: 10.1038/nature06246, PMID 17943118

Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M, Dobrinskikh E, Busson P, Polyak SJ, Hirashima M, Rosen HR. 2010. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 5(3):e9504. doi: 10.1371/journal.pone.0009504, PMID 20209097

Michalek RD, Rathmell JC. 2010. The metabolic life and times of a T-cell. Immunol Rev 236:190-202. doi: 10.1111/j.1600-065X.2010.00911.x, PMID 20636818

Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. 2019. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20(3):326-336. doi: 10.1038/s41590-019-0312-6, PMID 30778252

Min B, Prout M, Hu-Li J, Zhu J, Jankovic D, Morgan ES, Urban JF Jr, Dvorak AM, Finkelman FD, LeGros G, Paul WE. 2004 Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J. Exp. Med. 200(4):507-517. doi: 10.1084/jem.20040590, PMID 15314076

Minter LM, Osborne BA. 2012. Notch and the survival of regulatory T cells: location is everything! Sci Signal 5(234):pe31. doi: 10.1126/scisignal.2003358, PMID 22827995

Moffett HF, Cartwright ANR, Kim HJ, Godec J2, Pyrdol J, Äijö T, Martinez GJ, Rao A, Lu J, Golub TR, Cantor H, Sharpe AH, Novina CD, Wucherpfennig KW. 2017. The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection. Nat Immunol 18(7):791-799. doi: 10.1038/ni.3755, PMID 28530712

Mombaerts P1, Clarke AR, Rudnicki MA, Iacomini J, Itohara S, Lafaille JJ, Wang L, Ichikawa Y, Jaenisch R, Hooper ML, Tonegawa S. 1992. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature 360(6401):225-31. doi 10.1038/360225a0, PMID 1359428

Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415(6871):536-41. doi: 10.1038/415536a, PMID 11823861

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267-73. doi 10.1038/ng1180, PMID 12808457

Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, Hogquist KA. 2011. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 208(6):1279-89. doi: 10.1084/jem.20110308, PMID 21606508

Morita S, Kojima T, Kitamura T. 2000. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7(12):1063-6. doi: 10.1038/sj.gt.3301206, PMID 10871756

Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362(6422):758-61. doi: 10.1038/362758a0, PMID 8469287

Mueller DL, Seiffert S, Fang W, Behrens TW. 1996. Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells. J Immunol 156(5):1764-71. PMID 8596025

Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, Schölmerich J, Hellerbrand C. 2002. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45(4):520-8. doi: 10.1016/j.jhep.2006.05.007, PMID 16876901

Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K. 2005. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 202(2):261-9. doi: 10.1084/jem.20050678, PMID 16009718

Müllbacher A, Lobigs M, Hla RT, Tran T, Stehle T, Simon MM. Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. J Immunol 169(1):145-50. doi: 10.4049/jimmunol.169.1.145, PMID 12077239

Mycko MP, Cichalewska M, Machlanska A, Cwiklinska H, Mariasiewicz M, Selmaj KW. 2012. MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci U S A 109(20):E1248-57. doi: 10.1073/pnas.1114325109, PMID 22517757

Nam Y, Weng AP, Aster JC, Blacklow SC. 2003. Structural requirements for assembly of the CSL-intracellular Notch1-mastermind-like 1 transcriptional activation complex. J Bio Chem 278:21232–9. doi:10.1074/jbc.M301567200, PMID 12644465

Newcomb DC, Cephus JY, Boswell MG, Fahrenholz JM, Langley EW, Feldman AS, Zhou W, Dulek DE, Goleniewska K, Woodward KB, Sevin CM, Hamilton RG, Kolls JK, Peebles RS Jr. 2015. Estrogen and progesterone decrease let-7f microRNA expression and increase IL-23/IL-23 receptor signaling and IL-17A production in patients with severe asthma. J Allergy Clin Immunol. 2015 Oct;136(4):1025-34.e11. doi: 10.1016/j.jaci.2015.05.046, PMID 26242299

Newman MA, Thomson JM, Hammond SM. 2008. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 14(8):1539-49. doi: 10.1261/rna.1155108, PMID 18566191

Nikolić-Žugić, J. 1991. Phenotypic and functional stages in the intrathymic development of αβ T cells. Immunology Today, 12(2), 65–70. doi:10.1016/0167-5699(91)90160-u, PMID 2059306

Nish SA, Schenten D, Wunderlich FT, Pope SD, Gao Y, Hoshi N, Yu S, Yan X, Lee HK, Pasman L, Brodsky I, Yordy B, Zhao H, Brüning J, Medzhitov R. 2012. T cell-intrinsic

role of IL-6 signaling in primary and memory responses. Elife 3:e01949. doi: 10.7554/eLife.01949, PMID 24842874

Ng CT, Oldstone MB. 2012. Infected CD8α- dendritic cells are the predominant source of IL-10 during establishment of persistent viral infection. Proc Natl Acad Sci U S A 109(35):14116-21. doi: 10.1073/pnas.1211910109, PMID 22893686

O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D. 2010. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33(4):607-19. doi: 10.1016/j.immuni.2010.09.009, PMID 20888269

Oestreich KJ, Yoon H, Ahmed R, Boss JM. 2008. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181(7):4832-9. doi: 10.4049/jimmunol.181.7.4832, PMID 18802087

Ohashi PS1. 2002. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol 2(6):427-38. doi: 10.1038/nri822, PMID 12093009

Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, Seabra MC, Wilson MS. 2014. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 41(1):89-103. doi: 10.1016/j.immuni.2014.05.019, PMID 25035954

Olson JA, McDonald-Hyman C, Jameson SC, Hamilton SE. 2013. Effector-like CD8[+] T cells in the memory population mediate potent protective immunity. Immunity 38(6):1250-60. doi: 10.1016/j.immuni.2013.05.009, PMID 23746652

Osborn JF, Hobbs SJ, Mooster JL, Khan TN, Kilgore AM, Harbour JC, Nolz JC. 2019. Central memory CD8+ T cells become CD69+ tissue-residents during viral skin infection independent of CD62L-mediated lymph node surveillance. PLoS Pathog 15(3):e1007633. doi: 10.1371/journal.ppat.1007633, PMID 30875408

Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, Zhang X, Song JS, Fisher DE. 2008. Chromatin structure analyses identify miRNA promoters. Genes Dev 22(22):3172-83. doi: 10.1101/gad.1706508, PMID 19056895

Pagès F, Ragueneau M, Klasen S, Battifora M, Couez D, Sweet R, Truneh A, Ward SG, Olive D. 1996. Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association. J Biol Chem 271: 9403–9409. doi: 10.1074/jbc.271.16.9403, PMID8621607

Palin AC, Ramachandran V, Acharya S, Lewis DB. 2013. Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a. J Immunol 190(6):2682-91. doi: 10.4049/jimmunol.1202534, PMID 23408835

Pancer Z, Cooper MD. The evolution of adaptive immunity. Annu Rev Immunol 24:497-518. doi: 10.1146/annurev.immunol.24.021605.090542, PMID 16551257

Pape KA, Khoruts A, Mondino A, Jenkins MK. 1997. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J. Immunol. 159:591–98. PMID 9218573

Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR. 2007. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316(5822):295-8. doi: 10.1126/science.1139221, PMID 17363629

Parish IA, Marshall HD, Staron MM, Lang PA, Brüstle A, Chen JH, Cui W, Tsui YC, Perry C, Laidlaw BJ, Ohashi PS, Weaver CT, Kaech SM. 2014. Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1. J Clin Invest 124(8):3455-68. doi: 10.1172/JCI66108, PMID 25003188

Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. 2000. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408(6808):86-9. doi: 10.1038/35040556, PMID 11081512

Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey B, Hay N. 2013. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2):213-228. doi: 10.1016/j.ccr.2013.06.014, PMID 23911236

Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA, Shen H, Cereb N, Yang SY, Lindsten T, Rossant J, Hunter CA, Reiner SL. 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302(5647):1041-3. doi: 10.1126/science.1090148, PMID 14605368

Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. 2009. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460(7251):103-7. doi: 10.1038/nature08097, PMID 19494812

Peled M, Dragovich MA, Adam K, Strazza M, Tocheva AS, Vega IE, Mor A. 2018. EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity. J Immunol 201(9):2824-2831. doi: 10.4049/jimmunol.1800839, PMID 30275048

Pellegrini M, Belz G, Bouillet P, Strasser A. 2003. Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc Natl Acad Sci U S A 100(24):14175-80. doi: 10.1073/pnas.2336198100, PMID 14623954

Pepper M, Jenkins MK. 2011. Origins of CD4(+) effector and central memory T cells. Nat Immunol 12(6):467-71. doi: 10.1038/ni.2038, PMID 21739668

Peters PJ, Borst J, Oorschot V, Fukuda M, Krähenbühl O, Tschopp J, Slot JW, Geuze HJ. 1991. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 173(5):1099-109. doi: 10.1084/jem.173.5.1099, PMID 2022921

Pircher H, Michalopoulos EE, Iwamoto A, Ohashi PS, Baenziger J, Hengartner H, Zinkernagel RM, Mak TW. 1987. Molecular analysis of the antigen receptor of virus-specific cytotoxic T cells and identification of a new V alpha family. Eur J Immunol 17(12):1843-6. doi: 10.1002/eji.1830171226, PMID 2961577

Piskounova E, Viswanathan SR, Janas M, LaPierre RJ, Daley GQ, Sliz P, Gregory RI. 2008. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem 283(31):21310-4. doi: 10.1074/jbc.C800108200, PMID 18550544

Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D, Gregory RI. 2011. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147(5):1066-79. doi: 10.1016/j.cell.2011.10.039, PMID 22118463

Plumlee CR, Sheridan BS, Cicek BB, Lefrançois L. 2013. Environmental cues dictate the fate of individual CD8+ T cells responding to infection. Immunity 39(2):347-56. doi: 10.1016/j.immuni.2013.07.014, PMID 23932571

Polikepahad S, Knight JM, Naghavi AO, Oplt T, Creighton CJ, Shaw C, Benham AL, Kim J, Soibam B, Harris RA, Coarfa C, Zariff A, Milosavljevic A, Batts LM, Kheradmand F, Gunaratne PH, Corry DB. 2010. Proinflammatory role for let-7 microRNAS in experimental asthma. J Biol Chem 285(39):30139-49. doi: 10.1074/jbc.M110.145698, PMID 20630862

Pobezinskaya EL, Wells AC, Angelou CC, Fagerberg E, Aral E, Iverson E, Kimura MY, Pobezinsky LA. 2019. Survival of Naive T Cells Requires the Expression of Let-7 miRNAs. Front Immunol 10:955. doi: 10.3389/fimmu.2019.00955, PMID 31130952

Pobezinsky LA, Etzensperger R, Jeurling S, Alag A, Kadakia T, McCaughtry TM, Kimura MY, Sharrow SO, Guinter TI, Feigenbaum L, Singer A. 2015. Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate terminal NKT cell differentiation and effector function. Nat Immunol 16(5):517-24. doi: 10.1038/ni.3146, PMID 25848867

Pollizzi KN, Sun IH, Patel CH, Lo YC, Oh MH, Waickman AT, Tam AJ, Blosser RL, Wen J, Delgoffe GM, Powell JD. 2016. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. Nat Immunol 17(6):704-11. doi: 10.1038/ni.3438, PMID 27064374

Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. 2007. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 178(1):39-48. doi: 10.4049/jimmunol.178.1.39, PMID 17182538

Portnoy DA, Schreiber RD, Connelly P, Tilney LG. 1989. Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med 170(6):2141-6. doi: 10.1084/jem.170.6.2141, PMID 2511268

Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. 2005. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6(3):280-6. doi: 10.1038/ni1165, PMID 15685176

Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY, Kadesch T, Hardy RR, Aster JC, Pear WS. 1999. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11(3):299-308. doi: 10.1016/s1074-7613(00)80105-3, PMID 10514008

Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S, Russell K, Toth I, Piechocka-Trocha A, Dolfi D, Angelosanto J, Crawford A, Shin H, Kwon DS, Zupkosky J, Francisco L, Freeman GJ, Wherry EJ, Kaufmann DE, Walker BD, Ebert B, Haining WN. 2010. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 16(10):1147-51. doi: 10.1038/nm.2232, PMID 20890291

Ramalingam P, Palanichamy JK, Singh A, Das P, Bhagat M, Kassab MA, Sinha S, Chattopadhyay P. 2014. Biogenesis of intronic miRNAs located in clusters by

independent transcription and alternative splicing. RNA 20(1):76-87. doi: 10.1261/rna.041814.113, PMID 24226766

Rand TA, Ginalski K, Grishin NV, Wang X. 2004. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci U S A 101(40):14385-9. doi: 10.1073/pnas.0405913101, PMID 15452342

Rangachari M, Kuchroo VK. 2013. Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 45:31-9. doi: 10.1016/j.jaut.2013.06.008, PMID 23849779

Ratner A, Clark WR. 1993. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J Immunol 150(10):4303-14. PMID 8482837

Raziorrouh B, Schraut W, Gerlach T, Nowack D, Grüner NH, Ulsenheimer A, Zachoval R, Wächtler M, Spannagl M, Haas J, Diepolder HM, Jung MC. 2010. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52(6):1934-47. doi: 10.1002/hep.23936, PMID 21064032

Reed JC, Nowell PC, Hoover RG. 1985. Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation. Proc Natl Acad Sci U S A 82(12):4221-4. doi: 10.1073/pnas.82.12.4221, PMID 3873657

Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615–23. PMID: 9620682

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403(6772):901-6. doi: 10.1038/35002607, PMID 10706289

Roberts AD, Ely KH, Woodland DL. 2014. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 202(1):123-33. doi: 10.1084/jem.20050137, PMID 15983064

Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH, Freeman GJ. 2003. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 33(11):3117-26. doi: 10.1002/eji.200324270, PMID 14579280

Rodrigues MM, Boscardin SB, Vasconcelos JR, Hiyane MI, Salay G, Soares IS. 2003. Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. An Acad Bras Cienc. 75(4):443-68. doi: 10.1590/s0001-37652003000400005, PMID: 14605680

Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. 2004. Identification of mammalian microRNA host genes and transcription units. Genome Res 14(10A):1902-10. doi: 10.1101/gr.2722704, PMID 15364901

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116, PMID 21498393

Rossi RL, Rossetti G, Wenandy L, Curti S, Ripamonti A, Bonnal RJ, Birolo RS, Moro M, Crosti MC, Gruarin P, Maglie S, Marabita F, Mascheroni D, Parente V, Comelli M, Trabucchi E, De Francesco R, Geginat J, Abrignani S, Pagani M. 2011. Nat Immunol 12(8):796-803. doi: 10.1038/ni.2057, PMID 21706005

Roush S, Slack FJ. 2008. The let-7 family of microRNAs. Trends Cell Biol 18(10):505-16. doi: 10.1016/j.tcb.2008.07.007, PMID 18774294

Rouvier E, Luciani MF, Golstein P. 1993. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 177(1):195-200. doi: 10.1084/jem.177.1.195, PMID 7678113

Ruby J, Ramshaw I. 1991. The antiviral activity of immune CD8+ T cells is dependent on interferon-gamma. Lymphokine Cytokine Res 10(5):353-8. PMID 1768738

Rudolph MG, Stanfield RL, Wilson IA. 2006. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24:419-66. doi: 10.1146/annurev.immunol.23.021704.115658, PMID 16551255

Ryser JE, Vassalli P. 1974. Mouse bone marrow lymphocytes and their differentiation. J Immunol 113(3):719-28. PMID 4213258

Saitoh T, Nakano H, Yamamoto N, Yamaoka S. Lymphotoxin-beta receptor mediates NEMO-independent NF-kappaB activation. FEBS Lett 532(1-2):45-51. doi: 10.1016/s0014-5793(02)03622-0, PMID 12459460

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of

a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151–1164. PMID 7636184

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187-94. doi: 10.1084/jem.20100643, PMID 20819927

Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708-12. doi: 10.1038/44385, PMID 10537110

Sallusto F, Geginat J, Lanzavecchia A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745-63. doi: 10.1146/annurev.immunol.22.012703.104702, PMID 15032595

Samelson LE, Patel MD, Weissman a M, Harford JB, Klausner RD. 1986. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 46: 1083–1090. doi: 10.1016/0092-8674(86)90708-7, PMID 2428504

Sato T, Ohno S, Hayashi T, Sato C, Kohu K, Satake M, Habu S. 2005. Dual functions of Runx proteins for reactivating CD8 and silencing CD4 at the commitment process into CD8 thymocytes. Immunity 22(3):317-28. doi: 10.1016/j.immuni.2005.01.012, PMID 15780989

Sawamura Y, Hosokawa M, Kuppner MC, Kobayashi H, Aida T, Abe H, de Tribolet N. 1989. Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49(7):1843-9. PMID 2784352

Sawant DV, Wu H, Kaplan MH, Dent AL. 2013. The Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway. Mol Immunol 54(3-4):435-42. doi: 10.1016/j.molimm.2013.01.006, PMID 23416424

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. 2016. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity 45(2):389-401. doi: 10.1016/j.immuni.2016.07.011, PMID 27521269

Schnall-Levin M, Zhao Y, Perrimon N, Berger B. 2010. Conserved microRNA targeting in Drosophila is as widespread in coding regions as in 3'UTRs. Proc Natl Acad Sci U S A 107(36):15751-6. doi: 10.1073/pnas.1006172107, PMID 20729470

Schulze-Luehrmann J, Ghosh S. 2006. Antigen-receptor signaling to nuclear factor kappa B. Immunity 25(5):701-15. doi: 10.1016/j.immuni.2006.10.010, PMID 17098202

Scott B, Blüthmann H, Teh HS, von Boehmer H. 1989. The generation of mature T cells requires interaction of the alpha beta T-cell receptor with major histocompatibility antigens. Nature 338(6216):591-3. doi: 10.1038/338591a0, PMID 2784545

Seder RA, Ahmed R. 2003. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 4(9):835-42. doi: 10.1038/ni969, PMID 12942084

Seddon B, Tomlinson P, Zamoyska R. 2003. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 4(7):680-6. doi: 10.1038/ni946, PMID 12808452

Semplici F, Meggio F, Pinna LA, Oliviero S. 2002. CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TrCP and enhances beta-catenin degradation. Oncogene 21(25):3978-87. doi: 10.1038/sj.onc.1205574, PMID 12037680

Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, Wang YH, López-Moyado IF, Georges RO, Zhang W, Onodera A, Wu CJ, Lu LF, Hogan PG, Bhandoola A, Rao A. 2019. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci U S A 116(25):12410-12415. doi: 10.1073/pnas.1905675116, PMID 31152140

Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL, Wherry EJ. 2009. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31(2):309-20. doi: 10.1016/j.immuni.2009.06.019, PMID 19664943

Shin HM, Tilahun ME, Cho OH, Chandiran K, Kuksin CA, Keerthivasan S, Fauq AH, Golde TE, Miele L, Thome M, Osborne BA, Minter LM. 2014. NOTCH1 Can Initiate NF-κB Activation via Cytosolic Interactions with Components of the T Cell Signalosome. Front Immunol 5:249. doi: 10.3389/fimmu.2014.00249, PMID 24904593

Shiow LR, Rosen DB, Brdicková N, Xu Y, An J, Lanier LL, Cyster JG, Matloubian M. 2006. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440(7083):540-4. doi: 10.1038/nature04606, PMID 16525420

Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. 2003. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197(12):1645-55. doi: 10.1084/jem.20030239, PMID 12810686

Singer A, Adoro S, Park JH. 2008. Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol 8(10):788-801. doi: 10.1038/nri2416, PMID 18802443

Slack FJ, Basson M, Liu Z, Ambros V, Horvitz HR, Ruvkun G. 2000. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell 5(4):659-69. doi: 10.1016/s1097-2765(00)80245-2, PMID 10882102

Smith NL, Wissink EM, Grimson A, Rudd BD. 2015. miR-150 Regulates Differentiation and Cytolytic Effector Function in CD8+ T cells. Sci Rep 5:16399. doi: 10.1038/srep16399, PMID 26549197

Smith-Garvin JE, Koretzky GA, Jordan MS. 2009. T cell activation. Annu Rev Immunol 27:591-619. doi: 10.1146/annurev.immunol.021908.132706, PMID 19132916

Snell LM, MacLeod BL, Law JC, Osokine I, Elsaesser HJ, Hezaveh K, Dickson RJ, Gavin MA, Guidos CJ, McGaha TL, Brooks DG. 2018. CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity. Immunity 49(4):678-694.e5. doi: 10.1016/j.immuni.2018.08.002, PMID 30314757

Sonderegger I, Iezzi G, Maier R, Schmitz N, Kurrer M, Kopf M. 2008. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 205(10):2281-94. doi: 10.1084/jem.20071119, PMID 18779348

Sørensen TL, Sellebjerg F. 2011. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 57(8):1371-6. doi: 10.1212/wnl.57.8.1371, PMID 11673573

Spath S, Komuczki J, Hermann M, Pelczar P, Mair F, Schreiner B, Becher B. 2017. Dysregulation of the Cytokine GM-CSF Induces Spontaneous Phagocyte Invasion and Immunopathology in the Central Nervous System. Immunity 46(2):245-260. doi: 10.1016/j.immuni.2017.01.007, PMID 28228281

Spits H. Development of αβ T cells in the human thymus. 2002.Nat Rev Immunol 2: 760–772. doi: 10.1038/nri913, PMID 12360214

Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. 2005. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell 123(6):1133-46. doi: 10.1016/j.cell.2005.11.023, PMID 16337999

Starr TK, Jameson SC, Hogquist KA. 2003. Positive and negative selection of T cells. Annu Rev Immunol 21:139-76. doi: 10.1146/annurev.immunol.21.120601.141107, PMID 12414722

Stein JV, Rot A, Luo Y, Narasimhaswamy M, Nakano H, Gunn MD, Matsuzawa A, Quackenbush EJ, Dorf ME, von Andrian UH. 2000. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J Exp Med 191(1):61-76. doi: 10.1084/jem.191.1.61, PMID 10620605

Steiner DF, Thomas MF, Hu JK, Yang Z, Babiarz JE, Allen CD, Matloubian M, Blelloch R, Ansel KM. 2011. MicroRNA-29 regulates T-box transcription factors and interferon-γ production in helper T cells. Immunity 35(2):169-81. doi: 10.1016/j.immuni.2011.07.009, PMID 21820330

Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H, Busch DH. 2007. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 27(6):985-97. doi: 10.1016/j.immuni.2007.10.012, PMID 10706289

Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, Nguyen JM, Sarmin F, Borowsky ME, Tchou J, Conejo-Garcia JR. 2014. Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 41(3):427-439. doi: 10.1016/j.immuni.2014.08.012, PMID 25238097

Stern LJ, Wiley DC. 1994. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 2(4):245-51. doi: 10.1016/s0969-2126(00)00026-5, PMID 8087551

Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger S, Eberlein B, Gieger C, Wichmann HE, Kunz M, Ike R, Krueger GG, Bowcock AM, Mrowietz U, Lim HW, Voorhees JJ, Abecasis GR, Weichenthal M, Franke A, Rahman P, Gladman DD, Elder JT. 2010. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet. 2010 Nov;42(11):1000-4. doi: 10.1038/ng.693, PMID 20953189

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545-50. doi: 10.1073/pnas.0506580102, PMID 16199517

Suda T, Nagata S. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179(3):873-9. doi: 10.1084/jem.179.3.873, PMID 7509364

Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, Kim VN, Kim KS. 2004. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 270(2):488-98. doi: 10.1016/j.ydbio.2004.02.019, PMID 15183728

Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L. 2013. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123(10):4479-88. doi: 10.1172/JCI69589, PMID 24091329

Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. 2003. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A. 100(26):15818-23. doi: 10.1073/pnas.2636938100, PMID 14673093

Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, Browne KA, Trapani JA. 2000. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 192(10):1403-14. doi: 10.1084/jem.192.10.1403, PMID 11085743

Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203(7):1685-91. doi: 10.1084/jem.20060285, PMID 16818675

Swain SL, Weinberg AD, English M, Huston G. 1990. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:3796–806. PMID: 2147202

Swaminathan S, Suzuki K, Seddiki N, Kaplan W, Cowley MJ, Hood CL, Clancy JL, Murray DD, Méndez C, Gelgor L, Anderson B, Roth N, Cooper DA, Kelleher AD. 2012. Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J Immunol 188(12):6238-46. doi: 10.4049/jimmunol.1101196, PMID 22586040

Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655–669. doi: 10.1016/s0092-8674(00)80702-3, PMID 10761931

Szczuciński A, Losy J. 2007. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 115(3):137-46. doi: 10.1111/j.1600-0404.2006.00749.x, PMID 17295707

Takahashi H, Kanno T, Nakayamada S, Hirahara K, Sciumè G, Muljo SA, Kuchen S, Casellas R, Wei L, Kanno Y, O'Shea JJ. 2012. TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol 13(6):587-95. doi: 10.1038/ni.2286, PMID 22544395

Tan H, Yang K, Li Y, Shaw TI, Wang Y, Blanco DB, Wang X, Cho JH, Wang H, Rankin S, Guy C, Peng J, Chi H. 2017. Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation. Immunity. 2017 Mar 21;46(3):488-503. doi: 10.1016/j.immuni.2017.02.010, PMID 28285833

Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, Byrom D, Matarin JA, Calon A, Rivas EI, Nebreda AR, Riera A, Attolini CS, Batlle E. 2018. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554(7693):538-543. doi: 10.1038/nature25492, PMID 29443964

Teleshova N, Pashenkov M, Huang YM, Söderström M, Kivisäkk P, Kostulas V, Haglund M, Link H. 2002. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol 249(6):723-9. doi: 10.1007/s00415-002-0699-z, PMID 12111306

Thomas DA, Massagué J. 2005. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369-80. doi: 10.1016/j.ccr.2005.10.012, PMID 16286245

Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. 2006. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20(16):2202-7. doi: 10.1101/gad.1444406, PMID 16882971

Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. 2009. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 31(1):145-57. doi: 10.1016/j.immuni.2009.06.015, PMID 19604493

Tong Q, Ouyang S, Chen R, Huang J, Guo L. 2019. MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis. Am J Cancer Res 9(9):1938-1956. PMID 31598396

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A,

Wigginton JM, Sznol M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-54. doi: 10.1056/NEJMoa1200690, PMID 22658127

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020-30. doi: 10.1200/JCO.2013.53.0105, PMID 24590637

Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T. 1990. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171(5):1393-405. doi: 10.1084/jem.171.5.1393, PMID 1692078

Trifari S, Pipkin ME, Bandukwala HS, Äijö T, Bassein J, Chen R, Martinez GJ, Rao A. 2013. MicroRNA-directed program of cytotoxic CD8+ T-cell differentiation. Proc Natl Acad Sci U S A110(46):18608-13. doi: 10.1073/pnas.1317191110, PMID 24163352

Tsai CY, Allie SR, Zhang W, Usherwood EJ. 2013. MicroRNA miR-155 affects antiviral effector and effector Memory CD8 T cell differentiation. J Virol 87(4):2348-51. doi: 10.1128/JVI.01742-12, PMID 23221547

Tzachanis D, Lafuente EM, Li L, Boussiotis VA. 2004. Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma 45(10):1959-67. doi: 10.1080/1042819042000219494, PMID 15370239

Valiante NM, Trinchieri G. 1993. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 178(4):1397-406. doi: 10.1084/jem.178.4.1397, PMID 8376943

Van den Berge K, Hembach KM, Soneson C, Tiberi S, Clement L, Love MI, Patro R, Robinson MD. 2019. RNA Sequencing Data: Hitchhiker's Guide to Expression Analysis. Annual Review of Biomedical Data Science 2(1):139-73. doi:10.1146/annurev-biodatasci-072018-021255

van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, Pearce EJ, Pearce EL. 2012. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36(1):68-78. doi: 10.1016/j.immuni.2011.12.007, PMID 22206904

Vella AT, Mitchell T, Groth B, Linsley PS, Green JM, Thompson CB, Kappler JW, Marrack P. 1997. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J. Immunol. 158:4714–20. PMID: 9144484

Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. 2004. The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3'UTR. Genes Dev 8(2):132-7. doi: 10.1101/gad.1165404, PMID 14729570

Viswanathan SR, Daley GQ, Gregory RI. 2008. Selective blockade of microRNA processing by Lin28. Science 320(5872):97-100. doi: 10.1126/science.1154040, PMID 18292307

Vivier E, Malissen B. 2005. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol 6(1):17-21. doi: 10.1038/ni1153, PMID 15611777

Waksman BH, Arnason BG, Jankovic BD. 1961. Role of the thymus in immune reactions in rats. III. Changes in the lymphoid organs of thymectomized rats. J Exp Med 116:187-206. doi: 10.1084/jem.116.2.187, PMID 14004487

Wang Q, Li YC, Wang J, Kong J, Qi Y, Quigg RJ, Li X. 2008. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci U S A 105(8):2889-94. doi: 10.1073/pnas.0800178105, PMID 18287052

Wang Z, Gerstein M, Snyder M. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10(1):57-63. doi: 10.1038/nrg2484, PMID 19015660

Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, Green DR. 2011. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35(6):871-82. doi: 10.1016/j.immuni.2011.09.021, PMID 22195744

Wang J, Wissink EM, Watson NB, Smith NL, Grimson A, Rudd BD. 2016. Fetal and adult progenitors give rise to unique populations of CD8+ T cells. Blood 128(26):3073-3082. doi: 10.1182/blood-2016-06-725366, PMID 28034872

Wells AC, Daniels KA, Angelou CC, Fagerberg E, Burnside AS, Markstein M, Alfandari D, Welsh RM, Pobezinskaya EL, Pobezinsky LA. 2017. Modulation of let-7 miRNAs controls the differentiation of effector CD8 T cells. Elife 6. pii: e26398. doi: 10.7554/eLife.26398, PMID 28737488

Wells AC, Pobezinskaya EL, Pobezinsky LA. 2020. Non-coding RNAs in CD8 T cell biology. Mol Immunol 120:67-73. doi: 10.1016/j.molimm.2020.01.023, PMID 32085976

Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77(8):4911-27. doi: 10.1128/jvi.77.8.4911-4927.2003, PMID 12663797

Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4(3):225-34. doi: 10.1038/ni889, PMID 12563257

Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. 2004. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 101(45):16004-9. doi: 10.1073/pnas.0407192101, PMID 15505208

Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27(4):670-84. doi: 10.1016/j.immuni.2007.09.006, PMID 17950003

Wing K, Sakaguchi S. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11(1):7-13. doi: 10.1038/ni.1818, PMID 20016504

Whitmire JK, Tan JT, Whitton JL. 2005. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. J Exp Med 201(7):1053-9. doi: 10.1084/jem.20041463, PMID 15809350

Whitmire JK, Eam B, Whitton JL. 2008. Tentative T cells: memory cells are quick to respond, but slow to divide. PLoS Pathog 4(4):e1000041. doi: 10.1371/journal.ppat.1000041, PMID 18404208

Williams RW, Rubin GM. 2002. ARGONAUTE1 is required for efficient RNA interference in Drosophila embryos. doi: 10.1073/pnas.072190799, PMID 12011447

Williams MA, Ravkov EV, Bevan MJ. 2008. Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 28(4):533-45. doi: 10.1016/j.immuni.2008.02.014, PMID 18356084

Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. 2017. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med 214(2):381-400. doi: 10.1084/jem.20160485, PMID 28115575

Wilson EB, Brooks DG. 2011. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 350:39-65. doi: 10.1007/82_2010_96, PMID 20703965

Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, Badovinac VP. 2010. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core

signature of memory CD8(+) T cell differentiation. Immunity 33(1):128-40. doi: 10.1016/j.immuni.2010.06.014, PMID 20619696

Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA. 2006. Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol 36(7):1694-706. doi: 10.1002/eji.200635897, PMID 16761315

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. 2013. Nivolumab plus ipilimumab in advanced melanoma. N Eng J Med ;369(2):122-33. doi: 10.1056/NEJMoa1302369, PMID 23724867

Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, Manjunath N. 2007. miRNA profiling of naive, effector and memory CD8 T cells. PLoS One 2(10):e1020. doi: 10.1371/journal.pone.0001020, 17925868

Wu K, Kovacev J, Pan ZQ. 2010. Priming and extending: a UbcH5/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate. Mol Cell 37(6):784-96. doi: 10.1016/j.molcel.2010.02.025, PMID 20347421

Wu T, Wieland A, Araki K, Davis CW, Ye L, Hale JS, Ahmed R. 2012. Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9965-70. doi: 10.1073/pnas.1207327109, PMID 22665768

Wucherpfennig KW. 2001. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108(8):1097–1104. doi:10.1172/JCI14235, PMID 11602615

Wykes MN, Lewin SR. 2018. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91-104. doi: 10.1038/nri.2017.112, PMID 28990586

Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9(4):405-14. doi: 10.1038/ni1575, PMID 18327259

Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA. 1994. Mice deficient for the CD40 ligand. Immunity 1(5):423-31. doi: 10.1016/1074-7613(94)90073-6, 7882172

Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z, Liu X. 2013. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-

activated protein kinase-kinase 3. BMC Cancer 13:469. doi: 10.1186/1471-2407-13-469, PMID 24112539

Xue HH, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, Leonard WJ. 2002. IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes. Proc Natl Acad Sci U S A 99(21):13759-64. doi: 10.1073/pnas.212214999, PMID 12354940

Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM, Dong C. 2008. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28: 29–39. doi: 10.1016/j.immuni.2007.11.016, PMID 18164222

Yang CY, Best JA, Knell J, Yang E, Sheridan AD, Jesionek AK, Li HS, Rivera RR, Lind KC, D'Cruz LM, Watowich SS, Murre C, Goldrath AW. 2011. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol 12(12):1221-9. doi: 10.1038/ni.2158, PMID 22057289

Yang L, Boldin MP, Yu Y, Liu CS, Ea CK, Ramakrishnan P, Taganov KD, Zhao JL, Baltimore D. 2012. miR-146a controls the resolution of T cell responses in mice. J Exp Med 209(9):1655-70. doi: 10.1084/jem.20112218, PMID 22891274

Yang J, Liu R, Deng Y, Qian J, Lu Z, Wang Y, Zhang D, Luo F, Chu Y. 2017. MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR. Int J Immunol 141(10):2082-2092. doi: 10.1002/ijc.30912, PMID 28758198

Yi R, Qin Y, Macara IG, Cullen BR. 2003. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17(24):3011-6. doi: 10.1101/gad.1158803, PMID 14681208

Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, Srivastava M, Linterman M, Zheng L, Simpson N, Ellyard JI, Parish IA, Ma CS, Li QJ, Parish CR, Mackay CR, Vinuesa CG. 2009. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31(3):457-68.doi: 10.1016/j.immuni.2009.07.002, PMID 19631565

Yu B, Zhang K, Milner JJ, Toma C, Chen R, Scott-Browne JP, Pereira RM, Crotty S, Chang JT, Pipkin ME, Wang W, Goldrath AW. 2017. Epigenetic landscapes reveal transcription factors that regulate CD8+ T cell differentiation. Nat Immunol 18(5):573-582. doi: 10.1038/ni.3706, PMID 28288100

Yu F, Sharma S, Jankovic D, Gurram RK, Su P, Hu G, Li R, Rieder S, Zhao K, Sun B, Zhu J. 2018. The transcription factor Bhlhe40 is a switch of inflammatory versus

antiinflammatory Th1 cell fate determination. J Exp Med 215(7):1813-1821. doi: 10.1084/jem.20170155, PMID 29773643

Yui K, Komori S, Katsumata M, Siegel RM, Greene MI. 1990. Self-reactive T cells can escape clonal deletion in T-cell receptor V beta 8.1 transgenic mice. Proc Natl Acad Sci U S A 87(18):7135-9. doi: 10.1073/pnas.87.18.7135, PMID 2402496

Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. 2007. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129(2):303-17. doi: 10.1016/j.cell.2007.03.030, PMID 17397913

Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188(12):2205-13. doi: 10.1084/jem.188.12.2205, PMID 9858507

Zhang X, Sun S, Hwang I, Tough DF, Sprent J. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8(5):591-9. doi: 10.1016/s1074-7613(00)80564-6, PMID 9620680

Zhang N, Bevan MJ. 2010. Dicer controls CD8+ T-cell activation, migration, and survival. Proc Natl Acad Sci U S A 107(50):21629-34. doi: 10.1073/pnas.1016299107, PMID 21098294

Zhang T, Zhang Z, Li F, Ping Y, Qin G, Zhang C, Zhang Y. 2018. miR-143 Regulates Memory T Cell Differentiation by Reprogramming T Cell Metabolism. J Immunol 201(7):2165-2175. doi: 10.4049/jimmunol.1800230, PMID 30150287

Zheng W, Flavell RA. 1997. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89: 587–596. doi: 10.1016/s0092-8674(00)80240-8, PMID 9160750

Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 8(9):967-974. doi: 10.1038/ni1488, PMID 17581537

Zhou X, Yu S, Zhao DM, Harty JT, Badovinac VP, Xue HH. 2010. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 33(2):229-40. doi: 10.1016/j.immuni.2010.08.002, PMID 20727791

Zhou X, Xue HH. 2012. Cutting edge: generation of memory precursors and functional memory CD8+ T cells depends on T cell factor-1 and lymphoid enhancer-binding factor-1. J Immunol 189(6):2722-6. doi: 10.4049/jimmunol.1201150, PMID 22875805

Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6(12):1245-52. doi: 10.1038/ni1271, PMID 16286920

Zhu J, Paul WE. 2008. CD4 T cells: fates, functions, and faults. Blood 112(5):1557-69. doi: 10.1182/blood-2008-05-078154, PMID: 18725574

Zhu J, Yamane H, Paul WE. 2010. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 28:445-89. doi: 10.1146/annurev-immunol-030409-101212, PMID 20192806

Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI; DIAGRAM Consortium; MAGIC Investigators, Altshuler D, Daley GQ. 2011. The Lin28/let-7 axis regulates glucose metabolism. Cell. 147(1):81-94. doi: 10.1016/j.cell.2011.08.033, PMID 21962509

Zinselmeyer BH, Heydari S, Sacristán C, Nayak D, Cammer M, Herz J, Cheng X, Davis SJ, Dustin ML, McGavern DB. 2013. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 210(4):757-74. doi: 10.1084/jem.20121416, PMID 23530125

Zwiers A, Kraal L, van de Pouw Kraan TC, Wurdinger T, Bouma G, Kraal G. 2012. Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J Immunol 188(4):1573-7. doi: 10.4049/jimmunol.1101494, PMID 22262659